<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Rowset rowCount='683'><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="68617">ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>ID93</Interventions><Patients>60</Patients><ProtocolAcronym/><ProtocolTitle>Phase IIa ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion</ProtocolTitle><Reference>IDRI-TBVPX-203; NCT02465216</Reference><Sponsor>Infectious Disease Research Institute</Sponsor><Trial id="231367"/><TrialStartDate>JUNE     , 30, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="26574">lamivudine + abacavir + zidovudine, GSK</Drug><EnrollmentCount>70</EnrollmentCount><Interventions>lamivudine + abacavir + zidovudine</Interventions><Patients>70</Patients><ProtocolAcronym>THIRST</ProtocolAcronym><ProtocolTitle>Tuberculosis and HIV Immune Reconstitution Syndrome Trial (THIRST)</ProtocolTitle><Reference>NCT00851630; Pro00013131; THIRST</Reference><Sponsor>Duke University</Sponsor><Trial id="47398"/><TrialStartDate>JUNE     , 30, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>rifampicin</Controls><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="31010">SQ-109</Drug><EnrollmentCount>90</EnrollmentCount><Interventions>SQ109</Interventions><Patients>90</Patients><ProtocolAcronym>SQ109EBA</ProtocolAcronym><ProtocolTitle>EBA of SQ-109 in Adult Subjects with Pulmonary TB</ProtocolTitle><Reference>20100606; LMU-IMPH-SQ109-01; NCT01218217; PACTR201009000252144; SQ109EBA</Reference><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><Trial id="71188"/><TrialStartDate>NOVEMBER , 30, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44303">midazolam hydrochloride</Drug><EnrollmentCount>37</EnrollmentCount><Interventions>midazolam; rifapentine</Interventions><Patients>37</Patients><ProtocolAcronym>TBTC S29B</ProtocolAcronym><ProtocolTitle>Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers</ProtocolTitle><Reference>CDC-NCHHSTP-5779; NCT01162486; TBTC S29B; TBTC S29B</Reference><Sponsor>Johns Hopkins University</Sponsor><Trial id="68204"/><TrialStartDate>APRIL    , 30, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Alanine transaminase; Aspartate aminotransferase; Blood platelets; Body temperature; CD40 ligand; Creatinine; Erythrocytes; Hemoglobin; Interferon gamma; Interleukin-2; Leukocyte count; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><EnrollmentCount>240</EnrollmentCount><Interventions>M-72</Interventions><Patients>240</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in HIV-positive Adults</ProtocolTitle><Reference>113935; NCT01262976</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="73200"/><TrialStartDate>JANUARY  , 17, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers>C-reactive protein</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="2807">atorvastatin</Drug><EnrollmentCount/><Interventions>atorvastatin; dexamethasone; dexamethasone (decadron); once-daily naproxen (oral controlled release, pain), Alvogen; once-daily naproxen (oral controlled release, pain), Alvogen</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial</ProtocolTitle><Reference>NCT01442428; WS967180</Reference><Sponsor>University of Minnesota - Clinical and Translational Science Institute</Sponsor><Trial id="199754"/><TrialStartDate>JANUARY  , 31, 2014</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Ag85B; CD4+; CD8+; IFN-alpha; IFN-gamma; IL-2; PPD</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="55569">VPM-1002</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>VPM-1-002</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>Dose-Escalation Study on Safety and Immunogenicity of VPM-1-002 in Comparison to BCG in Healthy Volunteers in South Africa</ProtocolTitle><Reference>DOH-27-0210-3083; NCT01113281; VPM1002-ZA-1.10TB</Reference><Sponsor>Vakzine Projekt Management GmbH</Sponsor><Trial id="65984"/><TrialStartDate>APRIL    , 30, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>216</EnrollmentCount><Interventions>ethambutol; isoniazid; moxifloxacin; pyrazinamide; pyridoxine; rifampin; rifapentine</Interventions><Patients>121</Patients><ProtocolAcronym/><ProtocolTitle>Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis</ProtocolTitle><Reference>06-0018; NCT00728507</Reference><Sponsor>Johns Hopkins University</Sponsor><Trial id="23035"/><TrialStartDate>NOVEMBER , 30, 2009</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount/><Interventions>efavirenz; rifabutin</Interventions><Patients/><ProtocolAcronym>USPHS-23</ProtocolAcronym><ProtocolTitle>Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen</ProtocolTitle><Reference>NCRR-M01RR00030-0162; NCT00018083; USPHS-23</Reference><Sponsor>National Institutes of Health</Sponsor><Trial id="10648"/><TrialStartDate>JULY     , 02, 2001</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers>T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>809</EnrollmentCount><Interventions>efavirenz; emtricitabine; tenofovir disoproxil fumarate; tenofovir disoproxil fumarate + emtricitabine</Interventions><Patients>780</Patients><ProtocolAcronym>STRIDE</ProtocolAcronym><ProtocolTitle>Immediate Versus Deferred Start of Anti-HIV Therapy in HIV Infected Adults Being Treated for Tuberculosis</ProtocolTitle><Reference>1U01AI068636; ACTG A5221; ACTG A5221; NCT00108862; STRIDE</Reference><Sponsor>AIDS Clinical Trials Group</Sponsor><Trial id="10681"/><TrialStartDate>AUGUST   , 31, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><EnrollmentCount>12</EnrollmentCount><Interventions>MVA85A</Interventions><Patients>12</Patients><ProtocolAcronym/><ProtocolTitle>A Phase I Study of the Safety and Immunogenicity of MVA85A in Healthy Gambian Volunteers</ProtocolTitle><Reference>AFTBVAC; NCT00423839</Reference><Sponsor>University of Oxford</Sponsor><Trial id="10872"/><TrialStartDate>MARCH    , 31, 2003</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>241</EnrollmentCount><Interventions>bedaquiline; bedaquiline; clofazimine</Interventions><Patients>233</Patients><ProtocolAcronym/><ProtocolTitle>To Evaluate the Safety, Tolerability, and Efficacy of TMC-207 as Part of an Individualized Multi-Drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-Positive Pulmonary MDR-TB</ProtocolTitle><Reference>2008-008444-25; CR012352; NCT00910871; NCT00980811; TMC207-TiDP13-C209</Reference><Sponsor>Johnson &amp; Johnson</Sponsor><Trial id="56974"/><TrialStartDate>SEPTEMBER, 30, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="50038">tenofovir disoproxil fumarate + emtricitabine + efavirenz, Gilead/BMS/Merck &amp; Co</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>tenofovir disoproxil fumarate + emtricitabine + efavirenz</Interventions><Patients>30</Patients><ProtocolAcronym>PETE</ProtocolAcronym><ProtocolTitle>Pharmacokinetics of Emtricitabine/Tenofovir + Efavirenz in HIV-Infected Patients With Tuberculosis</ProtocolTitle><Reference>NCT00474435; PETE; UMCN-AKF 04.03</Reference><Sponsor>Poverty Related Infection Oriented Research</Sponsor><Trial id="10945"/><TrialStartDate>NOVEMBER , 30, 2008</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>BMI; Complete blood count; Erythrocyte sedimentation rate; Fasting blood glucose; Height; Hemoglobin; Serum albumin; Serum uric acid; Total body mass; Weight</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><EnrollmentCount>135</EnrollmentCount><Interventions>efavirenz; lamivudine + zidovudine, GlaxoSmithKline; nevirapine; rifampicin</Interventions><Patients>135</Patients><ProtocolAcronym>"NVP"</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB</ProtocolTitle><Reference>"NVP"; NCT01805258; SKS/NACO-1/2006-07</Reference><Sponsor>All India Institute of Medical Sciences</Sponsor><Trial id="114300"/><TrialStartDate>JUNE     , 30, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Alanine transaminase; Aspartate aminotransferase; QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyraziminide; rifampicin</Controls><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>240</EnrollmentCount><Interventions>bedaquiline; moxifloxacin; pretomanid; pyraziminide</Interventions><Patients>240</Patients><ProtocolAcronym/><ProtocolTitle>A Phase II to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Reference>NC-005; NC-005-(J-M-PA-Z); NCT02193776</Reference><Sponsor>TB Alliance</Sponsor><Trial id="210646"/><TrialStartDate>OCTOBER  , 23, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers>Alanine transaminase; Blood platelets; Body temperature; CD40 ligand; Creatinine; Cytotoxic T-Lymphocytes; Hemoglobin; Interferon gamma; Interleukin-2; Leukocyte count; T-Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Menjugate; Polio Sabin; Prevnar; Tritanrix HB</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3612">meningococcal C/CRM-197 conjugate vaccine, Chiron</Drug><EnrollmentCount>302</EnrollmentCount><Interventions>GSK-692342; GSK-692342a; Polio Sabin; Prevnar; Tritanrix HB</Interventions><Patients>302</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants</ProtocolTitle><Reference>112899; 2012-004380-44; NCT01098474; TUBERCULOSIS-013 PRI</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="65639"/><TrialStartDate>JULY     , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><EnrollmentCount>48</EnrollmentCount><Interventions>BCG; BCG; MVA-85A</Interventions><Patients>48</Patients><ProtocolAcronym/><ProtocolTitle>A BCG Challenge Model Study to Assess Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA-85A</ProtocolTitle><Reference>NCT01194180; TB023</Reference><Sponsor>University of Oxford</Sponsor><Trial id="69926"/><TrialStartDate>MAY      , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>6</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><EnrollmentCount>200</EnrollmentCount><Interventions>ethambutol; isoniazid; lopinavir + ritonavir; nevirapine; pyrazinamide; rifampicin</Interventions><Patients>39</Patients><ProtocolAcronym>DATiC</ProtocolAcronym><ProtocolTitle>Optimal Dosing of First-Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)</ProtocolTitle><Reference>DATiC; DATiC; NCT01637558</Reference><Sponsor>University of Cape Town</Sponsor><Trial id="89135"/><TrialStartDate>NOVEMBER , 30, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-17A; Interleukin-2; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><EnrollmentCount>650</EnrollmentCount><Interventions>MVA-85A</Interventions><Patients>650</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy Against TB Disease, Safety, and Immunogenicity of MVA-85A/AERAS-485 in HIV-Infected Adults</ProtocolTitle><Reference>C-030-485; NCT01151189</Reference><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><Trial id="67841"/><TrialStartDate>JULY     , 31, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="54488">raltegravir</Drug><EnrollmentCount>140</EnrollmentCount><Interventions>Aluvia; raltegravir; rifabutin</Interventions><Patients>140</Patients><ProtocolAcronym/><ProtocolTitle>EARNEST Rifabutin Pharmacokinetics (PK) Substudy</ProtocolTitle><Reference>ISRCTN13074752; NCT01663168</Reference><Sponsor>Joint Clinical Research Centre, Medical Research Council</Sponsor><Trial id="90175"/><TrialStartDate>MAY      , 03, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>5</ArmCount><Biomarkers>Body Mass Index; C-reactive protein; MDR1; N-acetyltransferase  (NAT2); Solute carrier organic anion transporter family member 1B1; Total body mass; UDP-galactose translocator</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>72</EnrollmentCount><Interventions>moxifloxacin; moxifloxacin; rifampin</Interventions><Patients>72</Patients><ProtocolAcronym>TBTC-27/28 PK</ProtocolAcronym><ProtocolTitle>TBTC Study 27/28 PK: Moxifloxacin Pharmacokinetics During TB Treatment</ProtocolTitle><Reference>CDC-NCHSTP-4222; NCT00164463; TBTC-27/28 PK</Reference><Sponsor>Centers for Disease Control and Prevention</Sponsor><Trial id="10847"/><TrialStartDate>JULY     , 31, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8050">thalidomide, Celgene</Drug><EnrollmentCount>50</EnrollmentCount><Interventions>thalidomide, Celgene</Interventions><Patients>50</Patients><ProtocolAcronym/><ProtocolTitle>Phase II, Placebo-Controlled Study of Thalidomide in Patients With Mycobacterial and HIV Infections</ProtocolTitle><Reference>199/11682; NCT00004276; RU-0300395</Reference><Sponsor>National Center for Research Resources</Sponsor><Trial id="92426"/><TrialStartDate>SEPTEMBER, 30, 1990</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>HIV negative; T-Helper Lymphocytes; T-Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="74849">SSI H56-IC31</Drug><EnrollmentCount>98</EnrollmentCount><Interventions>SSI H56-IC31</Interventions><Patients>98</Patients><ProtocolAcronym/><ProtocolTitle>A Phase I/IIa Safety And Immunogenicity of AERAS-456 in HIV-Negative Adults With And Without Latent Tuberculosis Infection</ProtocolTitle><Reference>C-035-456; NCT01865487</Reference><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><Trial id="136263"/><TrialStartDate>AUGUST   , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>5</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>antiretroviral therapy; optimized background regimen therapy</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="16545">delamanid</Drug><EnrollmentCount>511</EnrollmentCount><Interventions>antiretroviral therapy; delamanid; optimized background regimen therapy</Interventions><Patients>511</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug Resistant Tuberculosis</ProtocolTitle><Reference>2010-022271-59; 242-09-213; NCT01424670</Reference><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><Trial id="80386"/><TrialStartDate>SEPTEMBER, 02, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount>182</EnrollmentCount><Interventions>levofloxacin; moxifloxacin</Interventions><Patients>182</Patients><ProtocolAcronym/><ProtocolTitle>Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients</ProtocolTitle><Reference>H-0911-068-301; NCT01055145</Reference><Sponsor>Seoul National University Hospital</Sponsor><Trial id="63801"/><TrialStartDate>MARCH    , 31, 2010</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><EnrollmentCount>150</EnrollmentCount><Interventions>efavirenz; ethambutol; isoniazid; lamivudine; nevirapine; pyrazinamide; rifampicin; zidovudine</Interventions><Patients>355</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis</ProtocolTitle><Reference>NCT00698334; SKS/NACO/2006</Reference><Sponsor>All India Institute of Medical Sciences</Sponsor><Trial id="161275"/><TrialStartDate>APRIL    , 30, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers>T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4728">emtricitabine</Drug><EnrollmentCount>809</EnrollmentCount><Interventions>efavirenz; emtricitabine; tenofovir disoproxil fumarate; tenofovir disoproxil fumarate + emtricitabine</Interventions><Patients>780</Patients><ProtocolAcronym>STRIDE</ProtocolAcronym><ProtocolTitle>Immediate Versus Deferred Start of Anti-HIV Therapy in HIV Infected Adults Being Treated for Tuberculosis</ProtocolTitle><Reference>1U01AI068636; ACTG A5221; ACTG A5221; NCT00108862; STRIDE</Reference><Sponsor>AIDS Clinical Trials Group</Sponsor><Trial id="10681"/><TrialStartDate>AUGUST   , 31, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Rifafour e</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>105</EnrollmentCount><Interventions>PA-824; TMC-207; clofazimine; clofazimine; pyrazinamide; pyrazinamide</Interventions><Patients>105</Patients><ProtocolAcronym>NC-003</ProtocolAcronym><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC-207 (J)-PA-824 (Pa)-Pyrazinamide (Z)</ProtocolTitle><Reference>NC-003; NC-003-(C-J-Pa-Z); NCT01691534</Reference><Sponsor>TB Alliance</Sponsor><Trial id="92275"/><TrialStartDate>OCTOBER  , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>BMI; Complete blood count; Erythrocyte sedimentation rate; Fasting blood glucose; Height; Hemoglobin; Serum albumin; Serum uric acid; Total body mass; Weight</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>135</EnrollmentCount><Interventions>efavirenz; lamivudine + zidovudine, GlaxoSmithKline; nevirapine; rifampicin</Interventions><Patients>135</Patients><ProtocolAcronym>"NVP"</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB</ProtocolTitle><Reference>"NVP"; NCT01805258; SKS/NACO-1/2006-07</Reference><Sponsor>All India Institute of Medical Sciences</Sponsor><Trial id="114300"/><TrialStartDate>JUNE     , 30, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Anti-Meningitis C antibodies; C-C motif chemokine 2; C-C motif chemokine 3; C-C motif chemokine 4; Cytokines; IgG; Interferon gamma; Interferon-alpha; Interleukin-1 alpha; Interleukin-1 beta; Interleukin-10; Interleukin-12; Interleukin-13; Interleukin-2; Interleukin-6</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10774">NeisVac-C</Drug><EnrollmentCount>28</EnrollmentCount><Interventions>BCG; Infanrix; Menitorix; NeisVac-C; Pentacel; Prevnar 13; Priorix; Rotarix</Interventions><Patients>28</Patients><ProtocolAcronym>BAM</ProtocolAcronym><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><Reference>2013-003488-71; BAM; NCT02002156; OVG-2013/04; UKCRN 15722</Reference><Sponsor>University of Oxford</Sponsor><Trial id="162886"/><TrialStartDate>JUNE     , 20, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>TMC-207; isoniazid; pyrazinamide</Controls><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>TMC-207; isoniazid; pyrazinamide; rifampicin</Interventions><Patients>60</Patients><ProtocolAcronym/><ProtocolTitle>An Open-Label Study to Evaluate the Extended Early Bactericidal Activity, Safety, Tolerability and Pharmacokinetics of Multiple Doses (md) of TMC-207 Oral Solution (Os) and Isoniazid (JH), TMC-207 Os and Pyrazinamide (JZ), TMC-207 Os and Rifampin (JR) or TMC-207 Os and Isoniazid and Pyrazinamide (JHZ), Compared to the three Principle Drugs of Standard Anti-Tuberculosis Treatment (HRZ) in Treatment-Naive Subjects With Sputum-Smear Positive Pulmonary Tuberculosis</ProtocolTitle><Reference>EudraCT 2004-005142-12; TMC207-C203</Reference><Sponsor>Janssen R&amp;D (Ireland)</Sponsor><Trial id="131253"/><TrialStartDate>JUNE     , 25, 2005</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="7310">ritonavir</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>indinavir; ritonavir</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>The Pharmacokinetics and Safety of indinavir/ritonavir With NRTIs in HIV/TB co-Infected Patients Receiving Rifampicin</ProtocolTitle><Reference>HIV-NAT 044; NCT00411996</Reference><Sponsor>The HIV Netherlands Australia Thailand Research Collaboration</Sponsor><Trial id="10871"/><TrialStartDate>DECEMBER , 31, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>69</EnrollmentCount><Interventions>ethambutol; isoniazid; moxifloxacin; pyrazinamide; rifampicin</Interventions><Patients>69</Patients><ProtocolAcronym/><ProtocolTitle>Essentiality of INH in TB Therapy</ProtocolTitle><Reference>1U01AI068636; ACTG A5307; NCT01589497</Reference><Sponsor>AIDS Clinical Trials Group</Sponsor><Trial id="87091"/><TrialStartDate>JUNE     , 30, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid; rifampicin</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>1000</EnrollmentCount><Interventions>isoniazid; rifapentine</Interventions><Patients>1004</Patients><ProtocolAcronym>TBTC-22</ProtocolAcronym><ProtocolTitle>TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis</ProtocolTitle><Reference>CDC-NCHSTP-1427; NCT00023335; TBTC Study 22; TBTC-22</Reference><Sponsor>Centers for Disease Control and Prevention</Sponsor><Trial id="10650"/><TrialStartDate>APRIL    , 30, 1995</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4481">stavudine</Drug><EnrollmentCount>44</EnrollmentCount><Interventions>lamivudine; nelfinavir mesylate; rifabutin; stavudine; zidovudine</Interventions><Patients>44</Patients><ProtocolAcronym/><ProtocolTitle>Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis</ProtocolTitle><Reference>AACTG A5062; ACTG A5062; NCT00004736</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="10646"/><TrialStartDate>FEBRUARY , 25, 2000</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><EnrollmentCount>44</EnrollmentCount><Interventions>lamivudine; nelfinavir mesylate; rifabutin; stavudine; zidovudine</Interventions><Patients>44</Patients><ProtocolAcronym/><ProtocolTitle>Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis</ProtocolTitle><Reference>AACTG A5062; ACTG A5062; NCT00004736</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="10646"/><TrialStartDate>FEBRUARY , 25, 2000</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>CD4 + cell</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>63</EnrollmentCount><Interventions>efavirenz; isoniazid; tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences</Interventions><Patients>63</Patients><ProtocolAcronym/><ProtocolTitle>Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment</ProtocolTitle><Reference>C43-06; NCT00737724</Reference><Sponsor>Instituto Nacional de Enfermedades Respiratorias</Sponsor><Trial id="169697"/><TrialStartDate>MARCH    , 31, 2008</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers>CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4481">stavudine</Drug><EnrollmentCount>142</EnrollmentCount><Interventions>efavirenz; nevirapine</Interventions><Patients>145</Patients><ProtocolAcronym>N2R</ProtocolAcronym><ProtocolTitle>Efavirenz-Based Versus Nevirapine-Based Antiretroviral Therapy Among HIV-Infected Patients Receiving Rifampin</ProtocolTitle><Reference>210041000824904203; N2R; NCT00483054</Reference><Sponsor>Bamrasnaradura Infectious Diseases Institute</Sponsor><Trial id="10947"/><TrialStartDate>JANUARY  , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><EnrollmentCount>37</EnrollmentCount><Interventions>MVA-85A</Interventions><Patients>37</Patients><ProtocolAcronym/><ProtocolTitle>Study Evaluating Aerosol and Intradermal Administration of a Candidate Tuberculosis (TB) Vaccine, MVA-85A, as a Way to Increase Immune Response and Avoid Anti-Vector Immunity</ProtocolTitle><Reference>13/SC/0329; 15209; 2013-002020-16; ISRCTN08234512; NCT01954563; TB035; UKCRN 15209</Reference><Sponsor>University of Oxford</Sponsor><Trial id="156675"/><TrialStartDate>OCTOBER  , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Lung</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>rifampin</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>rifapentine</Interventions><Patients>60</Patients><ProtocolAcronym>TBTC-29PK</ProtocolAcronym><ProtocolTitle>High-Dose Rifapentine Pharmacokinetics, Tolerability and Safety Dosage Rifapentine for Treatment of Tuberculosis</ProtocolTitle><Reference>NCT01043575; TBTC Study 29PK; TBTC-29PK</Reference><Sponsor>Centers for Disease Control and Prevention</Sponsor><Trial id="63261"/><TrialStartDate>APRIL    , 30, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><EnrollmentCount>10</EnrollmentCount><Interventions>abacavir; lamivudine; raltegravir</Interventions><Patients>10</Patients><ProtocolAcronym/><ProtocolTitle>Raltegravir + ABC/3TC in HIV/TB Co-Infected Patients</ProtocolTitle><Reference>NCT01059422; RAL/ABC/3TC - HIV/TB</Reference><Sponsor>Central Research Institute of Epidemiology</Sponsor><Trial id="63729"/><TrialStartDate>OCTOBER  , 31, 2010</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Cytokines</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C0">Phase 0 Clinical</DevStatus><Drug id="13624">BCG vaccine, Organon</Drug><EnrollmentCount>10</EnrollmentCount><Interventions>TiceBCG</Interventions><Patients>10</Patients><ProtocolAcronym/><ProtocolTitle>Leukapheresis Sampling for Immune Responses After BCG Vaccination in BCG-naive Healthy Adults in the US</ProtocolTitle><Reference>A-046; NCT02413502</Reference><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><Trial id="227341"/><TrialStartDate>MAY      , 31, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3610">meloxicam</Drug><EnrollmentCount>200</EnrollmentCount><Interventions>meloxicam</Interventions><Patients>200</Patients><ProtocolAcronym/><ProtocolTitle>TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial</ProtocolTitle><Reference>NCT02060006; PRO13060453</Reference><Sponsor>University of Stellenbosch</Sponsor><Trial id="172626"/><TrialStartDate>APRIL    , 30, 2014</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>CD4+</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><EnrollmentCount>180</EnrollmentCount><Interventions>didanosine; efavirenz; efavirenz +  didanosine + lamivudine; ethambutol; ethambutol + isoniazid + rifampicin + pyrazinamide; isoniazid; isoniazid + rifampicin; lamivudine; nevirapine; nevirapine + didanosine + lamivudine; pyrazinamide; rifampicin</Interventions><Patients>116</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-Tuberculosis Treatment</ProtocolTitle><Reference>NCT00332306; trc23</Reference><Sponsor>Tuberculosis Research Centre</Sponsor><Trial id="10863"/><TrialStartDate>JUNE     , 30, 2006</TrialStartDate><TrialStatus>Suspended</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><EnrollmentCount>181</EnrollmentCount><Interventions>GSK-692342</Interventions><Patients>181</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (692342) in Healthy Adults</ProtocolTitle><Reference>110345; NCT00621322</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="11263"/><TrialStartDate>APRIL    , 30, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Hepatitis B large envelope protein; Hepatitis B virus external core antigen; T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="49219">tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences</Drug><EnrollmentCount>2073</EnrollmentCount><Interventions>efavirenz; isoniazid; lopinavir + ritonavir; tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences</Interventions><Patients>1107</Patients><ProtocolAcronym>TEMPRANO</ProtocolAcronym><ProtocolTitle>Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-Infected Adults</ProtocolTitle><Reference>ANRS 12136 TEMPRANO; NCT00495651; TEMPRANO</Reference><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><Trial id="195741"/><TrialStartDate>MARCH    , 31, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Arylamine N-acetyltransferase 2; Solute carrier organic anion transporter family member 1B1</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount/><Interventions>isoniazid; rifapentine</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics of rifapentine and isoniazid and NAT2 and SLCO1B1 polymorphisms in pediatric Thai patients with latent tuberculosis infection</ProtocolTitle><Reference>TCTR20190423002</Reference><Sponsor>Chulalongkorn University</Sponsor><Trial id="379095"/><TrialStartDate>JUNE     , 01, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>2516</EnrollmentCount><Interventions>ethambutol; isoniazid; moxifloxacin; pyrazinamide; pyridoxine; rifampin; rifapentine</Interventions><Patients>2516</Patients><ProtocolAcronym/><ProtocolTitle>Rifapentine-containing Tuberculosis Treatment Shortening Regimens</ProtocolTitle><Reference>6655; ACTG Study A5349; CTRI/2017/09/009772; NCT02410772; S31/A5349; TBTC Study 31</Reference><Sponsor>Centers for Disease Control and Prevention</Sponsor><Trial id="226815"/><TrialStartDate>JANUARY  , 25, 2016</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>566</EnrollmentCount><Interventions>isoniazid; rifapentine</Interventions><Patients>566</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention</ProtocolTitle><Reference>81373064; NCT02430259</Reference><Sponsor>Huashan Hospital</Sponsor><Trial id="228560"/><TrialStartDate>MARCH    , 31, 2015</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>BMI; Complete blood count; Erythrocyte sedimentation rate; Fasting blood glucose; Height; Hemoglobin; Serum albumin; Serum uric acid; Total body mass; Weight</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="16696">lamivudine + zidovudine, GlaxoSmithKline</Drug><EnrollmentCount>135</EnrollmentCount><Interventions>efavirenz; lamivudine + zidovudine, GlaxoSmithKline; nevirapine; rifampicin</Interventions><Patients>135</Patients><ProtocolAcronym>"NVP"</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB</ProtocolTitle><Reference>"NVP"; NCT01805258; SKS/NACO-1/2006-07</Reference><Sponsor>All India Institute of Medical Sciences</Sponsor><Trial id="114300"/><TrialStartDate>JUNE     , 30, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Blood platelets; Cytochrome P450 2B6</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="49219">tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences</Drug><EnrollmentCount>35</EnrollmentCount><Interventions>efavirenz; lamivudine+ zidovudine; rifampicin + isoniazid (Rifinah); tenofovir disoproxil fumarate + emtricitabine; tenofovir+ lamivudine</Interventions><Patients>26</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid</ProtocolTitle><Reference>2014-002608-26; NCT02832778; SSAT062</Reference><Sponsor>St Stephens Aids Trust</Sponsor><Trial id="265766"/><TrialStartDate>OCTOBER  , 21, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>900</EnrollmentCount><Interventions>bedaquiline; clofazimine; ethambutol; isoniazid; levofloxacin; linezolid; pyrazinamide; rifampicin; rifapentine</Interventions><Patients>900</Patients><ProtocolAcronym>TRUNCATE-TB</ProtocolAcronym><ProtocolTitle>A 2 Month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-Sensitive Tuberculosis</ProtocolTitle><Reference>2016-CT0376; NCT03474198; PHRR170327-001522; TRUNCATE-TB; TRUNCATE-TB</Reference><Sponsor>Syneos Health Inc, University College London</Sponsor><Trial id="333435"/><TrialStartDate>MARCH    , 21, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>4 beta-Hydroxycholesterol/Cholesterol ratio</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Lamprene; ethambutol (Myambutol); isoniazid (Nydrazid); kanamycin (Kantrex); moxifloxacin; prothionamide (Peteha); pyrazinamide (Zinamide)</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount>530</EnrollmentCount><Interventions>Lamprene; Regimen A locally-used WHO-approved MDR-TB regimen; bedaquiline; ethambutol (Myambutol); isoniazid (Nydrazid); kanamycin (Kantrex); levofloxacin; moxifloxacin; prothionamide (Peteha); pyrazinamide (Zinamide)</Interventions><Patients>530</Patients><ProtocolAcronym>STREAM</ProtocolAcronym><ProtocolTitle>The Evaluation of a Standard Treatment Regimen of Anti-Tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><Reference>18148631; 78372190; 78372190/18148631 (Stage 1/2); CTRI/2017/09/009693; ISRCTN78372190; NCT02409290; STREAM</Reference><Sponsor>International Union Against Tuberculosis and Lung Diseases</Sponsor><Trial id="228190"/><TrialStartDate>APRIL    , 30, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>6+</ArmCount><Biomarkers>Chemokines; Cytokines</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>262</EnrollmentCount><Interventions>ethambutol; ethambutol; isonizaid; isonizaid; moxifloxacin; moxifloxacin; pyrazindamide; pyrazindamide; rifampicin; rifampicin</Interventions><Patients>262</Patients><ProtocolAcronym/><ProtocolTitle>NexGen EBA Radiological and Immunological Biomarkers of Sterilizing Drug Activity in Tuberculosis</ProtocolTitle><Reference>15-I-N070; 999915070; NCT02371681</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="222933"/><TrialStartDate>FEBRUARY , 25, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>kanamycin; moxifloxacin</Controls><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount>300</EnrollmentCount><Interventions>bedaqualine; ethionamide; isoniazid; levofloxacin; linezolid; pyrazinamide; terizidone</Interventions><Patients>300</Patients><ProtocolAcronym>NEXT</ProtocolAcronym><ProtocolTitle>An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multidrug-resistant Tuberculosis</ProtocolTitle><Reference>NCT02454205; NEXT; NEXT-5001</Reference><Sponsor>University of Cape Town</Sponsor><Trial id="230529"/><TrialStartDate>OCTOBER  , 31, 2015</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>1500</EnrollmentCount><Interventions>isoniazid; rifapentine</Interventions><Patients>1500</Patients><ProtocolAcronym/><ProtocolTitle>Latent Mycobacterium tuberculosis infection treatment among individuals with a history of prior tuberculosis: a randomized, controlled trial</ProtocolTitle><Reference>ChiCTR1800018224</Reference><Sponsor>Chinese Academy of Medical Sciences &amp; Peking Union Medical College</Sponsor><Trial id="352729"/><TrialStartDate>SEPTEMBER, 01, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampin</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11089">nitazoxanide</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>ethambutol; isoniazid; nitazoxanide; pyrazinamide; rifampin</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>A 14-Day Early Bactericidal Activity Study of Nitazoxanide for the Treatment of Tuberculosis</ProtocolTitle><Reference>NCT02684240; NZT001</Reference><Sponsor>Weill Medical College of Cornell University</Sponsor><Trial id="253491"/><TrialStartDate>FEBRUARY , 29, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount>1556</EnrollmentCount><Interventions>levofloxacin</Interventions><Patients>1556</Patients><ProtocolAcronym>TB-CHAMP trial</ProtocolAcronym><ProtocolTitle>Tuberculosis child multidrug-resistant preventive therapy</ProtocolTitle><Reference>ISRCTN92634082; MR/M007340/1; TB-CHAMP trial</Reference><Sponsor>University of Stellenbosch</Sponsor><Trial id="259562"/><TrialStartDate>JANUARY  , 01, 2016</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>630</EnrollmentCount><Interventions>Lamprene; bedaquiline; linezolid; moxifloxacin; pretomanid</Interventions><Patients>630</Patients><ProtocolAcronym>TB-PRACTECAL</ProtocolAcronym><ProtocolTitle>Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)</ProtocolTitle><Reference>1541; NCT02589782; TB-PRACTECAL</Reference><Sponsor>Medecins Sans Frontieres</Sponsor><Trial id="244304"/><TrialStartDate>JANUARY  , 31, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2935">didanosine</Drug><EnrollmentCount>592</EnrollmentCount><Interventions>didanosine; efavirenz; lamivudine; standard TB therapy</Interventions><Patients>592</Patients><ProtocolAcronym/><ProtocolTitle>Effectiveness of Directly Observed Therapy in Combined HIV and Tuberculosis Treatment in Resource-Limited Settings</ProtocolTitle><Reference>CAPRISA 001; CAPRISA START; CIPRA; NCT00091936; START</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="8820"/><TrialStartDate>AUGUST   , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount/><Interventions>clarithromycin; levofloxacin; moxifloxacin; moxifloxacin; rifabutin</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>The research of new regimen for multidrug-resistant tuberculosis treatment</ProtocolTitle><Reference>ChiCTR-IOR-15007291</Reference><Sponsor>Beijing Chest Hospital, Beijing Tuberculosis &amp; Thoracic Tumor Research Institute, Capital Medical University</Sponsor><Trial id="244777"/><TrialStartDate>OCTOBER  , 01, 2008</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><EnrollmentCount>230</EnrollmentCount><Interventions>Viread; efavirenz; ethambutol; isoniazid; lamivudine; pyrazinamide; rifabutin; zidovudine</Interventions><Patients>230</Patients><ProtocolAcronym>RRHT</ProtocolAcronym><ProtocolTitle>Rifampicin versus Rifabutin in HIV/AIDS Patients Combined With Tuberculosis</ProtocolTitle><Reference>2017ZX10202101-002; NCT03478033; RRHT</Reference><Sponsor>Shanghai Public Health Clinical Center</Sponsor><Trial id="334027"/><TrialStartDate>APRIL    , 15, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Avelox</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>32</EnrollmentCount><Interventions>moxifloxacin, Synthesis</Interventions><Patients>32</Patients><ProtocolAcronym/><ProtocolTitle>Open-label, randomized, crossover study of the comparative pharmacokinetics and bioequivalence of drugs moxifloxacin film-coated tablets 400 mg (JSC "Synthesis", Russia) and Avelox tablets, film-coated 400 mg (Bayer Pharma AG, Germany) in healthy volunteers on an empty stomach</ProtocolTitle><Reference>21092015-MoxSin-001</Reference><Sponsor>Joint Stock Company Kurganskoye medicines and medical products" Synthesis</Sponsor><Trial id="255583"/><TrialStartDate>MARCH    , 04, 2016</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Avelox</Controls><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>42</EnrollmentCount><Interventions>moxifloxacin, Pharmasyntez</Interventions><Patients>42</Patients><ProtocolAcronym/><ProtocolTitle>Open, randomized, crossover study of comparative pharmacokinetics and bioequivalence of drugs Moxifloxacin tablets, film-coated, 400 mg (JSC "Pharmasyntez", Russia) and Avelox tablets, film-coated, 400 mg ("Bayer Pharma AG", Germany)</ProtocolTitle><Reference>P03 / 2015</Reference><Sponsor>Pharmasyntez</Sponsor><Trial id="247038"/><TrialStartDate>NOVEMBER , 23, 2015</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="87251">Perchlozone</Drug><EnrollmentCount>120</EnrollmentCount><Interventions>Perchlozone</Interventions><Patients>120</Patients><ProtocolAcronym/><ProtocolTitle>An Open, Prospective, Comparative, Randomized, Controlled Clinical Trial Of Efficacy And Safety Perhlozone Capsules (JSC 'Pharmasyntez', Russia), Used In Doses Of 9.5 And 12.5 mg/kg Night In The Complex Treatment Of Pulmonary Tuberculosis</ProtocolTitle><Reference>PERHL-02-2012</Reference><Sponsor>Pharmasyntez</Sponsor><Trial id="169098"/><TrialStartDate>JANUARY  , 28, 2013</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="6050">metformin hydrochloride</Drug><EnrollmentCount>316</EnrollmentCount><Interventions>ethambutol; isoniazid; metformin; pyrazinamide; rifampicin</Interventions><Patients>316</Patients><ProtocolAcronym/><ProtocolTitle>Metformin in tuberculosis</ProtocolTitle><Reference>CTRI/2018/01/011176; Version 1.0</Reference><Sponsor>Open Source Pharma Foundation, Tuberculosis Research Centre</Sponsor><Trial id="325158"/><TrialStartDate>NOVEMBER , 01, 2018</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4155">pravastatin</Drug><EnrollmentCount>40</EnrollmentCount><Interventions>ethambutol; isoniazid; pravastatin; pyrazinamide; rifampin</Interventions><Patients>40</Patients><ProtocolAcronym>StAT-TB</ProtocolAcronym><ProtocolTitle>Statin Adjunctive Therapy for TB</ProtocolTitle><Reference>IRB00145353; NCT03456102; StAT-TB</Reference><Sponsor>Johns Hopkins University</Sponsor><Trial id="331728"/><TrialStartDate>AUGUST   , 15, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Cytokines; T-Lymphocytes</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="71323">Ad5Ag85A</Drug><EnrollmentCount>28</EnrollmentCount><Interventions>Ad5Ag85A</Interventions><Patients>28</Patients><ProtocolAcronym/><ProtocolTitle>Phase I Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol</ProtocolTitle><Reference>M002; NCT02337270</Reference><Sponsor>McMaster University</Sponsor><Trial id="219950"/><TrialStartDate>SEPTEMBER, 05, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>background regimen therapy; bedaquiline</Interventions><Patients>60</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic Study to Evaluate Anti-Mycobacterial Activity of TMC-207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents Pulmonary MDR-TB</ProtocolTitle><Reference>2014-003372-23; 2016-CT0355; CR106371; CTRI/2018/03/012637; NCT02354014; PHRR160801-001314; TMC207-C211; TMC207-TIDP59-C211</Reference><Sponsor>Janssen Research &amp; Development LLC, Janssen-Cilag International NV (BE), Quintiles Philippines, Inc</Sponsor><Trial id="221523"/><TrialStartDate>MAY      , 03, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>lopinavir+ritonavir; rifabutin</Interventions><Patients>30</Patients><ProtocolAcronym>RIFLOPI</ProtocolAcronym><ProtocolTitle>Rifabutin With Lopinavir/ritonavir in Patients Coinfected With Tuberculosis and HIV in Burkina Faso</ProtocolTitle><Reference>PACTR201310000629390; RIFLOPI</Reference><Sponsor>Institut de Recherche en Sciences de la Sante (IRSS), Burkina Faso</Sponsor><Trial id="161441"/><TrialStartDate>NOVEMBER , 28, 2013</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>gatifloxacin; levofloxacin; moxifloxacin; p-aminosalycilic acid; prothionamide</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount>320</EnrollmentCount><Interventions>clofazimine; gatifloxacin; levofloxacin; moxifloxacin; p-aminosalycilic acid; prothionamide</Interventions><Patients>140</Patients><ProtocolAcronym/><ProtocolTitle>Multicenter, controlled clinical study of the safety, tolerability and efficacy of clofazimine in the treatment of drug-resistant tuberculosis</ProtocolTitle><Reference>ChiCTR1800014800</Reference><Sponsor>Beijing Chest Hospital</Sponsor><Trial id="328802"/><TrialStartDate>DECEMBER , 01, 2009</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount>900</EnrollmentCount><Interventions>bedaquiline; clofazimine; ethambutol; isoniazid; levofloxacin; linezolid; pyrazinamide; rifampicin; rifapentine</Interventions><Patients>900</Patients><ProtocolAcronym>TRUNCATE-TB</ProtocolAcronym><ProtocolTitle>A 2 Month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-Sensitive Tuberculosis</ProtocolTitle><Reference>2016-CT0376; NCT03474198; PHRR170327-001522; TRUNCATE-TB; TRUNCATE-TB</Reference><Sponsor>Syneos Health Inc, University College London</Sponsor><Trial id="333435"/><TrialStartDate>MARCH    , 21, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Rifafour e-275</Controls><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="13323">pretomanid</Drug><EnrollmentCount>69</EnrollmentCount><Interventions>PA-824</Interventions><Patients>69</Patients><ProtocolAcronym/><ProtocolTitle>Phase IIa Evaluation of Early Bactericidal Activity of PA-824 in Pulmonary Tuberculosis</ProtocolTitle><Reference>NCT00567840; PA-824-CL-007</Reference><Sponsor>TB Alliance</Sponsor><Trial id="9381"/><TrialStartDate>AUGUST   , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><EnrollmentCount>6</EnrollmentCount><Interventions>PA-824</Interventions><Patients>6</Patients><ProtocolAcronym>CL-004</ProtocolAcronym><ProtocolTitle>A Study of the Safety, Tolerability, and Absorption, Metabolism, and Excretion of PA-824 in Healthy Adult Male Subjects</ProtocolTitle><Reference>CL-004; NCT03202693; PA 824-CL-004</Reference><Sponsor>TB Alliance</Sponsor><Trial id="303299"/><TrialStartDate>MARCH    , 31, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bilirubin; Blood platelets; Calcium; Carbon dioxide; Chlorides; Creatine kinase; Creatinine; Diastolic blood pressure; Eosinophils; Erythrocytes; Glucose; Heart rate; Hematocrit; Hemoglobin; Leukocyte count; Lymphocytes; Mean corpuscular hemoglobin; Mean corpuscular volume; Monocytes; Neutrophils; Potassium; Reticulocytes; Sodium; Systolic blood pressure; Urea; gamma-Glutamyltransferase</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><EnrollmentCount>15</EnrollmentCount><Interventions>cabotegravir; cabotegravir; rifabutin</Interventions><Patients>15</Patients><ProtocolAcronym/><ProtocolTitle>Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects</ProtocolTitle><Reference>205712; NCT03149848</Reference><Sponsor>ViiV Healthcare Ltd</Sponsor><Trial id="298711"/><TrialStartDate>JUNE     , 06, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><EnrollmentCount>230</EnrollmentCount><Interventions>Viread; efavirenz; ethambutol; isoniazid; lamivudine; pyrazinamide; rifabutin; zidovudine</Interventions><Patients>230</Patients><ProtocolAcronym>RRHT</ProtocolAcronym><ProtocolTitle>Rifampicin versus Rifabutin in HIV/AIDS Patients Combined With Tuberculosis</ProtocolTitle><Reference>2017ZX10202101-002; NCT03478033; RRHT</Reference><Sponsor>Shanghai Public Health Clinical Center</Sponsor><Trial id="334027"/><TrialStartDate>APRIL    , 15, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="85970">telacebec</Drug><EnrollmentCount>70</EnrollmentCount><Interventions>Q-203, Qurient / Infectex</Interventions><Patients>70</Patients><ProtocolAcronym/><ProtocolTitle>Open, phase I clinical trial to evaluate the safety, tolerability and pharmacokinetic parameters of Q-203 after single and multiple doses in healthy volunteers</ProtocolTitle><Reference>INX-Q101</Reference><Sponsor>Infectex</Sponsor><Trial id="255234"/><TrialStartDate>JANUARY  , 12, 2016</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><EnrollmentCount>180</EnrollmentCount><Interventions>bedaquiline; linezolid; pretomanid</Interventions><Patients>180</Patients><ProtocolAcronym>ZeNiX</ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre-XDR-TB or Non-responsive/Intolerant MDR-TB</ProtocolTitle><Reference>NC-007- (B-Pa-L); NCT03086486; ZENIX (B-PA-L) NC-007; ZeNiX</Reference><Sponsor>TB Alliance</Sponsor><Trial id="293734"/><TrialStartDate>OCTOBER  , 31, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>clofazimine; ethambutol; isoniazid; kanamycin; moxifloxacin; prothionamide; pyrazinamide</Controls><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>250</EnrollmentCount><Interventions>clofazimine; econazole; ethambutol; isoniazid; kanamycin; moxifloxacin; prothionamide; pyrazinamide</Interventions><Patients>250</Patients><ProtocolAcronym>RESWMEN</ProtocolAcronym><ProtocolTitle>Using econazole to attempt to shorten the duration of treatment in MDR tuberculosis</ProtocolTitle><Reference>CTRI/2019/03/018237; PGI-MDR TB/01 version 2 dated 12.09.2018; RESWMEN</Reference><Sponsor>Indian Council of Medical Research</Sponsor><Trial id="374838"/><TrialStartDate>MAY      , 01, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>450</EnrollmentCount><Interventions>bedaquiline; moxifloxacin; pretomanid; pyrazinamide</Interventions><Patients>450</Patients><ProtocolAcronym>SIMPLICITB</ProtocolAcronym><ProtocolTitle>Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients</ProtocolTitle><Reference>39186; B-Pa-M-Z; NC-008; NC-008 (B-Pa-M-Z); NC-008 (B-Pa-M-Z) 39186; NCT03338621; NMRR-17-2826-39186; PHRR180723-001867; SIMPLICITB; SIMPLICITB (B-PA-M-Z) NC-008</Reference><Sponsor>PPD Pharmaceutical Development Philippines Corporation, TB Alliance</Sponsor><Trial id="319125"/><TrialStartDate>JULY     , 30, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="52139">ofloxacin</Drug><EnrollmentCount>217</EnrollmentCount><Interventions>gatifloxacin; isoniazid; moxifloxacin; ofloxacin; pyrazinamide; rifampicin</Interventions><Patients>217</Patients><ProtocolAcronym/><ProtocolTitle>A Comparative Study of the Bactericidal and Sterilising Activity of Three Fluoroquinolones: Gatifloxacin, Moxifloxacin and Ofloxacin Substituted for Ethambutol in the Two Month Initial Phase of the Standard Anti-Tuberculosis Treatment Regimen Also Containing Rifampicin, Isoniazid and Pyrazinamide (South Africa)</ProtocolTitle><Reference>ISRCTN13670619; RPC078</Reference><Sponsor>United Nations International Children's Fund</Sponsor><Trial id="152200"/><TrialStartDate>NOVEMBER , 25, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Alanine transaminase; Aspartate aminotransferase; Bilirubin; Blood cells; Creatine kinase; Creatinine; Estimated glomerular filtration rate; Lipase; Lipids</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="72148">darunavir + cobicistat (fixed dose, HIV infection), Janssen R&amp;D/ Gilead</Drug><EnrollmentCount>75</EnrollmentCount><Interventions>Prezcobix; dolutegravir; isoniazid; rifapentine</Interventions><Patients>75</Patients><ProtocolAcronym/><ProtocolTitle>Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers</ProtocolTitle><Reference>16-CC-0112; 160112; NCT02771249</Reference><Sponsor>National Institutes of Health Clinical Center</Sponsor><Trial id="260814"/><TrialStartDate>JUNE     , 03, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><EnrollmentCount>62</EnrollmentCount><Interventions>pretomanid</Interventions><Patients>62</Patients><ProtocolAcronym/><ProtocolTitle>Phase I clinical trial of single-dose of PA-824</ProtocolTitle><Reference>CTR20181897; LSF-157-SD-P-V1.2</Reference><Sponsor>Shanghai Fosun Pharmaceutical (Group) Co Ltd, Shanghai Fosun Pharmaceutical Industry Development Co Ltd</Sponsor><Trial id="362102"/><TrialStartDate>MARCH    , 14, 2018</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><EnrollmentCount>12</EnrollmentCount><Interventions>GSK-692342</Interventions><Patients>12</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD-Negative Adults</ProtocolTitle><Reference>692342/001; CCTB001-01; NCT00730795</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="23067"/><TrialStartDate>JANUARY  , 31, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>5+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>bedaquiline; bedaquiline; clofazimine; clofazimine; delamanid; delamanid; linezolid; linezolid</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>500</EnrollmentCount><Interventions>bedaquiline; clofazimine; delamanid; linezolid</Interventions><Patients>500</Patients><ProtocolAcronym>endTB-Q</ProtocolAcronym><ProtocolTitle>Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance</ProtocolTitle><Reference>MSF ERB-1761; NCT03896685; endTB-Q</Reference><Sponsor>Mdecins Sans Frontires France</Sponsor><Trial id="375499"/><TrialStartDate>JUNE     , 30, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>AS-02</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><EnrollmentCount>50</EnrollmentCount><Interventions>Mtb72F/AS02A</Interventions><Patients>50</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02 in Healthy PPD-Negative Adults</ProtocolTitle><Reference>102039; NCT00291889</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="9540"/><TrialStartDate>JULY     , 31, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>T-Helper Lymphocytes; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44309">ranitidine</Drug><EnrollmentCount>400</EnrollmentCount><Interventions>aspirin; isoniazid; levofloxacin; pyrazinamide; ranitidine; rifampicin</Interventions><Patients>400</Patients><ProtocolAcronym>SURE</ProtocolAcronym><ProtocolTitle>Short Intensive Treatment For Children With Tuberculous Meningitis</ProtocolTitle><Reference>ISRCTN40829906; SURE; SURE</Reference><Sponsor>University College London</Sponsor><Trial id="360104"/><TrialStartDate>JANUARY  , 02, 2018</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Heart rate; PR interval; QRS complex; QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><EnrollmentCount>380</EnrollmentCount><Interventions>Lamprene</Interventions><Patients>380</Patients><ProtocolAcronym/><ProtocolTitle>Clofazimine treatment of multidrug-resistant tuberculosis (MDRTB)</ProtocolTitle><Reference>2015-004440-19; CLAM320B2202</Reference><Sponsor>Novartis AG</Sponsor><Trial id="284370"/><TrialStartDate>MARCH    , 01, 2016</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Intracranial pressure</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><EnrollmentCount>36</EnrollmentCount><Interventions>Gabriox; ethambutol; isoniazid; pyrazinamide; rifampicin</Interventions><Patients>36</Patients><ProtocolAcronym>SIMPLE</ProtocolAcronym><ProtocolTitle>Pharmacokinetic Study of Linezolid for TB Meningitis</ProtocolTitle><Reference>NCT03537495; SIMPLE; TB-201805.01</Reference><Sponsor>Universitas Padjadjaran</Sponsor><Trial id="340851"/><TrialStartDate>JUNE     , 30, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="11036">linezolid</Drug><EnrollmentCount>448</EnrollmentCount><Interventions>amikacin; amoxicillin + clavulanate; azithromycin; bedaquiline; capreomycin; clarithromycin; clofazimine; cycloserine; delaminid; ethambutol; ethionamide; gatifloxacin; imipenem/cilastatin; isoniazid; kanamycin; levofloxacin; linezolid; meropenem; moxifloxacin; ofloxacin; para-aminosalicylic acid; pretomanid; prothionamide; pyrazinamide; rifabutin; rifampicin; streptomycin; sutezolid; terizidone; thioacetazone; whole genome sequencing</Interventions><Patients>448</Patients><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Reference>CAP 020; InDEX; NCT03237182</Reference><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><Trial id="307654"/><TrialStartDate>JUNE     , 14, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="55569">VPM-1002</Drug><EnrollmentCount>2000</EnrollmentCount><Interventions>VPM-1002</Interventions><Patients>2000</Patients><ProtocolAcronym/><ProtocolTitle>Phase II/III Study To Check The Efficacy And Safety Of Recombinant BCG Vaccine In TB Patients In India</ProtocolTitle><Reference>CTRI/2017/03/008266; VPM1002-IN-3.01TBR Version 2.0</Reference><Sponsor>Serum Institute of India Ltd</Sponsor><Trial id="292836"/><TrialStartDate>APRIL    , 01, 2017</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin; streptomycin</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><EnrollmentCount>100</EnrollmentCount><Interventions>ethambutol; isoniazid; linezolid; pyrazinamide; rifampicin; streptomycin</Interventions><Patients>100</Patients><ProtocolAcronym>ESCALATE</ProtocolAcronym><ProtocolTitle>To observe if administration of drug namely linezolid along with standard four drug regimen in intensive(initial) phase of Tubercular meningitis will help reduce death and disability among patients when compared to standard four drug antitubercular drug therapy alone</ProtocolTitle><Reference>CTRI/2019/06/019501; ESCALATE</Reference><Sponsor>All India Institute of Medical Sciences</Sponsor><Trial id="383209"/><TrialStartDate>JUNE     , 07, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44316">zidovudine</Drug><EnrollmentCount>230</EnrollmentCount><Interventions>Viread; efavirenz; ethambutol; isoniazid; lamivudine; pyrazinamide; rifabutin; zidovudine</Interventions><Patients>230</Patients><ProtocolAcronym>RRHT</ProtocolAcronym><ProtocolTitle>Rifampicin versus Rifabutin in HIV/AIDS Patients Combined With Tuberculosis</ProtocolTitle><Reference>2017ZX10202101-002; NCT03478033; RRHT</Reference><Sponsor>Shanghai Public Health Clinical Center</Sponsor><Trial id="334027"/><TrialStartDate>APRIL    , 15, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>38</EnrollmentCount><Interventions>rifapentine</Interventions><Patients>38</Patients><ProtocolAcronym/><ProtocolTitle>The safety and efficacy of high dose rifapentine in treatment of tuberculosis</ProtocolTitle><Reference>ChiCTR1800019294</Reference><Sponsor>Shanghai Public Health Clinical Center</Sponsor><Trial id="359664"/><TrialStartDate>JANUARY  , 01, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>CD4+</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="26574">lamivudine + abacavir + zidovudine, GSK</Drug><EnrollmentCount>350</EnrollmentCount><Interventions>lamivudine + abacavir + zidovudine</Interventions><Patients>350</Patients><ProtocolAcronym/><ProtocolTitle>Anti-HIV Drugs for Ugandan Patients With HIV and Tuberculosis</ProtocolTitle><Reference>1 R01 AI051219-01A2; 1R01AI051219-01A2; NCT00078247</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="8801"/><TrialStartDate>OCTOBER  , 31, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Blood pressure; Body temperature; Heart rate; Respiratory frequency</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="95442">ESAT-6CFP10</Drug><EnrollmentCount>96</EnrollmentCount><Interventions>ESAT-6CFP10; tuberculin purified protein derivative (AnHui Longcom Biologic Pharmacy Co Ltd)</Interventions><Patients>96</Patients><ProtocolAcronym/><ProtocolTitle>Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT-6CFP10 Allergen for Children</ProtocolTitle><Reference>LTAO-EC III-CHILDREN; NCT03027154</Reference><Sponsor>Anhui Zhifei Longcom Biopharmaceutical Co Ltd</Sponsor><Trial id="285889"/><TrialStartDate>OCTOBER  , 31, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Cytotoxic T-Lymphocytes; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="48499">H4:IC31</Drug><EnrollmentCount>84</EnrollmentCount><Interventions>BCG; H4 + IC31; SSI H56-IC31</Interventions><Patients>84</Patients><ProtocolAcronym>A-042</ProtocolAcronym><ProtocolTitle>Phase Ib, Safety and Immunogenicity Trial of BCG Revaccination, H4:IC31 and H56:IC31 in Healthy, HIV-1-Uninfected Adolescents</ProtocolTitle><Reference>A-042; HVTN 602 / AERAS A-042; NCT02378207</Reference><Sponsor>Aeras</Sponsor><Trial id="223463"/><TrialStartDate>MAY      , 31, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Cytokines; Immunoglobulin G</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="74849">SSI H56-IC31</Drug><EnrollmentCount>900</EnrollmentCount><Interventions>SSI H56-IC31</Interventions><Patients>900</Patients><ProtocolAcronym/><ProtocolTitle>Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence</ProtocolTitle><Reference>A-055; NCT03512249</Reference><Sponsor>Aeras</Sponsor><Trial id="337957"/><TrialStartDate>JANUARY  , 31, 2019</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>4+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>delamanid; ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="104447">OPC-167832</Drug><EnrollmentCount>125</EnrollmentCount><Interventions>OPC-167832; OPC-167832; delamanid</Interventions><Patients>125</Patients><ProtocolAcronym/><ProtocolTitle>A Phase I/II Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis</ProtocolTitle><Reference>323-201-00003; NCT03678688; OPP1178898</Reference><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><Trial id="353987"/><TrialStartDate>OCTOBER  , 25, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>C-reactive protein</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>etanercept</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4567">etanercept</Drug><EnrollmentCount>174</EnrollmentCount><Interventions>tofacitinib</Interventions><Patients>174</Patients><ProtocolAcronym/><ProtocolTitle>Risk of Tuberculosis and Other Infections in Patients of Spondyloarthritis Treated With Tofacitinib in Bangladesh</ProtocolTitle><Reference>2018/547; NCT03504072</Reference><Sponsor>Bangabandhu Sheikh Mujib Medical University</Sponsor><Trial id="337163"/><TrialStartDate>JANUARY  , 16, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>dolutegravir + lamivudine + tenofovir</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59062">dolutegravir</Drug><EnrollmentCount>108</EnrollmentCount><Interventions>dolutegravir; dolutegravir + lamivudine + tenofovir</Interventions><Patients>108</Patients><ProtocolAcronym>RADIANT-TB</ProtocolAcronym><ProtocolTitle>Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis</ProtocolTitle><Reference>CIDRI003; NCT03851588; RADIANT-TB</Reference><Sponsor>University of Cape Town</Sponsor><Trial id="371202"/><TrialStartDate>MAY      , 01, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>11</EnrollmentCount><Interventions>doravirine; isoniazid; rifapentine</Interventions><Patients>11</Patients><ProtocolAcronym>DORIIS</ProtocolAcronym><ProtocolTitle>Doravirine, Rifapentine and Isoniazid Interaction</ProtocolTitle><Reference>12690; DORIIS; NCT03886701</Reference><Sponsor>Thomas Jefferson University</Sponsor><Trial id="374387"/><TrialStartDate>APRIL    , 30, 2019</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55173">cadi-05</Drug><EnrollmentCount>300</EnrollmentCount><Interventions>cadi-05</Interventions><Patients>300</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis (Category I) Patients</ProtocolTitle><Reference>CR-01C-1/2003-10; NCT00341328; NI-894</Reference><Sponsor>Ministry of Science and Technology, India</Sponsor><Trial id="10866"/><TrialStartDate>MARCH    , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3474">lamivudine</Drug><EnrollmentCount>400</EnrollmentCount><Interventions>efavirenz; ethambutol; isoniazid; lamivudine; pyrazinamide; rifabutin; rifampicin; stavudine; zidovudine</Interventions><Patients>400</Patients><ProtocolAcronym/><ProtocolTitle>Acquired Immunodeficiency Syndrome (AIDS) and Tuberculosis (TB) Co-Infection Treatment Strategies Study of China</ProtocolTitle><Reference>2008ZX10001-008; NCT01344148</Reference><Sponsor>Shanghai Public Health Clinical Center</Sponsor><Trial id="76946"/><TrialStartDate>FEBRUARY , 28, 2009</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><EnrollmentCount>47</EnrollmentCount><Interventions>efavirenz; lopinavir + ritonavir; nevirapine; rifabutin</Interventions><Patients>47</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-Infection in Vietnam</ProtocolTitle><Reference>ANRS12150b; NCT00651066</Reference><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><Trial id="11188"/><TrialStartDate>JUNE     , 30, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Matrix Metalloproteinases; Metalloproteinase inhibitor 1; Procollagen type III-N-terminal peptide</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; pyridoxine; rifampicin</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="46927">doxycycline hyclate</Drug><EnrollmentCount>40</EnrollmentCount><Interventions>doxycycline hyclate; ethambutol; isoniazid; pyrazinamide; pyridoxine; rifampicin</Interventions><Patients>40</Patients><ProtocolAcronym>Doxy-TB</ProtocolAcronym><ProtocolTitle>Doxycycline in Human Pulmonary Tuberculosis</ProtocolTitle><Reference>DOXY_TB; Doxy-TB; NCT02774993</Reference><Sponsor>National University Hospital (Singapore) Pte Ltd</Sponsor><Trial id="261320"/><TrialStartDate>SEPTEMBER, 30, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount>111</EnrollmentCount><Interventions>levofloxacin; optimized background regimen therapy</Interventions><Patients>101</Patients><ProtocolAcronym>Opti-Q</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB</ProtocolTitle><Reference>1U01AI100805 - 01A1; H-32150; NCT01918397; Opti-Q; TBTC Study 32</Reference><Sponsor>Boston University</Sponsor><Trial id="149562"/><TrialStartDate>JANUARY  , 31, 2015</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>4+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>32</EnrollmentCount><Interventions>bedaquiline; bedaquiline; rifampicin; rifampicin; rifapentine; rifapentine</Interventions><Patients>32</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic Interaction Between Rifapentine or Rifampicin and a Single-dose of TMC-207 in Healthy Subjects</ProtocolTitle><Reference>NCT02216331; TMC207-CL002</Reference><Sponsor>TB Alliance</Sponsor><Trial id="208141"/><TrialStartDate>MARCH    , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>410</EnrollmentCount><Interventions>isoniazid; moxifloxacin</Interventions><Patients>410</Patients><ProtocolAcronym>TBTC/UITB Study 28</ProtocolAcronym><ProtocolTitle>Evaluation of a Moxifloxacin-Based, Isoniazid-Sparing Regimen for Tuberculosis Treatment TBTC/UITB Study 28</ProtocolTitle><Reference>EudraCT 2005-003312-29; TBTC/UITB Study 28</Reference><Sponsor>Tuberculosis Investigation Unit of Barcelona</Sponsor><Trial id="155451"/><TrialStartDate>MAY      , 01, 2006</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>CD4+ T cell</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>efavirenz; rifabutin; rifabutin</Interventions><Patients>15</Patients><ProtocolAcronym>TBTC-23C</ProtocolAcronym><ProtocolTitle>Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz</ProtocolTitle><Reference>23C; CDC-NCHSTP-2588; NCT00023413; TBTC-23C</Reference><Sponsor>Centers for Disease Control and Prevention</Sponsor><Trial id="10657"/><TrialStartDate>NOVEMBER , 30, 1999</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers>CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>142</EnrollmentCount><Interventions>efavirenz; nevirapine</Interventions><Patients>145</Patients><ProtocolAcronym>N2R</ProtocolAcronym><ProtocolTitle>Efavirenz-Based Versus Nevirapine-Based Antiretroviral Therapy Among HIV-Infected Patients Receiving Rifampin</ProtocolTitle><Reference>210041000824904203; N2R; NCT00483054</Reference><Sponsor>Bamrasnaradura Infectious Diseases Institute</Sponsor><Trial id="10947"/><TrialStartDate>JANUARY  , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>130</EnrollmentCount><Interventions>efavirenz; isoniazid; lamivudine; pyrazinamide; rifampicin; zidovudine</Interventions><Patients>130</Patients><ProtocolAcronym>IPEC-EFV</ProtocolAcronym><ProtocolTitle>Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X  800 mg</ProtocolTitle><Reference>CAAE-0017.1.009.000-03; IPEC-EFV; NCT00533390</Reference><Sponsor>Fundacao Oswaldo Cruz (Fiocruz)</Sponsor><Trial id="11181"/><TrialStartDate>JANUARY  , 31, 2007</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><EnrollmentCount>214</EnrollmentCount><Interventions>MVA-85A</Interventions><Patients>214</Patients><ProtocolAcronym/><ProtocolTitle>Safety, Immunogenicity and Impact of MVA-85A, on the Immunogenicity of the EPI Vaccines</ProtocolTitle><Reference>NCT00480454; TB012</Reference><Sponsor>University of Oxford</Sponsor><Trial id="52375"/><TrialStartDate>OCTOBER  , 31, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>18</EnrollmentCount><Interventions>moxifloxacin; moxifloxacin (HiGlance Laboratories pvt.Ltd)</Interventions><Patients>18</Patients><ProtocolAcronym/><ProtocolTitle>An Open-Label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Haynemoks, 400 mg (Hayglans Laboratories Pvt. Ltd., India) and Avelox, 400 mg (Bayer Healthcare AG, Germany) in Healthy Volunteers</ProtocolTitle><Reference>CPM-09-2012</Reference><Sponsor>HiGlance Laboratories Pvt ltd</Sponsor><Trial id="168898"/><TrialStartDate>OCTOBER  , 29, 2012</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44316">zidovudine</Drug><EnrollmentCount>400</EnrollmentCount><Interventions>efavirenz; ethambutol; isoniazid; lamivudine; pyrazinamide; rifabutin; rifampicin; stavudine; zidovudine</Interventions><Patients>400</Patients><ProtocolAcronym/><ProtocolTitle>Acquired Immunodeficiency Syndrome (AIDS) and Tuberculosis (TB) Co-Infection Treatment Strategies Study of China</ProtocolTitle><Reference>2008ZX10001-008; NCT01344148</Reference><Sponsor>Shanghai Public Health Clinical Center</Sponsor><Trial id="76946"/><TrialStartDate>FEBRUARY , 28, 2009</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>5</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid</Controls><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="7017">gatifloxacin</Drug><EnrollmentCount>70</EnrollmentCount><Interventions>gatifloxacin; levofloxacin; linezolid; moxifloxacin</Interventions><Patients>70</Patients><ProtocolAcronym>TBRU 10</ProtocolAcronym><ProtocolTitle>Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis</ProtocolTitle><Reference>01-553; NCT00396084; TBRU 10; TBRU 10</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="10869"/><TrialStartDate>FEBRUARY , 29, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>16</EnrollmentCount><Interventions>TMC-207; nevirapine</Interventions><Patients>16</Patients><ProtocolAcronym/><ProtocolTitle>TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)</ProtocolTitle><Reference>CR015793; NCT00910806; NCT00980668; TMC207-TiDP13-C117</Reference><Sponsor>Janssen Diagnostics BVBA, Johnson &amp; Johnson</Sponsor><Trial id="56959"/><TrialStartDate>JUNE     , 30, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Rifafour</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><EnrollmentCount>85</EnrollmentCount><Interventions>PA-824; Rifafour; TMC-207; moxifloxacin; pyrazinamide</Interventions><Patients>65</Patients><ProtocolAcronym/><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With</ProtocolTitle><Reference>NC-001; NC-001-(J-M-Pa-Z); NCT01215851</Reference><Sponsor>TB Alliance</Sponsor><Trial id="71107"/><TrialStartDate>OCTOBER  , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>rifafour</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><EnrollmentCount>69</EnrollmentCount><Interventions>PA-824</Interventions><Patients>60</Patients><ProtocolAcronym/><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis</ProtocolTitle><Reference>CL-010; NCT00944021; PA-824-CL-010</Reference><Sponsor>TB Alliance</Sponsor><Trial id="59043"/><TrialStartDate>AUGUST   , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>28</EnrollmentCount><Interventions>TMC-207</Interventions><Patients>28</Patients><ProtocolAcronym/><ProtocolTitle>A Study to Determine the Relative Oral Bioavailability of Single Dose Administration of TMC207, Under Fed and Fasted Conditions in Healthy Participants</ProtocolTitle><Reference>CR007504; NCT00946842; TMC207-TiDP13-C111</Reference><Sponsor>Janssen Diagnostics BVBA</Sponsor><Trial id="59134"/><TrialStartDate>AUGUST   , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>MVA-85A</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>Safety of Tuberculosis Vaccine, MVA-85A, Administered by the Intramuscular Route and the Intradermal Route</ProtocolTitle><Reference>076943; 2009-015973-11; ISRCTN46804531; NCT01181856; TB022</Reference><Sponsor>University of Oxford</Sponsor><Trial id="69212"/><TrialStartDate>JANUARY  , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54488">raltegravir</Drug><EnrollmentCount>18</EnrollmentCount><Interventions>raltegravir</Interventions><Patients>18</Patients><ProtocolAcronym>RIFRAL</ProtocolAcronym><ProtocolTitle>The Effect of Intermittent Rifampicin on Raltegravir</ProtocolTitle><Reference>2010-021461-73; NCT01424826; RIFRAL; UKCRN 12695; UoL000643</Reference><Sponsor>The University of Liverpool</Sponsor><Trial id="80394"/><TrialStartDate>JANUARY  , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Cytokines; Interferon gamma; Interleukin-2; T-Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="53975">AERAS-402</Drug><EnrollmentCount>487</EnrollmentCount><Interventions>AERAS-402</Interventions><Patients>487</Patients><ProtocolAcronym/><ProtocolTitle>Study of AERAS-402 in Healthy Infants</ProtocolTitle><Reference>C-029-402; NCT01198366; PACTR201203000306280</Reference><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><Trial id="70158"/><TrialStartDate>SEPTEMBER, 30, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Cytokine</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>TiceBCG</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="62397">AERAS-407 rBCG</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>AERAS-422</Interventions><Patients>24</Patients><ProtocolAcronym>AERAS 422</ProtocolAcronym><ProtocolTitle>Study of AERAS-422 in Healthy Adults</ProtocolTitle><Reference>AERAS 422; C-007-422; NCT01340820</Reference><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><Trial id="76756"/><TrialStartDate>DECEMBER , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>16</EnrollmentCount><Interventions>TMC-207</Interventions><Patients>16</Patients><ProtocolAcronym/><ProtocolTitle>A Study to Investigate Pharmacokinetics, Safety and Tolerability of TMC-207 in Patients With Moderately Impaired Hepatic Function</ProtocolTitle><Reference>2009-016437-99; CR007501; NCT01012284; TMC207-TiDP13-C112</Reference><Sponsor>Janssen Diagnostics BVBA</Sponsor><Trial id="61895"/><TrialStartDate>JANUARY  , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampin</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>433</EnrollmentCount><Interventions>ethambutol; moxifloxacin; pyrazinamide; rifampin</Interventions><Patients>433</Patients><ProtocolAcronym/><ProtocolTitle>TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment</ProtocolTitle><Reference>CDC-NCHSTP-4448; NCT00144417</Reference><Sponsor>Centers for Disease Control and Prevention</Sponsor><Trial id="10685"/><TrialStartDate>FEBRUARY , 28, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>CD4; CD8</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="53975">AERAS-402</Drug><EnrollmentCount>12</EnrollmentCount><Interventions>AERAS-402</Interventions><Patients>12</Patients><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate Safety and Immunogenicity of AERAS-402</ProtocolTitle><Reference>C004-402; NCT01378312</Reference><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><Trial id="78482"/><TrialStartDate>FEBRUARY , 28, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Cytochrome (CYP) enzyme</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3517">losartan</Drug><EnrollmentCount>13</EnrollmentCount><Interventions>caffeine; dextromethorphan; losartan; midazolam; omeprazole; rifampicin</Interventions><Patients>13</Patients><ProtocolAcronym/><ProtocolTitle>The Influence of Rifampicin Discontinuation on Rifampicin-Induced Cytochrome P450 Enzyme Activity</ProtocolTitle><Reference>JPRN-UMIN000004083</Reference><Sponsor>Hamamatsu University School of Medicine</Sponsor><Trial id="122291"/><TrialStartDate>JULY     , 01, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><EnrollmentCount>90</EnrollmentCount><Interventions>Rimactane, Rifadin, Tubocin, Benemycin; lopinavir+ritonavir</Interventions><Patients>90</Patients><ProtocolAcronym/><ProtocolTitle>An Open-Label, Sequential Non-Randomized Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir Superboosted With Ritonavir (1 : 1 Ratio) in the Presence of Rifampicin or Lopinavir Boosted With Ritonavir (4 : 1 Ratio) in the Absence of Rifampicin in HIV and TB Co-Infected Children in South Africa</ProtocolTitle><Reference>PACTR201302000426554</Reference><Sponsor>Drugs for Neglected Diseases Initiative</Sponsor><Trial id="142540"/><TrialStartDate>DECEMBER , 01, 2012</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>CD4 T cells; CD8 T cells; IFN-gamma; IL-17; IL-2; TNF-alpha</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Candin</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><EnrollmentCount>248</EnrollmentCount><Interventions>MVA-85A</Interventions><Patients>248</Patients><ProtocolAcronym>MVA(TB)029</ProtocolAcronym><ProtocolTitle>Safety and Immunogenicity of MVA-85A Prime and Bacille Calmette-Guerin Boost Vaccination</ProtocolTitle><Reference>G1100570; G1100570/1; MVA(TB)029; NCT01650389</Reference><Sponsor>University of Cape Town</Sponsor><Trial id="89833"/><TrialStartDate>OCTOBER  , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Anti-Meningitis C antibodies; C-C motif chemokine 2; C-C motif chemokine 3; C-C motif chemokine 4; Cytokines; IgG; Interferon gamma; Interferon-alpha; Interleukin-1 alpha; Interleukin-1 beta; Interleukin-10; Interleukin-12; Interleukin-13; Interleukin-2; Interleukin-6</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12813">Rotarix</Drug><EnrollmentCount>28</EnrollmentCount><Interventions>BCG; Infanrix; Menitorix; NeisVac-C; Pentacel; Prevnar 13; Priorix; Rotarix</Interventions><Patients>28</Patients><ProtocolAcronym>BAM</ProtocolAcronym><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><Reference>2013-003488-71; BAM; NCT02002156; OVG-2013/04; UKCRN 15722</Reference><Sponsor>University of Oxford</Sponsor><Trial id="162886"/><TrialStartDate>JUNE     , 20, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><EnrollmentCount>6</EnrollmentCount><Interventions>amikacin; amoxicillin-clavulanate; bedaquiline; clofazimine; cycloserine; enviomycin; ethambutol; ethionamide; fluoroquinolone therapy; kanamycin; levofloxacin; linezolid; para-aminosalicylic acid; pyrazinamide; streptomycin</Interventions><Patients>6</Patients><ProtocolAcronym/><ProtocolTitle>An Exploratory Study of TMC-207 in Japanese Participants with Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)</ProtocolTitle><Reference>CR105158; JapicCTI-163116; NCT02365623; TMC207TBC2001</Reference><Sponsor>Janssen Pharmaceutical KK</Sponsor><Trial id="222400"/><TrialStartDate>FEBRUARY , 18, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8255">nelfinavir</Drug><EnrollmentCount>44</EnrollmentCount><Interventions>lamivudine; nelfinavir mesylate; rifabutin; stavudine; zidovudine</Interventions><Patients>44</Patients><ProtocolAcronym/><ProtocolTitle>Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis</ProtocolTitle><Reference>AACTG A5062; ACTG A5062; NCT00004736</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="10646"/><TrialStartDate>FEBRUARY , 25, 2000</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>661</EnrollmentCount><Interventions>efavirenz; efavirenz + lamivudine + stavudine; lamivudine; stavudine</Interventions><Patients>540</Patients><ProtocolAcronym>ANRS 1295 CAMELIA</ProtocolAcronym><ProtocolTitle>Early versus Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis</ProtocolTitle><Reference>ANRS 1295 CAMELIA; ANRS 1295 CAMELIA; CIPRA KH 001; NCT00226434; NCT00498823</Reference><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><Trial id="145651"/><TrialStartDate>JANUARY  , 31, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44316">zidovudine</Drug><EnrollmentCount>150</EnrollmentCount><Interventions>efavirenz; ethambutol; isoniazid; lamivudine; nevirapine; pyrazinamide; rifampicin; zidovudine</Interventions><Patients>355</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis</ProtocolTitle><Reference>NCT00698334; SKS/NACO/2006</Reference><Sponsor>All India Institute of Medical Sciences</Sponsor><Trial id="161275"/><TrialStartDate>APRIL    , 30, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><EnrollmentCount>26</EnrollmentCount><Interventions>linezolid</Interventions><Patients>26</Patients><ProtocolAcronym>S30PK</ProtocolAcronym><ProtocolTitle>Linezolid Pharmacokinetics (PK) in Multi-Drug Resistant (MDR)/Extensively-Drug Resistant (XDR) Tuberculosis (TB)</ProtocolTitle><Reference>NCT00691392; S30PK; TBTC Study 30PK</Reference><Sponsor>Centers for Disease Control and Prevention</Sponsor><Trial id="48035"/><TrialStartDate>APRIL    , 30, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="98373">TB/FLU-04L</Drug><EnrollmentCount>36</EnrollmentCount><Interventions>TB/FLU-04L</Interventions><Patients>36</Patients><ProtocolAcronym/><ProtocolTitle>Reactogenicity, Safety and Immunogenicity of a TB/FLU-04L Tuberculosis Vaccine</ProtocolTitle><Reference>NCT02501421; VPT-I-01/2013</Reference><Sponsor>National Center for Biotechnology of the Republic of Kazakhstan</Sponsor><Trial id="235054"/><TrialStartDate>OCTOBER  , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><EnrollmentCount>42</EnrollmentCount><Interventions>nevirapine</Interventions><Patients>42</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy Safety Study Comparing two Doses of NVP After Initiating Rifampin-Containing TB Therapy</ProtocolTitle><Reference>HIV-NAT 033; NCT00476853</Reference><Sponsor>The HIV Netherlands Australia Thailand Research Collaboration</Sponsor><Trial id="10946"/><TrialStartDate>OCTOBER  , 31, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="39069">simeprevir</Drug><EnrollmentCount>21</EnrollmentCount><Interventions>TMC-435; TMC-435; rifampin; rifampin</Interventions><Patients>21</Patients><ProtocolAcronym/><ProtocolTitle>TMC-435350-TiDP16-C105:  Phase I, Three-Way Crossover, Drug-Drug Interaction Between TMC-435350 and Rifampin After Multiple Dosing</ProtocolTitle><Reference>CR015412; NCT00741169; TMC-435350-TiDP16-C105</Reference><Sponsor>Janssen R&amp;D (Ireland)</Sponsor><Trial id="25800"/><TrialStartDate>JUNE     , 30, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers>CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><EnrollmentCount>142</EnrollmentCount><Interventions>efavirenz; nevirapine</Interventions><Patients>145</Patients><ProtocolAcronym>N2R</ProtocolAcronym><ProtocolTitle>Efavirenz-Based Versus Nevirapine-Based Antiretroviral Therapy Among HIV-Infected Patients Receiving Rifampin</ProtocolTitle><Reference>210041000824904203; N2R; NCT00483054</Reference><Sponsor>Bamrasnaradura Infectious Diseases Institute</Sponsor><Trial id="10947"/><TrialStartDate>JANUARY  , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Solute carrier organic anion transporter family member 1B1</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><EnrollmentCount>48</EnrollmentCount><Interventions>efavirenz; isoniazid; lamivudine; lopinavir + ritonavir; nevirapine; rifabutin; stavudine</Interventions><Patients>35</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa</ProtocolTitle><Reference>ANRS12150a; NCT00640887</Reference><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><Trial id="11187"/><TrialStartDate>FEBRUARY , 28, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44316">zidovudine</Drug><EnrollmentCount>44</EnrollmentCount><Interventions>lamivudine; nelfinavir mesylate; rifabutin; stavudine; zidovudine</Interventions><Patients>44</Patients><ProtocolAcronym/><ProtocolTitle>Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis</ProtocolTitle><Reference>AACTG A5062; ACTG A5062; NCT00004736</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="10646"/><TrialStartDate>FEBRUARY , 25, 2000</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>44</EnrollmentCount><Interventions>efavirenz; pyridoxine</Interventions><Patients>44</Patients><ProtocolAcronym>PrOMPT</ProtocolAcronym><ProtocolTitle>Prevention of Early Mortality by Presumptive Tuberculosis (TB) Treatment</ProtocolTitle><Reference>AIGHD_001; NCT01417988; PrOMPT</Reference><Sponsor>University of Amsterdam</Sponsor><Trial id="182316"/><TrialStartDate>AUGUST   , 31, 2011</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="87251">Perchlozone</Drug><EnrollmentCount>340</EnrollmentCount><Interventions>Perchlozone</Interventions><Patients>340</Patients><ProtocolAcronym/><ProtocolTitle>Multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of the drug Perhlozone in the treatment of patients with pulmonary MDR MBT, including the presence of HIV infection</ProtocolTitle><Reference>PERHL-03-2013</Reference><Sponsor>Pharmasyntez</Sponsor><Trial id="183939"/><TrialStartDate>APRIL    , 08, 2014</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Hepatitis B large envelope protein; Hepatitis B virus external core antigen; T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>2073</EnrollmentCount><Interventions>efavirenz; isoniazid; lopinavir + ritonavir; tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences</Interventions><Patients>1107</Patients><ProtocolAcronym>TEMPRANO</ProtocolAcronym><ProtocolTitle>Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-Infected Adults</ProtocolTitle><Reference>ANRS 12136 TEMPRANO; NCT00495651; TEMPRANO</Reference><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><Trial id="195741"/><TrialStartDate>MARCH    , 31, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>CD4 Positive T Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2935">didanosine</Drug><EnrollmentCount>642</EnrollmentCount><Interventions>didanosine; efavirenz; lamivudine; lamivudine + efavirenz + didanosine; trimethoprim + sulfamethoxazole</Interventions><Patients>642</Patients><ProtocolAcronym>SAPIT</ProtocolAcronym><ProtocolTitle>A Study to Compare Three Existing Starting Points of Antiretroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients</ProtocolTitle><Reference>CAPRISA 003; NCT00398996; SAPIT</Reference><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><Trial id="201474"/><TrialStartDate>JUNE     , 30, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>32</EnrollmentCount><Interventions>bedaquiline; bedaquiline; rifampicin; rifampicin; rifapentine; rifapentine</Interventions><Patients>32</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic Interaction Between Rifapentine or Rifampicin and a Single-dose of TMC-207 in Healthy Subjects</ProtocolTitle><Reference>NCT02216331; TMC207-CL002</Reference><Sponsor>TB Alliance</Sponsor><Trial id="208141"/><TrialStartDate>MARCH    , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>8</ArmCount><Biomarkers>Body Mass Index; Body height; Interferon gamma; Regulatory T-Lymphocytes; Th1 cells; Th2 cells; Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>albendazole; ivermectin; metronidazole</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12132">albendazole</Drug><EnrollmentCount>120</EnrollmentCount><Interventions>Nutritional Supplementation Meal; albendazole; ivermectin; metronidazole; multivitamin therapy</Interventions><Patients>120</Patients><ProtocolAcronym>TB-LION</ProtocolAcronym><ProtocolTitle>Tuberculosis - Learning the Impact of Nutrition</ProtocolTitle><Reference>6005415; CTRI/2019/05/018968; H-37473; NCT03598842; TB-LION</Reference><Sponsor>Boston Medical Center Corp</Sponsor><Trial id="347635"/><TrialStartDate>JUNE     , 30, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>150</EnrollmentCount><Interventions>isoniazid; rifapentine</Interventions><Patients>150</Patients><ProtocolAcronym>TBTC Study 25</ProtocolAcronym><ProtocolTitle>TBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the Treatment of Tuberculosis</ProtocolTitle><Reference>25; CDC-NCHSTP-2404; HCK45; NCT00023426; TBTC Study 25</Reference><Sponsor>Centers for Disease Control and Prevention</Sponsor><Trial id="8751"/><TrialStartDate>JULY     , 31, 1999</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="87251">Perchlozone</Drug><EnrollmentCount>200</EnrollmentCount><Interventions>Perchlozone</Interventions><Patients>200</Patients><ProtocolAcronym/><ProtocolTitle>An international, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of Perchlozone in the treatment of patients with pulmonary tuberculosis with MDR-TB, including HIV</ProtocolTitle><Reference>PERHL-03-2013-i</Reference><Sponsor>Pharmasyntez</Sponsor><Trial id="291547"/><TrialStartDate>MARCH    , 10, 2017</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Cytokines; Cytotoxic T-Lymphocytes; Immunoglobulin G; Interferon gamma; Interleukin-2; T-Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Th1 cytokines; Th2 cytokines; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="68617">ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis</Drug><EnrollmentCount>70</EnrollmentCount><Interventions>AP10-602; GLA-SE; ID-93; ID-93</Interventions><Patients>70</Patients><ProtocolAcronym/><ProtocolTitle>Safety, Tolerability and Immunogenicity of the Vaccine Candidates ID-93 + AP10-602 and ID-93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects</ProtocolTitle><Reference>12-0109; HHSN272201300020I; NCT02508376</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="235751"/><TrialStartDate>OCTOBER  , 22, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="30819">tedizolid phosphate</Drug><EnrollmentCount/><Interventions>rifampicin; torezolid</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>Evaluating Pharmacokinetics and Whole Blood Bactericidal Activity Against Mycobacterium Tuberculosis of Single-Doses of Tedizolid Plus Rifampicin in Healthy Volunteers</ProtocolTitle><Reference>2017/00909</Reference><Sponsor>National University Hospital (Singapore) Pte Ltd</Sponsor><Trial id="331225"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Alanine transaminase; Aspartate aminotransferase; Bilirubin; Blood cells; Creatine kinase; Creatinine; Estimated glomerular filtration rate; Lipase; Lipids</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>75</EnrollmentCount><Interventions>Prezcobix; dolutegravir; isoniazid; rifapentine</Interventions><Patients>75</Patients><ProtocolAcronym/><ProtocolTitle>Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers</ProtocolTitle><Reference>16-CC-0112; 160112; NCT02771249</Reference><Sponsor>National Institutes of Health Clinical Center</Sponsor><Trial id="260814"/><TrialStartDate>JUNE     , 03, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bicarbonates; Bilirubin; Blood platelets; Calcium; Chlorides; Creatine kinase; Creatinine; Diastolic blood pressure; Eosinophils; Erythrocytes; Glucose; Heart rate; Hematocrit; Hemoglobin; Leukocyte count; Lymphocytes; Monocytes; Neutrophils; Potassium; Sodium; Systolic blood pressure; Total protein; Urea; Uric acid</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid; rifampicin</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="89460">rifampicin + isoniazid (fixed dose combination, tuberculosis), Pfizer</Drug><EnrollmentCount>28</EnrollmentCount><Interventions>rifampicin + isoniazid (fixed dose combination, tuberculosis), Pfizer</Interventions><Patients>28</Patients><ProtocolAcronym/><ProtocolTitle>A Bioequivalence Study Comparing A Fixed Dose Combination Formulation, RIN-150 And Individual Reference Drugs In Healthy Volunteers</ProtocolTitle><Reference>B3801003; NCT02014272</Reference><Sponsor>Pfizer Inc</Sponsor><Trial id="164292"/><TrialStartDate>SEPTEMBER, 30, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>4027</EnrollmentCount><Interventions>isoniazid; isoniazid; rifapentine</Interventions><Patients>4027</Patients><ProtocolAcronym>WHIP3TB</ProtocolAcronym><ProtocolTitle>Evaluation of the Effect of 3HP versus Periodic 3HP versus 6H in HIV-Positive Individuals</ProtocolTitle><Reference>3HP-AUR1-1-170; NCT02980016; WHIP3TB</Reference><Sponsor>Aurum Institute</Sponsor><Trial id="281055"/><TrialStartDate>NOVEMBER , 30, 2016</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid; rifampin; rifapentine</Controls><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>3400</EnrollmentCount><Interventions>rifapentine</Interventions><Patients>3400</Patients><ProtocolAcronym>ASTEROID</ProtocolAcronym><ProtocolTitle>Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI</ProtocolTitle><Reference>ASTEROID; CDC-NCHSTP-7024; NCT03474029</Reference><Sponsor>Centers for Disease Control and Prevention</Sponsor><Trial id="333384"/><TrialStartDate>JULY     , 31, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="82062">ethambutol hydrochloride (250 mg) + pyrazinamide (400 mg) + rifampicin (120 mg) + isoniazid (120 mg) (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>Double J stent; ethambutol hydrochloride + pyrazinamide + rifampicin + isoniazid</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>The Efficacy and Safety of Early Double J Stent Placement in Treatment of Renal Tuberculosis: A Novel Renal Function Protective Strategy</ProtocolTitle><Reference>ACTRN12612001244897; U1111-1136-5967</Reference><Sponsor>Shanghai Changzheng Hospital</Sponsor><Trial id="132105"/><TrialStartDate>JUNE     , 06, 2012</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>2516</EnrollmentCount><Interventions>ethambutol; isoniazid; moxifloxacin; pyrazinamide; pyridoxine; rifampin; rifapentine</Interventions><Patients>2516</Patients><ProtocolAcronym/><ProtocolTitle>Rifapentine-containing Tuberculosis Treatment Shortening Regimens</ProtocolTitle><Reference>6655; ACTG Study A5349; CTRI/2017/09/009772; NCT02410772; S31/A5349; TBTC Study 31</Reference><Sponsor>Centers for Disease Control and Prevention</Sponsor><Trial id="226815"/><TrialStartDate>JANUARY  , 25, 2016</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>4 beta-Hydroxycholesterol/Cholesterol ratio</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Lamprene; ethambutol (Myambutol); isoniazid (Nydrazid); kanamycin (Kantrex); moxifloxacin; prothionamide (Peteha); pyrazinamide (Zinamide)</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>530</EnrollmentCount><Interventions>Lamprene; Regimen A locally-used WHO-approved MDR-TB regimen; bedaquiline; ethambutol (Myambutol); isoniazid (Nydrazid); kanamycin (Kantrex); levofloxacin; moxifloxacin; prothionamide (Peteha); pyrazinamide (Zinamide)</Interventions><Patients>530</Patients><ProtocolAcronym>STREAM</ProtocolAcronym><ProtocolTitle>The Evaluation of a Standard Treatment Regimen of Anti-Tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><Reference>18148631; 78372190; 78372190/18148631 (Stage 1/2); CTRI/2017/09/009693; ISRCTN78372190; NCT02409290; STREAM</Reference><Sponsor>International Union Against Tuberculosis and Lung Diseases</Sponsor><Trial id="228190"/><TrialStartDate>APRIL    , 30, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Creatinine; Human immunodeficiency virus RNA; T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C0">Phase 0 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><EnrollmentCount>419</EnrollmentCount><Interventions>efavirenz; emtricitabine; lamivudine; tenofovir</Interventions><Patients>419</Patients><ProtocolAcronym/><ProtocolTitle>TasP in Correctional Facilities</ProtocolTitle><Reference>15-1473; NCT02946762; Z 31501</Reference><Sponsor>University of North Carolina</Sponsor><Trial id="280225"/><TrialStartDate>FEBRUARY , 01, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="107523">TBA-7371</Drug><EnrollmentCount>74</EnrollmentCount><Interventions>TBA-7371; TBA-7371; bupropion; midazolam</Interventions><Patients>74</Patients><ProtocolAcronym/><ProtocolTitle>A Phase I Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371</ProtocolTitle><Reference>NCT03199339; TBA-7371-CL001</Reference><Sponsor>TB Alliance</Sponsor><Trial id="303756"/><TrialStartDate>AUGUST   , 29, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>levofloxacin</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount>3000</EnrollmentCount><Interventions>isoniazid; rifampicin</Interventions><Patients>3000</Patients><ProtocolAcronym>TriDoRe</ProtocolAcronym><ProtocolTitle>Novel Triple-Dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More</ProtocolTitle><Reference>NCT03862248; TRIDORE; TriDoRe</Reference><Sponsor>Institute of Tropical Medicine, Belgium</Sponsor><Trial id="372353"/><TrialStartDate>SEPTEMBER, 30, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><EnrollmentCount>15</EnrollmentCount><Interventions>lopinavir + ritonavir; rifabutin</Interventions><Patients>15</Patients><ProtocolAcronym/><ProtocolTitle>A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects</ProtocolTitle><Reference>M10-457; NCT00743470</Reference><Sponsor>Abbott Laboratories</Sponsor><Trial id="25327"/><TrialStartDate>AUGUST   , 31, 2008</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampin</Controls><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="13323">pretomanid</Drug><EnrollmentCount>183</EnrollmentCount><Interventions>isoniazid; pretomanid; pyrazinamide; rifabutin; rifampin</Interventions><Patients>183</Patients><ProtocolAcronym>APT</ProtocolAcronym><ProtocolTitle>Assessing PA-824 for Tuberculosis</ProtocolTitle><Reference>#FD-R-004794-01; APT; NA_00093014; NCT02256696</Reference><Sponsor>Johns Hopkins Hospital</Sponsor><Trial id="213394"/><TrialStartDate>APRIL    , 29, 2015</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>450</EnrollmentCount><Interventions>bedaquiline; moxifloxacin; pretomanid; pyrazinamide</Interventions><Patients>450</Patients><ProtocolAcronym>SIMPLICITB</ProtocolAcronym><ProtocolTitle>Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients</ProtocolTitle><Reference>39186; B-Pa-M-Z; NC-008; NC-008 (B-Pa-M-Z); NC-008 (B-Pa-M-Z) 39186; NCT03338621; NMRR-17-2826-39186; PHRR180723-001867; SIMPLICITB; SIMPLICITB (B-PA-M-Z) NC-008</Reference><Sponsor>PPD Pharmaceutical Development Philippines Corporation, TB Alliance</Sponsor><Trial id="319125"/><TrialStartDate>JULY     , 30, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Body height; Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><EnrollmentCount>36</EnrollmentCount><Interventions>pretomanid</Interventions><Patients>36</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics and Safety of PA-824 in Subjects With Mild, Moderate, and Severe Hepatic Impairment to Matched, Non-Hepatically Impaired Subjects</ProtocolTitle><Reference>13-0053; HHSN272201300017I; NCT02422524</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="227410"/><TrialStartDate>DECEMBER , 11, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>BCG vaccine</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="108779">GC-3107</Drug><EnrollmentCount>750</EnrollmentCount><Interventions>GC-3107</Interventions><Patients>750</Patients><ProtocolAcronym/><ProtocolTitle>A Study of GC-3107(BCG Vaccine) in Healthy Infants</ProtocolTitle><Reference>GC3107_P3; NCT03947138; TCTR20190325003</Reference><Sponsor>GC Pharma</Sponsor><Trial id="380364"/><TrialStartDate>JUNE     , 01, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>WHO approved regimen-based therapy</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="16545">delamanid</Drug><EnrollmentCount/><Interventions>Deltyba; Levaquin; Zyvox; pyrazinamide</Interventions><Patients/><ProtocolAcronym>DAZZLE</ProtocolAcronym><ProtocolTitle>Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin</ProtocolTitle><Reference>DAZZLE; H-36160; NCT02975570</Reference><Sponsor>Boston University</Sponsor><Trial id="280651"/><TrialStartDate>AUGUST   , 31, 2017</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2587">azithromycin</Drug><EnrollmentCount/><Interventions>azithromycin</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Safety and Efficacy of Azithromycin in Individual Patients With Serious Nontuberculous Mycobacterial Disease Who Are Failing or Intolerant of Other Available Therapy</ProtocolTitle><Reference>058D; 066-169; NCT00002085</Reference><Sponsor>Pfizer Inc</Sponsor><Trial id="8647"/><TrialStartDate>NOVEMBER , 02, 1999</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Cytokines</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><EnrollmentCount>2</EnrollmentCount><Interventions>MVA-85A</Interventions><Patients>2</Patients><ProtocolAcronym/><ProtocolTitle>MVA-85A Aerosol Versus Intramuscular Vaccination in Adults With Latent Mycobacterium Tuberculosis (M tb) Infection</ProtocolTitle><Reference>NCT02532036; TB040</Reference><Sponsor>University of Oxford</Sponsor><Trial id="238674"/><TrialStartDate>SEPTEMBER, 30, 2015</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><EnrollmentCount>450</EnrollmentCount><Interventions>bedaquiline; moxifloxacin; pretomanid; pyrazinamide</Interventions><Patients>450</Patients><ProtocolAcronym>SIMPLICITB</ProtocolAcronym><ProtocolTitle>Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients</ProtocolTitle><Reference>39186; B-Pa-M-Z; NC-008; NC-008 (B-Pa-M-Z); NC-008 (B-Pa-M-Z) 39186; NCT03338621; NMRR-17-2826-39186; PHRR180723-001867; SIMPLICITB; SIMPLICITB (B-PA-M-Z) NC-008</Reference><Sponsor>PPD Pharmaceutical Development Philippines Corporation, TB Alliance</Sponsor><Trial id="319125"/><TrialStartDate>JULY     , 30, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>standardized regimen</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4492">faropenem</Drug><EnrollmentCount>400</EnrollmentCount><Interventions>faropenem</Interventions><Patients>400</Patients><ProtocolAcronym/><ProtocolTitle>Prospective, Randomized Control, Non-inferiority Study of the Use of Faropenem for Patients with etiology Positive Pulmonary Tuberculosis</ProtocolTitle><Reference>ChiCTR1800015959</Reference><Sponsor>Zhejiang University</Sponsor><Trial id="338648"/><TrialStartDate>MAY      , 15, 2018</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Anti-Meningitis C antibodies; C-C motif chemokine 2; C-C motif chemokine 3; C-C motif chemokine 4; Cytokines; IgG; Interferon gamma; Interferon-alpha; Interleukin-1 alpha; Interleukin-1 beta; Interleukin-10; Interleukin-12; Interleukin-13; Interleukin-2; Interleukin-6</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="6229">Infanrix</Drug><EnrollmentCount>28</EnrollmentCount><Interventions>BCG; Infanrix; Menitorix; NeisVac-C; Pentacel; Prevnar 13; Priorix; Rotarix</Interventions><Patients>28</Patients><ProtocolAcronym>BAM</ProtocolAcronym><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><Reference>2013-003488-71; BAM; NCT02002156; OVG-2013/04; UKCRN 15722</Reference><Sponsor>University of Oxford</Sponsor><Trial id="162886"/><TrialStartDate>JUNE     , 20, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Cytokines; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>BCG vaccine</Controls><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="89744">MTBVAC</Drug><EnrollmentCount>99</EnrollmentCount><Interventions>MTBVAC</Interventions><Patients>99</Patients><ProtocolAcronym/><ProtocolTitle>Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates</ProtocolTitle><Reference>MTBVAC-03; NCT03536117</Reference><Sponsor>Biofabri SL</Sponsor><Trial id="340636"/><TrialStartDate>FEBRUARY , 11, 2019</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Cytokines; Immunoglobulin G; Interferon gamma</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="74849">SSI H56-IC31</Drug><EnrollmentCount>22</EnrollmentCount><Interventions>SSI H56-IC31</Interventions><Patients>22</Patients><ProtocolAcronym/><ProtocolTitle>A Phase I Study of Safety and Immunogenicity of AERAS-456 in HIV-Negative Adults Treated for Drug-susceptible Pulmonary TB</ProtocolTitle><Reference>C-037-456; NCT02375698</Reference><Sponsor>Aeras</Sponsor><Trial id="223291"/><TrialStartDate>NOVEMBER , 21, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="98373">TB/FLU-04L</Drug><EnrollmentCount>80</EnrollmentCount><Interventions>TB/FLU-04L</Interventions><Patients>80</Patients><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-controlled, phase II clinical trial of TB/FLU-04L TB vaccine in adult volunteers with signs of latent tuberculosis infection</ProtocolTitle><Reference>VPT-II-01/2015</Reference><Sponsor>National Center for Biotechnology of the Republic of Kazakhstan</Sponsor><Trial id="301908"/><TrialStartDate>JUNE     , 05, 2017</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-2; Interleukin-2 receptor alpha chain ; Monocytes; Myeloid-derived suppressor cells; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="74849">SSI H56-IC31</Drug><EnrollmentCount>39</EnrollmentCount><Interventions>SSI H56-IC31; SSI H56-IC31; etoricoxib; etoricoxib</Interventions><Patients>39</Patients><ProtocolAcronym>TBCOX2</ProtocolAcronym><ProtocolTitle>Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic</ProtocolTitle><Reference>2014-004986-26; 2015/692; NCT02503839; TBCOX2</Reference><Sponsor>Oslo University Hospital</Sponsor><Trial id="235355"/><TrialStartDate>NOVEMBER , 30, 2015</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="76307">delpazolid</Drug><EnrollmentCount>52</EnrollmentCount><Interventions>delpazolid</Interventions><Patients>52</Patients><ProtocolAcronym/><ProtocolTitle>Phase I study Evaluating the Safety, Tolerability and Pharmacokinetic Characteristics of RMX-2001</ProtocolTitle><Reference>CTR20190843; RMX2001-101</Reference><Sponsor>Nome West (Shanghai) Pharmaceutical Technology Co., Ltd</Sponsor><Trial id="381962"/><TrialStartDate/><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Amyloid; C-reactive protein; Collagen type I; Collagen type III; Cytokines; Interferon gamma; Interleukin-10; Interleukin-17A; Interleukin-2; Interleukin-4; Interleukin-6; Interleukin-8; Leukocyte count; Leukocyte elastase; Matrix metalloproteinase-9; Myeloperoxidase; Neutrophil collagenase; Procalcitonin; Transforming Growth Factor beta; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2587">azithromycin</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>azithromycin; ethambutol; isoniazid; pyrazinamide; rifampicin</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>Azithromycin as Host-directed Therapy for Pulmonary Tuberculosis</ProtocolTitle><Reference>2017-001929-40; AZT_DSTB_BB; NCT03160638</Reference><Sponsor>University Medical Center Groningen</Sponsor><Trial id="298743"/><TrialStartDate>FEBRUARY , 01, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>5+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>bedaquiline; bedaquiline; clofazimine; clofazimine; delamanid; delamanid; linezolid; linezolid</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="16545">delamanid</Drug><EnrollmentCount>500</EnrollmentCount><Interventions>bedaquiline; clofazimine; delamanid; linezolid</Interventions><Patients>500</Patients><ProtocolAcronym>endTB-Q</ProtocolAcronym><ProtocolTitle>Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance</ProtocolTitle><Reference>MSF ERB-1761; NCT03896685; endTB-Q</Reference><Sponsor>Mdecins Sans Frontires France</Sponsor><Trial id="375499"/><TrialStartDate>JUNE     , 30, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="55569">VPM-1002</Drug><EnrollmentCount>2000</EnrollmentCount><Interventions>VPM-1002</Interventions><Patients>2000</Patients><ProtocolAcronym/><ProtocolTitle>Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence in India</ProtocolTitle><Reference>NCT03152903; VPM1002-IN-3.01TBR</Reference><Sponsor>Serum Institute of India Ltd</Sponsor><Trial id="298671"/><TrialStartDate>DECEMBER , 15, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Standard of care</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44279">amoxicillin</Drug><EnrollmentCount>1875</EnrollmentCount><Interventions>amoxicillin; azithromycin</Interventions><Patients>1875</Patients><ProtocolAcronym>ACT-TB</ProtocolAcronym><ProtocolTitle>Accuracy and Consequences of Using Trial-of-antibiotics for TB Diagnosis</ProtocolTitle><Reference>15232; ACT-TB; NCT03545373</Reference><Sponsor>London School of Hygiene and Tropical Medicine</Sponsor><Trial id="341686"/><TrialStartDate>FEBRUARY , 25, 2019</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>clofazimine; ethambutol; isoniazid; kanamycin; moxifloxacin; prothionamide; pyrazinamide</Controls><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><EnrollmentCount>250</EnrollmentCount><Interventions>clofazimine; econazole; ethambutol; isoniazid; kanamycin; moxifloxacin; prothionamide; pyrazinamide</Interventions><Patients>250</Patients><ProtocolAcronym>RESWMEN</ProtocolAcronym><ProtocolTitle>Using econazole to attempt to shorten the duration of treatment in MDR tuberculosis</ProtocolTitle><Reference>CTRI/2019/03/018237; PGI-MDR TB/01 version 2 dated 12.09.2018; RESWMEN</Reference><Sponsor>Indian Council of Medical Research</Sponsor><Trial id="374838"/><TrialStartDate>MAY      , 01, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>amikacin; cycloserine; moxifloxacin; prothionamide; pyrazinamide</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><EnrollmentCount>488</EnrollmentCount><Interventions>amikacin; clofazimine; cycloserine; ethambutol; linezolid; moxifloxacin; prothionamide; pyrazinamide</Interventions><Patients>488</Patients><ProtocolAcronym>GRACE-TB</ProtocolAcronym><ProtocolTitle>NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB</ProtocolTitle><Reference>GRACE-TB; KY2018-291; NCT03604848</Reference><Sponsor>Huashan Hospital</Sponsor><Trial id="348056"/><TrialStartDate>AUGUST   , 05, 2018</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bilirubin; Blood platelets; Carbon dioxide; Chlorine; Creatine kinase; Creatinine; Eosinophils; Erythrocytes; Estimated glomerular filtration rate; Glucose; Hematocrit; Hemoglobin; High-density lipoprotein cholesterol; High-density lipoprotein cholesterol; Human immunodeficiency virus RNA; Lactate dehydrogenase; Leukocyte count; Lipase; Lipids; Lymphocytes; Mean corpuscular volume; Monocytes; Neutrophils; Ox-LDL/ LDL-C ratio; Ox-LDL/ LDL-C ratio; Phosphate; Potassium; Sodium; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; Total cholesterol; Total cholesterol; Triglycerides; Triglycerides; Urea</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>efavirenz; ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="59062">dolutegravir</Drug><EnrollmentCount>113</EnrollmentCount><Interventions>Group 1; Group 2; dolutegravir; ethambutol; isoniazid; pyrazinamide; rifampicin</Interventions><Patients>113</Patients><ProtocolAcronym>INSPIRING</ProtocolAcronym><ProtocolTitle>Open-Label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV)-Tuberculosis (TB) Co-infection</ProtocolTitle><Reference>117175; ING117175; INSPIRING; NCT02178592</Reference><Sponsor>ViiV Healthcare Ltd</Sponsor><Trial id="201302"/><TrialStartDate>JANUARY  , 23, 2015</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>6</ArmCount><Biomarkers>C-reactive protein; Forced expiratory volume; Neopterin; Programmed cell death protein 1; Standardized uptake value; T-Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>rifabutin-modified TB therapy</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59386">CC-11050</Drug><EnrollmentCount>200</EnrollmentCount><Interventions>CC-11050; auranofin; everolimus; rifabutin-modified TB therapy; vitamin D3</Interventions><Patients>200</Patients><ProtocolAcronym>TBHDT</ProtocolAcronym><ProtocolTitle>TB Host Directed Therapy</ProtocolTitle><Reference>NCT02968927; TBHDT; TBHDT-AUR1-8-178</Reference><Sponsor>Aurum Institute</Sponsor><Trial id="279898"/><TrialStartDate>NOVEMBER , 30, 2016</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Alanine transaminase; Aspartate aminotransferase; Bilirubin; Blood cells; Creatine kinase; Creatinine; Estimated glomerular filtration rate; Lipase; Lipids</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59062">dolutegravir</Drug><EnrollmentCount>75</EnrollmentCount><Interventions>Prezcobix; dolutegravir; isoniazid; rifapentine</Interventions><Patients>75</Patients><ProtocolAcronym/><ProtocolTitle>Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers</ProtocolTitle><Reference>16-CC-0112; 160112; NCT02771249</Reference><Sponsor>National Institutes of Health Clinical Center</Sponsor><Trial id="260814"/><TrialStartDate>JUNE     , 03, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Human immunodeficiency virus RNA; T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59062">dolutegravir</Drug><EnrollmentCount>200</EnrollmentCount><Interventions>dolutegravir; food intake; nucleoside reverse transcriptase inhibitor therapy; rifampicin</Interventions><Patients>200</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy, Safety and Pharmacokinetics of DTG With RIF</ProtocolTitle><Reference>HIV-NAT 254; NCT03731559</Reference><Sponsor>The HIV Netherlands Australia Thailand Research Collaboration</Sponsor><Trial id="359086"/><TrialStartDate>MARCH    , 01, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="31010">SQ-109</Drug><EnrollmentCount/><Interventions>SQ-109</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>Evaluation of SQ-109 Plus PPI in Urea Breath Test-Positive Volunteers</ProtocolTitle><Reference>NCT01252108; SQ109-H001</Reference><Sponsor>Sequella Inc</Sponsor><Trial id="72716"/><TrialStartDate>MARCH    , 31, 2012</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers>C-reactive protein</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="12013">once-daily naproxen (oral controlled release, pain), Alvogen</Drug><EnrollmentCount/><Interventions>atorvastatin; dexamethasone; dexamethasone (decadron); once-daily naproxen (oral controlled release, pain), Alvogen; once-daily naproxen (oral controlled release, pain), Alvogen</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial</ProtocolTitle><Reference>NCT01442428; WS967180</Reference><Sponsor>University of Minnesota - Clinical and Translational Science Institute</Sponsor><Trial id="199754"/><TrialStartDate>JANUARY  , 31, 2014</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers>T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="49219">tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences</Drug><EnrollmentCount>809</EnrollmentCount><Interventions>efavirenz; emtricitabine; tenofovir disoproxil fumarate; tenofovir disoproxil fumarate + emtricitabine</Interventions><Patients>780</Patients><ProtocolAcronym>STRIDE</ProtocolAcronym><ProtocolTitle>Immediate Versus Deferred Start of Anti-HIV Therapy in HIV Infected Adults Being Treated for Tuberculosis</ProtocolTitle><Reference>1U01AI068636; ACTG A5221; ACTG A5221; NCT00108862; STRIDE</Reference><Sponsor>AIDS Clinical Trials Group</Sponsor><Trial id="10681"/><TrialStartDate>AUGUST   , 31, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>429</EnrollmentCount><Interventions>ethambutol; gatifloxacin; isoniazid; moxifloxacin; pyrazinamide; rifampicin</Interventions><Patients>416</Patients><ProtocolAcronym/><ProtocolTitle>Thrice-Weekly, 4- Months Moxifloxacin or Gatifloxacin Regimens for Pulmonary TB</ProtocolTitle><Reference>CTRI/2012/10/003060</Reference><Sponsor>Indian Council of Medical Research</Sponsor><Trial id="150332"/><TrialStartDate>MAY      , 14, 2004</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7310">ritonavir</Drug><EnrollmentCount>9</EnrollmentCount><Interventions>Kaletra; rifampin; ritonavir</Interventions><Patients>9</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin</ProtocolTitle><Reference>20100325; NCT01700790</Reference><Sponsor>University of Miami</Sponsor><Trial id="93494"/><TrialStartDate>FEBRUARY , 29, 2016</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Body temperature; CD40 ligand; Interferon gamma; Interleukin-17A; Interleukin-2; T-Helper Lymphocytes; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><EnrollmentCount>142</EnrollmentCount><Interventions>MTB72F vaccine (tuberculosis), GSK/Aeras</Interventions><Patients>142</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With Tuberculosis (TB) Disease</ProtocolTitle><Reference>114886; NCT01424501</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="80383"/><TrialStartDate>NOVEMBER , 14, 2011</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><EnrollmentCount>12</EnrollmentCount><Interventions>MVA85A</Interventions><Patients>12</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity of MVA85A in Volunteers Latently Infected With TB</ProtocolTitle><Reference>NCT00456183; TB007</Reference><Sponsor>University of Oxford</Sponsor><Trial id="10941"/><TrialStartDate>AUGUST   , 31, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44409">Fluzone</Drug><EnrollmentCount>301</EnrollmentCount><Interventions>Vaxigrip</Interventions><Patients>301</Patients><ProtocolAcronym>TIV_HIV_TB</ProtocolAcronym><ProtocolTitle>Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults</ProtocolTitle><Reference>NCT01811823; TIV_HIV_TB; TIV_HIV_TB</Reference><Sponsor>University of Witwatersrand</Sponsor><Trial id="116439"/><TrialStartDate>MARCH    , 31, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; piperine; pyrazinamide; rifampicin</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="69440">rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals</Drug><EnrollmentCount>144</EnrollmentCount><Interventions>Risorine; ethambutol; pyrazinamide</Interventions><Patients>144</Patients><ProtocolAcronym/><ProtocolTitle>Clinical Trial for Comparing Safety and Efficacy of Bio-enhanced Rifampicin (Risorine) Capsule in newly diagnosed Pulmonary Tuberculosis in Adult Patients</ProtocolTitle><Reference>CTRI/2017/04/008329</Reference><Sponsor>All India Institute of Medical Sciences</Sponsor><Trial id="295037"/><TrialStartDate>APRIL    , 17, 2017</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><EnrollmentCount>12</EnrollmentCount><Interventions>MVA-85A</Interventions><Patients>12</Patients><ProtocolAcronym/><ProtocolTitle>TCell Turnover Following Vaccination With MVA-85A</ProtocolTitle><Reference>EudraCT number: 2007001293-8; NCT00548444; TB018</Reference><Sponsor>University of Oxford</Sponsor><Trial id="11182"/><TrialStartDate>OCTOBER  , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Glucose</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount>100</EnrollmentCount><Interventions>amikacin; clarithromycin; isoniazid; levofloxacin; prothionamide; pyrazinamide</Interventions><Patients>152</Patients><ProtocolAcronym/><ProtocolTitle>Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide</ProtocolTitle><Reference>2013ZX10003008-003; KY2013-260; NCT02120638</Reference><Sponsor>Huashan Hospital</Sponsor><Trial id="183613"/><TrialStartDate>APRIL    , 30, 2014</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Alanine transaminase; QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Rifafour e275</Controls><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="11088">sutezolid</Drug><EnrollmentCount>59</EnrollmentCount><Interventions>PNU-100480</Interventions><Patients>59</Patients><ProtocolAcronym/><ProtocolTitle>PNU-100480 In Newly Diagnosed, Treatment Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay</ProtocolTitle><Reference>B1171003; NCT01225640</Reference><Sponsor>Sequella Inc</Sponsor><Trial id="71511"/><TrialStartDate>AUGUST   , 31, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>CD4+ T cell</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>efavirenz; rifabutin; rifabutin</Interventions><Patients>15</Patients><ProtocolAcronym>TBTC-23C</ProtocolAcronym><ProtocolTitle>Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz</ProtocolTitle><Reference>23C; CDC-NCHSTP-2588; NCT00023413; TBTC-23C</Reference><Sponsor>Centers for Disease Control and Prevention</Sponsor><Trial id="10657"/><TrialStartDate>NOVEMBER , 30, 1999</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4+</ArmCount><Biomarkers>CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3700">nevirapine</Drug><EnrollmentCount>100</EnrollmentCount><Interventions>efavirenz; lamivudine; nevirapine; nevirapine</Interventions><Patients>100</Patients><ProtocolAcronym/><ProtocolTitle>Once-Daily Dose of Nevirapine (400 mg) Versus Twice Daily Dose (200 mg) of Nevirapine in HIV and Tuberculosis Infection</ProtocolTitle><Reference>CTRI/2012/08/002923</Reference><Sponsor>National AIDS Control Organization</Sponsor><Trial id="126486"/><TrialStartDate>SEPTEMBER, 01, 2012</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>CD4/CD8 ratio; CD40 ligand; Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-2; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><EnrollmentCount>37</EnrollmentCount><Interventions>GSK-692342</Interventions><Patients>37</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in HIV-Positive Adults</ProtocolTitle><Reference>111517; NCT00707967</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="19230"/><TrialStartDate>JUNE     , 30, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Mycocox-4; ethambutol; pyrazinamide</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="69440">rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals</Drug><EnrollmentCount>144</EnrollmentCount><Interventions>Risorine</Interventions><Patients>144</Patients><ProtocolAcronym/><ProtocolTitle>Comparative Evaluation of the Effect of Risorine in Patients With Newly Diagnosed Sputum Smear Positive Pulmonary Tuberculosis</ProtocolTitle><Reference>CTRI/2012/06/002742</Reference><Sponsor>Cadila Pharmaceuticals Ltd</Sponsor><Trial id="118547"/><TrialStartDate>FEBRUARY , 10, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>CD4; albumin</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="14493">tenofovir disoproxil fumarate</Drug><EnrollmentCount>156</EnrollmentCount><Interventions>efavirenz; lamivudine; lamivudine + efavirenz + tenofovir disoproxil fumarate; tenofovir disoproxil fumarate</Interventions><Patients>156</Patients><ProtocolAcronym>TIME</ProtocolAcronym><ProtocolTitle>Appropriate Timing of HAART in Co-infected HIV/TB Patients</ProtocolTitle><Reference>0435.3/1551; NCT01014481; TIME</Reference><Sponsor>Bamrasnaradura Infectious Diseases Institute</Sponsor><Trial id="61991"/><TrialStartDate>OCTOBER  , 31, 2009</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>5</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>150</EnrollmentCount><Interventions>capreomycin; isoniazid; moxifloxacin; rifabutin; rifampicin</Interventions><Patients>150</Patients><ProtocolAcronym>BBA</ProtocolAcronym><ProtocolTitle>Brief Bactericidal Activity of Anti-Tuberculosis Drugs</ProtocolTitle><Reference>BBA; CDC-NCHHSTP-6435; NCT02236078</Reference><Sponsor>Centers for Disease Control and Prevention</Sponsor><Trial id="210083"/><TrialStartDate>NOVEMBER , 30, 2015</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Blood cells; Creatine phosphokinase; fbpB; hspX; icl1; rrnA-p1</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Rifafour</Controls><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="26493">posizolid</Drug><EnrollmentCount>75</EnrollmentCount><Interventions>AZD-5847</Interventions><Patients>75</Patients><ProtocolAcronym/><ProtocolTitle>Phase IIa EBA Trial of AZD-5847</ProtocolTitle><Reference>11-0006; N01AI70022C; NCT01516203</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="84246"/><TrialStartDate>DECEMBER , 05, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="69440">rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals</Drug><EnrollmentCount>50</EnrollmentCount><Interventions>Risorine</Interventions><Patients>50</Patients><ProtocolAcronym/><ProtocolTitle>A Risorine Study in Sputum Positive Patients After 8 Weeks of Conventional Treatment</ProtocolTitle><Reference>CRSC12005 Version. 01; CTRI/2012/11/003096</Reference><Sponsor>Cadila Pharmaceuticals Ltd</Sponsor><Trial id="138715"/><TrialStartDate>JUNE     , 10, 2012</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>4+</ArmCount><Biomarkers>CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3474">lamivudine</Drug><EnrollmentCount>100</EnrollmentCount><Interventions>efavirenz; lamivudine; nevirapine; nevirapine</Interventions><Patients>100</Patients><ProtocolAcronym/><ProtocolTitle>Once-Daily Dose of Nevirapine (400 mg) Versus Twice Daily Dose (200 mg) of Nevirapine in HIV and Tuberculosis Infection</ProtocolTitle><Reference>CTRI/2012/08/002923</Reference><Sponsor>National AIDS Control Organization</Sponsor><Trial id="126486"/><TrialStartDate>SEPTEMBER, 01, 2012</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>5</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid</Controls><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount>70</EnrollmentCount><Interventions>gatifloxacin; levofloxacin; linezolid; moxifloxacin</Interventions><Patients>70</Patients><ProtocolAcronym>TBRU 10</ProtocolAcronym><ProtocolTitle>Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis</ProtocolTitle><Reference>01-553; NCT00396084; TBRU 10; TBRU 10</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="10869"/><TrialStartDate>FEBRUARY , 29, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Lung</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampin</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>865</EnrollmentCount><Interventions>ethambutol; isoniazid; pyrazinamide; rifapentine</Interventions><Patients>529</Patients><ProtocolAcronym>TBTC Study 29</ProtocolAcronym><ProtocolTitle>Rifapentine During Intensive Phase Tuberculosis (TB) Treatment</ProtocolTitle><Reference>2008-003633-24; CDC-NCHSTP-5399; NCT00694629; TBTC Study 29; UITB-Study-29</Reference><Sponsor>Centers for Disease Control and Prevention, Tuberculosis Investigation Unit of Barcelona</Sponsor><Trial id="17237"/><TrialStartDate>DECEMBER , 31, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3700">nevirapine</Drug><EnrollmentCount>53</EnrollmentCount><Interventions>nevirapine; rifampicin</Interventions><Patients>53</Patients><ProtocolAcronym/><ProtocolTitle>Population Pharmacokinetics of Nevirapine in Combination With Rifampicin-Based Short Course Chemotherapy in HIV- and Tuberculosis-Infected South African Patients</ProtocolTitle><Reference>PMID:18751690</Reference><Sponsor>Uppsala University</Sponsor><Trial id="149504"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>15</EnrollmentCount><Interventions>moxifloxacin; moxifloxacin; rifapentine</Interventions><Patients>15</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine</ProtocolTitle><Reference>06-0050; NA_00007322; NCT00460759</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="10943"/><TrialStartDate>JUNE     , 30, 2007</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="53724">artenimol + piperaquine (malaria), Sigma-Tau</Drug><EnrollmentCount>36</EnrollmentCount><Interventions>artesunate; artesunate + amodiaquine; desethylamodiaquine; dihydroartemisinin; dihydroartemisinin + piperaquine; piperaquine</Interventions><Patients>36</Patients><ProtocolAcronym>ARTEM-TB STUDY</ProtocolAcronym><ProtocolTitle>Evaluating Pharmacokinetic Interactions Between Artemisinin-Based Therapies and Rifampacin-Based Tuberculosis Treatment in African Patients</ProtocolTitle><Reference>ARTEM-TB STUDY; HS1294; PACTR201302000483287</Reference><Sponsor>Infectious Diseases Institute of Makerer University</Sponsor><Trial id="142485"/><TrialStartDate>JANUARY  , 31, 2013</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>182</EnrollmentCount><Interventions>levofloxacin; moxifloxacin</Interventions><Patients>182</Patients><ProtocolAcronym/><ProtocolTitle>Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients</ProtocolTitle><Reference>H-0911-068-301; NCT01055145</Reference><Sponsor>Seoul National University Hospital</Sponsor><Trial id="63801"/><TrialStartDate>MARCH    , 31, 2010</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><EnrollmentCount>52</EnrollmentCount><Interventions>PA-824; efavirenz; lopinavir + ritonavir; rifampin</Interventions><Patients>52</Patients><ProtocolAcronym/><ProtocolTitle>Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir or Rifampin</ProtocolTitle><Reference>11829; A5306; ACTG5306; NCT01571414</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="86312"/><TrialStartDate>MAY      , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-2; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><EnrollmentCount>40</EnrollmentCount><Interventions>AERAS-402; AERAS-402; MVA-85A</Interventions><Patients>40</Patients><ProtocolAcronym/><ProtocolTitle>Safety Study of Tuberculosis Vaccines AERAS-402 and MVA-85A</ProtocolTitle><Reference>2012-002007-18; NCT01683773; TB032; UKCRN 13671</Reference><Sponsor>University of Oxford</Sponsor><Trial id="91280"/><TrialStartDate>SEPTEMBER, 30, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-2; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="53975">AERAS-402</Drug><EnrollmentCount>40</EnrollmentCount><Interventions>AERAS-402; AERAS-402; MVA-85A</Interventions><Patients>40</Patients><ProtocolAcronym/><ProtocolTitle>Safety Study of Tuberculosis Vaccines AERAS-402 and MVA-85A</ProtocolTitle><Reference>2012-002007-18; NCT01683773; TB032; UKCRN 13671</Reference><Sponsor>University of Oxford</Sponsor><Trial id="91280"/><TrialStartDate>SEPTEMBER, 30, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>moxifloxacin</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>88</EnrollmentCount><Interventions>TMC-207</Interventions><Patients>88</Patients><ProtocolAcronym/><ProtocolTitle>TMC207TBC1003 - A Study in Healthy Volunteers Investigating the Effect of Single-Dose TMC-207 on the QT/QTc Interval Under Fed Conditions</ProtocolTitle><Reference>CR017167; NCT01291563; TMC-207-TBC1003</Reference><Sponsor>Janssen Diagnostics BVBA</Sponsor><Trial id="74529"/><TrialStartDate>FEBRUARY , 28, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Anti-Meningitis C antibodies; C-C motif chemokine 2; C-C motif chemokine 3; C-C motif chemokine 4; Cytokines; IgG; Interferon gamma; Interferon-alpha; Interleukin-1 alpha; Interleukin-1 beta; Interleukin-10; Interleukin-12; Interleukin-13; Interleukin-2; Interleukin-6</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="11457">Priorix</Drug><EnrollmentCount>28</EnrollmentCount><Interventions>BCG; Infanrix; Menitorix; NeisVac-C; Pentacel; Prevnar 13; Priorix; Rotarix</Interventions><Patients>28</Patients><ProtocolAcronym>BAM</ProtocolAcronym><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><Reference>2013-003488-71; BAM; NCT02002156; OVG-2013/04; UKCRN 15722</Reference><Sponsor>University of Oxford</Sponsor><Trial id="162886"/><TrialStartDate>JUNE     , 20, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>200</EnrollmentCount><Interventions>efavirenz; emtricitabine; emtricitabine; lopinavir + ritonavir; rifabutin; rifampicin; tenofovir disoproxil fumarate; tenofovir disoproxil fumarate</Interventions><Patients>200</Patients><ProtocolAcronym>RIFART</ProtocolAcronym><ProtocolTitle>RIFART</ProtocolTitle><Reference>EudraCT 2007-007935-14; MI2-RIFART-2005; RIFART</Reference><Sponsor>Azienda Ospedaliera Spedali Civili di Brescia</Sponsor><Trial id="131240"/><TrialStartDate>MARCH    , 15, 2005</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4229">rifabutin</Drug><EnrollmentCount>215</EnrollmentCount><Interventions>rifabutin</Interventions><Patients>215</Patients><ProtocolAcronym>TBTC-23</ProtocolAcronym><ProtocolTitle>Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen</ProtocolTitle><Reference>CDC-NCHSTP-2174; NCT00023361; TBTC STUDY 23; TBTC-23</Reference><Sponsor>Centers for Disease Control and Prevention</Sponsor><Trial id="10653"/><TrialStartDate>FEBRUARY , 28, 1999</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><EnrollmentCount>18</EnrollmentCount><Interventions>nevirapine; rifampicin</Interventions><Patients>18</Patients><ProtocolAcronym/><ProtocolTitle>Nevirapine Drug Levels in HIV Positive Patients Also Receiving Rifampicin for Tuberculosis</ProtocolTitle><Reference>CPR 004; NCT00617643</Reference><Sponsor>Makerere University</Sponsor><Trial id="11184"/><TrialStartDate>MAY      , 31, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><EnrollmentCount>47</EnrollmentCount><Interventions>efavirenz; lopinavir + ritonavir; nevirapine; rifabutin</Interventions><Patients>47</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-Infection in Vietnam</ProtocolTitle><Reference>ANRS12150b; NCT00651066</Reference><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><Trial id="11188"/><TrialStartDate>JUNE     , 30, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Alanine transaminase; Bilirubin; C-reactive protein; Glucose; Hemoglobin; Leukocyte count; Serum potassium; Serum sodium; White blood cell</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>240</EnrollmentCount><Interventions>prednisone</Interventions><Patients>240</Patients><ProtocolAcronym>Pred-ART</ProtocolAcronym><ProtocolTitle>Preventing TB-IRIS in High-risk Patients: a Randomized, Placebo-controlled Trial of Prednisone</ProtocolTitle><Reference>CIDRI_001; DOH-27-0813-4336; NCT01924286; PACTR201304000511413; Pred-ART; SP.2011.41304.074</Reference><Sponsor>University of Cape Town</Sponsor><Trial id="150793"/><TrialStartDate>AUGUST   , 30, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><EnrollmentCount>16</EnrollmentCount><Interventions>pretomanid</Interventions><Patients>16</Patients><ProtocolAcronym/><ProtocolTitle>Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects</ProtocolTitle><Reference>CL-003; NCT01828827; PA-824 CL-003</Reference><Sponsor>TB Alliance</Sponsor><Trial id="120522"/><TrialStartDate>MARCH    , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="48499">H4:IC31</Drug><EnrollmentCount>243</EnrollmentCount><Interventions>H4+IC31</Interventions><Patients>243</Patients><ProtocolAcronym/><ProtocolTitle>Phase I/II, Safety and Immunogenicity Study of AERAS-404 in BCG-Primed Infants</ProtocolTitle><Reference>C-015-404; C-015-404/ IMPAACT P1113; NCT01861730; U01AI068632</Reference><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><Trial id="134374"/><TrialStartDate>JULY     , 01, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><EnrollmentCount>16</EnrollmentCount><Interventions>bedaquiline; lopinavir + ritonavir</Interventions><Patients>16</Patients><ProtocolAcronym/><ProtocolTitle>TMC207-TiDP13-C110: Interaction Study With Lopinavir/Ritonavir in Healthy Volunteer</ProtocolTitle><Reference>CR002545; NCT00828529; NCT00980291</Reference><Sponsor>Janssen Diagnostics BVBA</Sponsor><Trial id="42128"/><TrialStartDate>FEBRUARY , 28, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><EnrollmentCount>130</EnrollmentCount><Interventions>efavirenz; isoniazid; lamivudine; pyrazinamide; rifampicin; zidovudine</Interventions><Patients>130</Patients><ProtocolAcronym>IPEC-EFV</ProtocolAcronym><ProtocolTitle>Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X  800 mg</ProtocolTitle><Reference>CAAE-0017.1.009.000-03; IPEC-EFV; NCT00533390</Reference><Sponsor>Fundacao Oswaldo Cruz (Fiocruz)</Sponsor><Trial id="11181"/><TrialStartDate>JANUARY  , 31, 2007</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><EnrollmentCount>16</EnrollmentCount><Interventions>TMC-207; nevirapine</Interventions><Patients>16</Patients><ProtocolAcronym/><ProtocolTitle>TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)</ProtocolTitle><Reference>CR015793; NCT00910806; NCT00980668; TMC207-TiDP13-C117</Reference><Sponsor>Janssen Diagnostics BVBA, Johnson &amp; Johnson</Sponsor><Trial id="56959"/><TrialStartDate>JUNE     , 30, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Hepatitis B large envelope protein; Hepatitis B virus external core antigen; T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><EnrollmentCount>2073</EnrollmentCount><Interventions>efavirenz; isoniazid; lopinavir + ritonavir; tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences</Interventions><Patients>1107</Patients><ProtocolAcronym>TEMPRANO</ProtocolAcronym><ProtocolTitle>Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-Infected Adults</ProtocolTitle><Reference>ANRS 12136 TEMPRANO; NCT00495651; TEMPRANO</Reference><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><Trial id="195741"/><TrialStartDate>MARCH    , 31, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Alanine transaminase; Aspartate aminotransferase; Cluster of differentiation 4; Hepatitis C virus RNA; Hepatitis C virus-RNA</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="5369">ribavirin</Drug><EnrollmentCount>550</EnrollmentCount><Interventions>peg-interferon alpha-2a; ribavirin</Interventions><Patients>550</Patients><ProtocolAcronym/><ProtocolTitle>Antivirus Therapy for Population with HIV, HCV and TB Co-infection Clinical Trial</ProtocolTitle><Reference>ChiCTR-TRC-00000407; ChiCTR-TRC-09000407</Reference><Sponsor>Guangzhou eighth People's Hospital</Sponsor><Trial id="162528"/><TrialStartDate>MAY      , 01, 2009</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>15</EnrollmentCount><Interventions>moxifloxacin; moxifloxacin; rifapentine</Interventions><Patients>15</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine</ProtocolTitle><Reference>06-0050; NA_00007322; NCT00460759</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="10943"/><TrialStartDate>JUNE     , 30, 2007</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Anti-Meningitis C antibodies; C-C motif chemokine 2; C-C motif chemokine 3; C-C motif chemokine 4; Cytokines; IgG; Interferon gamma; Interferon-alpha; Interleukin-1 alpha; Interleukin-1 beta; Interleukin-10; Interleukin-12; Interleukin-13; Interleukin-2; Interleukin-6</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="34281">Prevnar 13</Drug><EnrollmentCount>28</EnrollmentCount><Interventions>BCG; Infanrix; Menitorix; NeisVac-C; Pentacel; Prevnar 13; Priorix; Rotarix</Interventions><Patients>28</Patients><ProtocolAcronym>BAM</ProtocolAcronym><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><Reference>2013-003488-71; BAM; NCT02002156; OVG-2013/04; UKCRN 15722</Reference><Sponsor>University of Oxford</Sponsor><Trial id="162886"/><TrialStartDate>JUNE     , 20, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>216</EnrollmentCount><Interventions>ethambutol; isoniazid; moxifloxacin; pyrazinamide; pyridoxine; rifampin; rifapentine</Interventions><Patients>121</Patients><ProtocolAcronym/><ProtocolTitle>Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis</ProtocolTitle><Reference>06-0018; NCT00728507</Reference><Sponsor>Johns Hopkins University</Sponsor><Trial id="23035"/><TrialStartDate>NOVEMBER , 30, 2009</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Blood pressure; Body temperature; Cytokines; Heart rate; Interferon gamma; Respiratory frequency</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="81363">AEC/BC02</Drug><EnrollmentCount>135</EnrollmentCount><Interventions>AEC/BC02</Interventions><Patients>135</Patients><ProtocolAcronym/><ProtocolTitle>A Phase I Study of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried</ProtocolTitle><Reference>AEC/BCO2; LTAO; LTAO-AEC/BCO2--HEALTHY; NCT03026972</Reference><Sponsor>Anhui Zhifei Longcom Biopharmaceutical Co Ltd</Sponsor><Trial id="285854"/><TrialStartDate>APRIL    , 16, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>1148</EnrollmentCount><Interventions>isoniazid; isoniazid; rifampin; rifapentine</Interventions><Patients>1148</Patients><ProtocolAcronym/><ProtocolTitle>Tuberculosis Prevention for HIV Infected Adults</ProtocolTitle><Reference>1R01AI48526-01A1; 5RO1AI048526-02; NCT00057122</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="8790"/><TrialStartDate>SEPTEMBER, 30, 2002</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="81363">AEC/BC02</Drug><EnrollmentCount>175</EnrollmentCount><Interventions>AEC/BC02; BC02</Interventions><Patients>175</Patients><ProtocolAcronym/><ProtocolTitle>Clinical study of freeze - dried recombinant tuberculosis vaccine (AEC/BC02)</ProtocolTitle><Reference>201601; CTR20150383</Reference><Sponsor>Chongqing Zhifei Biological Products Co Ltd</Sponsor><Trial id="291253"/><TrialStartDate/><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Interferon gamma; Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>2927</EnrollmentCount><Interventions>isoniazid; pyridoxine; rifapentine</Interventions><Patients>2927</Patients><ProtocolAcronym>CORTIS</ProtocolAcronym><ProtocolTitle>The Correlate of Risk Targeted Intervention Study</ProtocolTitle><Reference>CORTIS; CORTIS-01; NCT02735590</Reference><Sponsor>University of Cape Town</Sponsor><Trial id="258043"/><TrialStartDate>SEPTEMBER, 20, 2016</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers>Alanine transaminase; Aspartate aminotransferase; T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>500</EnrollmentCount><Interventions>isoniazid; isoniazid; methadone; naltrexone; rifapentine</Interventions><Patients>500</Patients><ProtocolAcronym>HARAPAN II</ProtocolAcronym><ProtocolTitle>Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings</ProtocolTitle><Reference>1R01DA041271; 2000020053; 33974; HARAPAN II; MECID.NO:201696-4220; NCT03089983; NMRR-17-19-33974</Reference><Sponsor>National Institutes of Health, Yale University</Sponsor><Trial id="294801"/><TrialStartDate>AUGUST   , 21, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Alanine transaminase; Arylacetamide deacetylase; Bilirubin; Blood cells; Creatinine; Nuclear receptor subfamily 1 group I member 2; Nuclear receptor subfamily 1 group I member 3; Solute carrier organic anion transporter family member 1B1</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampin</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>153</EnrollmentCount><Interventions>ethambutol; isoniazid; pyrazinamide; rifapentine</Interventions><Patients>153</Patients><ProtocolAcronym/><ProtocolTitle>Study of Daily Rifapentine for Pulmonary Tuberculosis</ProtocolTitle><Reference>3524; NA_00019095; NCT00814671</Reference><Sponsor>Johns Hopkins University</Sponsor><Trial id="39550"/><TrialStartDate>APRIL    , 30, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount>6</EnrollmentCount><Interventions>amikacin; amoxicillin-clavulanate; bedaquiline; clofazimine; cycloserine; enviomycin; ethambutol; ethionamide; fluoroquinolone therapy; kanamycin; levofloxacin; linezolid; para-aminosalicylic acid; pyrazinamide; streptomycin</Interventions><Patients>6</Patients><ProtocolAcronym/><ProtocolTitle>An Exploratory Study of TMC-207 in Japanese Participants with Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)</ProtocolTitle><Reference>CR105158; JapicCTI-163116; NCT02365623; TMC207TBC2001</Reference><Sponsor>Janssen Pharmaceutical KK</Sponsor><Trial id="222400"/><TrialStartDate>FEBRUARY , 18, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Human immunodeficiency virus RNA; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>efavirenz; lamivudine; tenofovir disoproxil fumarate</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><EnrollmentCount>460</EnrollmentCount><Interventions>lamivudine; raltegravir; rifampin; tenofovir disoproxil fumarate</Interventions><Patients>460</Patients><ProtocolAcronym>REFLATE TB2</ProtocolAcronym><ProtocolTitle>Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><Reference>ANRS 12300 REFLATE TB2; NCT02273765; REFLATE TB2</Reference><Sponsor>INSERM</Sponsor><Trial id="214156"/><TrialStartDate>SEPTEMBER, 30, 2015</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>500</EnrollmentCount><Interventions>isoniazid; isoniazid; rifapentine</Interventions><Patients>500</Patients><ProtocolAcronym/><ProtocolTitle>A 9-Month Isoniazid versus 3-Month Isoniazid plus Rifapentine for Treatment of Tuberculosis Infection in Rheumatic Patients: a Randomized, Controlled Trial</ProtocolTitle><Reference>ChiCTR1800018242</Reference><Sponsor>Peking Union Medical College Hospital</Sponsor><Trial id="352748"/><TrialStartDate>SEPTEMBER, 01, 2017</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; pyridoxine; rifampin</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>ethambutol; isoniazid; moxifloxacin; pyrazinamide; pyridoxine; rifampin; rifapentine</Interventions><Patients>60</Patients><ProtocolAcronym>S31PK/PD</ProtocolAcronym><ProtocolTitle>Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis</ProtocolTitle><Reference>CDC-NCHHSTP-6719; NCT02563327; S31PK/PD</Reference><Sponsor>Centers for Disease Control and Prevention</Sponsor><Trial id="242269"/><TrialStartDate>MAY      , 30, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>pryrazinamide</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount>750</EnrollmentCount><Interventions>Lamprene; bedaquiline; delamanid; levofloxacin; linezolid; moxifloxacin; pryrazinamide</Interventions><Patients>750</Patients><ProtocolAcronym>endTB</ProtocolAcronym><ProtocolTitle>Evaluating Newly Approved Drugs for Multidrug-resistant TB</ProtocolTitle><Reference>MSF ERB-1555; NCT02754765; endTB</Reference><Sponsor>Mdecins Sans Frontires France</Sponsor><Trial id="259506"/><TrialStartDate>DECEMBER , 31, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="90085">macozinone</Drug><EnrollmentCount>192</EnrollmentCount><Interventions>PBTZ-169</Interventions><Patients>192</Patients><ProtocolAcronym/><ProtocolTitle>International, multicenter, double-blind, placebo-controlled, randomized trial to evaluate the efficacy, safety and pharmacokinetics of PBTZ-169 when used in combination therapy in patients with tuberculosis of respiratory organs with bacterial excretion and drug resistance</ProtocolTitle><Reference>PBTZ169-A15-C2b-1</Reference><Sponsor>Nearmedic Plus</Sponsor><Trial id="316145"/><TrialStartDate>AUGUST   , 17, 2017</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>WHO regimen therapy</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount/><Interventions>Deltyba; Lamprene; Levaquin; Sirturo; Zyvox</Interventions><Patients/><ProtocolAcronym>DRAMATIC</ProtocolAcronym><ProtocolTitle>Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB</ProtocolTitle><Reference>DRAMATIC; H38212; NCT03828201</Reference><Sponsor>Boston University</Sponsor><Trial id="368916"/><TrialStartDate>JANUARY  , 31, 2020</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; rifampicin</Controls><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount>120</EnrollmentCount><Interventions>ethambutol; isoniazid; levofloxacin; pyrazinamide; rifampicin</Interventions><Patients>120</Patients><ProtocolAcronym>TBM-KIDS</ProtocolAcronym><ProtocolTitle>Optimizing Treatment to Improve TBM Outcomes in Children</ProtocolTitle><Reference>CTRI/2017/03/008004; IRB00051196; NCT02958709; TBM-KIDS</Reference><Sponsor>Johns Hopkins University</Sponsor><Trial id="278847"/><TrialStartDate>FEBRUARY , 22, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>109</EnrollmentCount><Interventions>bedaquiline; bedaquiline; linezolid; pretomanid</Interventions><Patients>109</Patients><ProtocolAcronym/><ProtocolTitle>A Phase III Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Reference>NCT02333799; NIX-TB-(B-L-PA)</Reference><Sponsor>TB Alliance</Sponsor><Trial id="219499"/><TrialStartDate>MARCH    , 31, 2015</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44406">imipenem + cilastatin</Drug><EnrollmentCount>448</EnrollmentCount><Interventions>amikacin; amoxicillin + clavulanate; azithromycin; bedaquiline; capreomycin; clarithromycin; clofazimine; cycloserine; delaminid; ethambutol; ethionamide; gatifloxacin; imipenem/cilastatin; isoniazid; kanamycin; levofloxacin; linezolid; meropenem; moxifloxacin; ofloxacin; para-aminosalicylic acid; pretomanid; prothionamide; pyrazinamide; rifabutin; rifampicin; streptomycin; sutezolid; terizidone; thioacetazone; whole genome sequencing</Interventions><Patients>448</Patients><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Reference>CAP 020; InDEX; NCT03237182</Reference><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><Trial id="307654"/><TrialStartDate>JUNE     , 14, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Cytokines</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>75</EnrollmentCount><Interventions>ethambutol; isoniazid; moxifloxacin; pyrazinamide; rifampicin</Interventions><Patients>75</Patients><ProtocolAcronym/><ProtocolTitle>A Comparative study of different treatment regimes for brain tuberculosis</ProtocolTitle><Reference>CTRI/2019/05/019222</Reference><Sponsor>Department of Science &amp; Technology</Sponsor><Trial id="382387"/><TrialStartDate>MAY      , 27, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>5</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4229">rifabutin</Drug><EnrollmentCount>150</EnrollmentCount><Interventions>capreomycin; isoniazid; moxifloxacin; rifabutin; rifampicin</Interventions><Patients>150</Patients><ProtocolAcronym>BBA</ProtocolAcronym><ProtocolTitle>Brief Bactericidal Activity of Anti-Tuberculosis Drugs</ProtocolTitle><Reference>BBA; CDC-NCHHSTP-6435; NCT02236078</Reference><Sponsor>Centers for Disease Control and Prevention</Sponsor><Trial id="210083"/><TrialStartDate>NOVEMBER , 30, 2015</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>WHO regimen therapy</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="16545">delamanid</Drug><EnrollmentCount/><Interventions>Deltyba; Lamprene; Levaquin; Sirturo; Zyvox</Interventions><Patients/><ProtocolAcronym>DRAMATIC</ProtocolAcronym><ProtocolTitle>Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB</ProtocolTitle><Reference>DRAMATIC; H38212; NCT03828201</Reference><Sponsor>Boston University</Sponsor><Trial id="368916"/><TrialStartDate>JANUARY  , 31, 2020</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>6</EnrollmentCount><Interventions>amikacin; amoxicillin-clavulanate; bedaquiline; clofazimine; cycloserine; enviomycin; ethambutol; ethionamide; fluoroquinolone therapy; kanamycin; levofloxacin; linezolid; para-aminosalicylic acid; pyrazinamide; streptomycin</Interventions><Patients>6</Patients><ProtocolAcronym/><ProtocolTitle>An Exploratory Study of TMC-207 in Japanese Participants with Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)</ProtocolTitle><Reference>CR105158; JapicCTI-163116; NCT02365623; TMC207TBC2001</Reference><Sponsor>Janssen Pharmaceutical KK</Sponsor><Trial id="222400"/><TrialStartDate>FEBRUARY , 18, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Blood pressure; Body temperature; Heart rate; Hydrocortisone; Partial Thromboplastin Time; Prothrombin time; Total body mass; Visual acuity</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="16545">delamanid</Drug><EnrollmentCount>213</EnrollmentCount><Interventions>delamanid</Interventions><Patients>213</Patients><ProtocolAcronym/><ProtocolTitle>A Phase II, Multicenter, Uncontrolled, Open-label Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683</ProtocolTitle><Reference>242-07-208; EudraCT 2008-005107-26; NCT02573350</Reference><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><Trial id="242789"/><TrialStartDate>MARCH    , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin; streptomycin</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><EnrollmentCount>864</EnrollmentCount><Interventions>ethambutol; isoniazid aminosalicylate; moxifloxacin; pyrazinamide; rifabutin</Interventions><Patients>80</Patients><ProtocolAcronym/><ProtocolTitle>Research on New Regimens for Retreatment Pulmonary Tuberculosis</ProtocolTitle><Reference>2013ZX10003009; NCT02331823</Reference><Sponsor>Shanghai Pulmonary Hospital</Sponsor><Trial id="220243"/><TrialStartDate>JUNE     , 30, 2013</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="31010">SQ-109</Drug><EnrollmentCount>170</EnrollmentCount><Interventions>SQ-109; chemotherapy</Interventions><Patients>140</Patients><ProtocolAcronym/><ProtocolTitle>A phase IIb/III, international, multicenter, prospective, randomized, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of chemotherapy regimens, including drug SQ-109 in patients with pulmonary multidrug-resistant mycobacterium tuberculosis</ProtocolTitle><Reference>MOSQ-109</Reference><Sponsor>Infectex</Sponsor><Trial id="168785"/><TrialStartDate>JUNE     , 27, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid; rifampin</Controls><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>75</EnrollmentCount><Interventions>TMC-207</Interventions><Patients>75</Patients><ProtocolAcronym/><ProtocolTitle>TMC207-C202: Study to Evaluate Bactericidal Activity of Multiple Oral Doses of TMC207 in Subjects With Sputum-Smear Positive Tuberculosis</ProtocolTitle><Reference>CR002725; NCT00523926; TMC207-C202</Reference><Sponsor>Janssen R&amp;D (Ireland)</Sponsor><Trial id="9315"/><TrialStartDate>MAY      , 31, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><EnrollmentCount>630</EnrollmentCount><Interventions>Lamprene; bedaquiline; linezolid; moxifloxacin; pretomanid</Interventions><Patients>630</Patients><ProtocolAcronym>TB-PRACTECAL</ProtocolAcronym><ProtocolTitle>Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)</ProtocolTitle><Reference>1541; NCT02589782; TB-PRACTECAL</Reference><Sponsor>Medecins Sans Frontieres</Sponsor><Trial id="244304"/><TrialStartDate>JANUARY  , 31, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount>44</EnrollmentCount><Interventions>isoniazid; levofloxacin; pyridoxine</Interventions><Patients>44</Patients><ProtocolAcronym/><ProtocolTitle>A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin</ProtocolTitle><Reference>DATRI 008; NCT00000778</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="8780"/><TrialStartDate>NOVEMBER , 01, 1999</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="11036">linezolid</Drug><EnrollmentCount>31</EnrollmentCount><Interventions>linezolid</Interventions><Patients>31</Patients><ProtocolAcronym>LINEZOLIDE</ProtocolAcronym><ProtocolTitle>Pharmacokinetic and Therapeutic Adaptation of Linezolid in the Treatment of Multi-Resistant Tuberculosis</ProtocolTitle><Reference>LINEZOLIDE; LINEZOLIDE; NCT02778828</Reference><Sponsor>Groupe Hospitalier Paris Saint-Joseph</Sponsor><Trial id="261481"/><TrialStartDate>NOVEMBER , 04, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Human immunodeficiency virus RNA</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="14493">tenofovir disoproxil fumarate</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>dolutegravir; emtricitabine; isoniazid; rifapentine; tenofovir disoproxil fumarate</Interventions><Patients>60</Patients><ProtocolAcronym>IMPAACT4TB</ProtocolAcronym><ProtocolTitle>Safety, Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine Isoniazid in HIV+ Patients</ProtocolTitle><Reference>3HP DTG AUR1-6-212 IMPAACT4TB; IMPAACT4TB; NCT03435146</Reference><Sponsor>Aurum Institute</Sponsor><Trial id="329251"/><TrialStartDate>JANUARY  , 18, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>900</EnrollmentCount><Interventions>bedaquiline; clofazimine; ethambutol; isoniazid; levofloxacin; linezolid; pyrazinamide; rifampicin; rifapentine</Interventions><Patients>900</Patients><ProtocolAcronym>TRUNCATE-TB</ProtocolAcronym><ProtocolTitle>A 2 Month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-Sensitive Tuberculosis</ProtocolTitle><Reference>2016-CT0376; NCT03474198; PHRR170327-001522; TRUNCATE-TB; TRUNCATE-TB</Reference><Sponsor>Syneos Health Inc, University College London</Sponsor><Trial id="333435"/><TrialStartDate>MARCH    , 21, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>72</EnrollmentCount><Interventions>isoniazid; rifapentine</Interventions><Patients>72</Patients><ProtocolAcronym/><ProtocolTitle>Tuberculosis Clinical Trials Consortium Study 35</ProtocolTitle><Reference>6993; NCT03730181</Reference><Sponsor>Centers for Disease Control and Prevention</Sponsor><Trial id="359122"/><TrialStartDate>SEPTEMBER, 30, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Blood pressure; Body temperature; Heart rate; Interferon gamma</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="95442">ESAT-6CFP10</Drug><EnrollmentCount>192</EnrollmentCount><Interventions>ESAT-6-CFP-10; TB-PPD</Interventions><Patients>192</Patients><ProtocolAcronym/><ProtocolTitle>Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT-6-CFP-10</ProtocolTitle><Reference>LTao-IIb-patient; NCT02336542</Reference><Sponsor>Anhui Zhifei Longcom Biopharmaceutical Co Ltd</Sponsor><Trial id="219931"/><TrialStartDate>NOVEMBER , 30, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>pryrazinamide</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><EnrollmentCount>750</EnrollmentCount><Interventions>Lamprene; bedaquiline; delamanid; levofloxacin; linezolid; moxifloxacin; pryrazinamide</Interventions><Patients>750</Patients><ProtocolAcronym>endTB</ProtocolAcronym><ProtocolTitle>Evaluating Newly Approved Drugs for Multidrug-resistant TB</ProtocolTitle><Reference>MSF ERB-1555; NCT02754765; endTB</Reference><Sponsor>Mdecins Sans Frontires France</Sponsor><Trial id="259506"/><TrialStartDate>DECEMBER , 31, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><EnrollmentCount>144</EnrollmentCount><Interventions>clofazimine (oral, tuberculosis), Novartis</Interventions><Patients>144</Patients><ProtocolAcronym/><ProtocolTitle>A randomized, multicenter, controlled trial for clofazimine-containing protocol in the treatment of newly diagnosed multidrug-resistant tuberculosis</ProtocolTitle><Reference>ChiCTR1800020391</Reference><Sponsor>Beijing Chest Hospital, Capital Medical University</Sponsor><Trial id="365020"/><TrialStartDate>DECEMBER , 01, 2012</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="16755">pafuramidine</Drug><EnrollmentCount>100</EnrollmentCount><Interventions>pafuramidine</Interventions><Patients>175</Patients><ProtocolAcronym/><ProtocolTitle>Randomized, double-blind, phase I safety and tolerability study of pafuramidine maleate (DB-289) in healthy subjects</ProtocolTitle><Reference>C05-013; NCT00619346</Reference><Sponsor>Immtech Pharmaceuticals Inc</Sponsor><Trial id="17432"/><TrialStartDate>NOVEMBER , 30, 2007</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampin</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><EnrollmentCount>320</EnrollmentCount><Interventions>clofazimine; isoniazid; pyrazinamide; rifampin</Interventions><Patients>320</Patients><ProtocolAcronym>CORTAIL</ProtocolAcronym><ProtocolTitle>Evaluation of clofazimine as a part of TB treatment in order to shorten the duration of treatment</ProtocolTitle><Reference>CORTAIL; CTRI/2019/03/018102</Reference><Sponsor>Indian Council of Medical Research</Sponsor><Trial id="373668"/><TrialStartDate>APRIL    , 01, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>3000</EnrollmentCount><Interventions>isoniazid; rifapentine</Interventions><Patients>3000</Patients><ProtocolAcronym/><ProtocolTitle>Study for latent tuberculosis infection intervention among close contacts of pulmonary tuberculosis patients</ProtocolTitle><Reference>ChiCTR1800019658</Reference><Sponsor>The Chinese Centre for Disease Control and Prevention</Sponsor><Trial id="361821"/><TrialStartDate>JUNE     , 10, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>bedaquiline; delamanid; moxifloxacin</Controls><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>75</EnrollmentCount><Interventions>bedaquiline; delamanid; midazolam; moxifloxacin; sutezolid</Interventions><Patients>75</Patients><ProtocolAcronym>SUDOCU</ProtocolAcronym><ProtocolTitle>PanACEA Sutezolid Dose-finding and Combination Evaluation</ProtocolTitle><Reference>NCT03959566; PANACEA-SUDOCU-01; SUDOCU</Reference><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><Trial id="381674"/><TrialStartDate>AUGUST   , 31, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>500</EnrollmentCount><Interventions>amikacin; bedaquiline; clarithromycin; clofazimine; cycloserine; ethambutol; linezolid; moxifloxacin; prothionamide; pyrazinamide; sodium para-aminosalicylate</Interventions><Patients>500</Patients><ProtocolAcronym/><ProtocolTitle>The Effect of 18-month Regimen Containing Six Anti-tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><Reference>2018ZX10722301-001; NCT03830671</Reference><Sponsor>Beijing Chest Hospital</Sponsor><Trial id="369109"/><TrialStartDate>MARCH    , 08, 2019</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>5+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>bedaquiline; bedaquiline; clofazimine; clofazimine; delamanid; delamanid; linezolid; linezolid</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><EnrollmentCount>500</EnrollmentCount><Interventions>bedaquiline; clofazimine; delamanid; linezolid</Interventions><Patients>500</Patients><ProtocolAcronym>endTB-Q</ProtocolAcronym><ProtocolTitle>Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance</ProtocolTitle><Reference>MSF ERB-1761; NCT03896685; endTB-Q</Reference><Sponsor>Mdecins Sans Frontires France</Sponsor><Trial id="375499"/><TrialStartDate>JUNE     , 30, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><EnrollmentCount>900</EnrollmentCount><Interventions>bedaquiline; clofazimine; ethambutol; isoniazid; levofloxacin; linezolid; pyrazinamide; rifampicin; rifapentine</Interventions><Patients>900</Patients><ProtocolAcronym>TRUNCATE-TB</ProtocolAcronym><ProtocolTitle>A 2 Month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-Sensitive Tuberculosis</ProtocolTitle><Reference>2016-CT0376; NCT03474198; PHRR170327-001522; TRUNCATE-TB; TRUNCATE-TB</Reference><Sponsor>Syneos Health Inc, University College London</Sponsor><Trial id="333435"/><TrialStartDate>MARCH    , 21, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="90231">DAR-901</Drug><EnrollmentCount>650</EnrollmentCount><Interventions>DAR-901</Interventions><Patients>650</Patients><ProtocolAcronym>DAR-PIA</ProtocolAcronym><ProtocolTitle>DAR-901 TB Booster Vaccine to Prevent TB in Adolescents</ProtocolTitle><Reference>29001; DAR-PIA; NCT02712424</Reference><Sponsor>Dartmouth-Hitchcock Medical Center</Sponsor><Trial id="256110"/><TrialStartDate>MARCH    , 31, 2016</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Th1 cytokines</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="48140">doxycycline (once-daily, oral controlled release), CollaGenex</Drug><EnrollmentCount>200</EnrollmentCount><Interventions>doxycycline (once-daily, oral controlled release), CollaGenex; doxycycline hyclate</Interventions><Patients>200</Patients><ProtocolAcronym>Map2Co</ProtocolAcronym><ProtocolTitle>Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana</ProtocolTitle><Reference>GZ:JA 1479/5-1; Map2Co; NCT02281643</Reference><Sponsor>kwame Nkrumah University of Science and Technology</Sponsor><Trial id="214864"/><TrialStartDate>OCTOBER  , 31, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Cytokines; Cytotoxic T-Lymphocytes; T-Helper Lymphocytes</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="48499">H4:IC31</Drug><EnrollmentCount>70</EnrollmentCount><Interventions>BCG SSI; HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Interventions><Patients>70</Patients><ProtocolAcronym/><ProtocolTitle>A Study for Safety and Immunogenicity of BCG and AERAS-404 in HIV-negative, TB-negative, BCG-naive Adults</ProtocolTitle><Reference>C-013-404; NCT02420444</Reference><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><Trial id="227111"/><TrialStartDate>JANUARY  , 31, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2829">clarithromycin</Drug><EnrollmentCount>500</EnrollmentCount><Interventions>amikacin; bedaquiline; clarithromycin; clofazimine; cycloserine; ethambutol; linezolid; moxifloxacin; prothionamide; pyrazinamide; sodium para-aminosalicylate</Interventions><Patients>500</Patients><ProtocolAcronym/><ProtocolTitle>The Effect of 18-month Regimen Containing Six Anti-tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><Reference>2018ZX10722301-001; NCT03830671</Reference><Sponsor>Beijing Chest Hospital</Sponsor><Trial id="369109"/><TrialStartDate>MARCH    , 08, 2019</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59062">dolutegravir</Drug><EnrollmentCount>16</EnrollmentCount><Interventions>dolutegravir; rifampicin</Interventions><Patients>16</Patients><ProtocolAcronym>RADIO</ProtocolAcronym><ProtocolTitle>A Clinical Study Investigating Rifampicin and Dolutegravir in Combination in Healthy Volunteers</ProtocolTitle><Reference>NCT03199690; RADIO; SSCR103</Reference><Sponsor>ST STEPHEN'S CLINICAL RESEARCH LIMITED</Sponsor><Trial id="303292"/><TrialStartDate>OCTOBER  , 31, 2017</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Human immunodeficiency virus RNA</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="59062">dolutegravir</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>dolutegravir; emtricitabine; isoniazid; rifapentine; tenofovir disoproxil fumarate</Interventions><Patients>60</Patients><ProtocolAcronym>IMPAACT4TB</ProtocolAcronym><ProtocolTitle>Safety, Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine Isoniazid in HIV+ Patients</ProtocolTitle><Reference>3HP DTG AUR1-6-212 IMPAACT4TB; IMPAACT4TB; NCT03435146</Reference><Sponsor>Aurum Institute</Sponsor><Trial id="329251"/><TrialStartDate>JANUARY  , 18, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2829">clarithromycin</Drug><EnrollmentCount>7</EnrollmentCount><Interventions>clarithromycin; linezolid; linezolid + clarithromycin</Interventions><Patients>7</Patients><ProtocolAcronym/><ProtocolTitle>Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients</ProtocolTitle><Reference>2011-000513-39; NCT01521364; NL35534.042.11; NTR3260</Reference><Sponsor>University Medical Center Groningen</Sponsor><Trial id="182646"/><TrialStartDate>DECEMBER , 31, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>B cells; CD4+; CD8+; Cytotoxic T-Lymphocytes; Interferon-gamma; Interleukin-2; T-Helper Lymphocytes; Tumor necrosis factor-alpha (TNF)</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55569">VPM-1002</Drug><EnrollmentCount>80</EnrollmentCount><Interventions>VPM-1-002</Interventions><Patients>80</Patients><ProtocolAcronym/><ProtocolTitle>Dose-Escalation Study on Safety and Immunogenicity of VPM-1-002 in Comparison With BCG in Healthy Male Volunteers</ProtocolTitle><Reference>EudraCT 2007-002789-37; NCT00749034; VPM1002-GE-1.01TB</Reference><Sponsor>Vakzine Projekt Management GmbH</Sponsor><Trial id="48943"/><TrialStartDate>SEPTEMBER, 30, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>CD4-count; Eosinophils; IFN-gamma; IL5; IgE; Interleukin-10; TGF-beta; Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12132">albendazole</Drug><EnrollmentCount>140</EnrollmentCount><Interventions>albendazole</Interventions><Patients>140</Patients><ProtocolAcronym/><ProtocolTitle>Deworming Against Tuberculosis</ProtocolTitle><Reference>ALBP; HLF-20060245; NCT00857116</Reference><Sponsor>Linkoping University</Sponsor><Trial id="48176"/><TrialStartDate>MARCH    , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>40</EnrollmentCount><Interventions>moxifloxacin</Interventions><Patients>39</Patients><ProtocolAcronym/><ProtocolTitle>The Effect of Ethnic on Moxifloxacin Induced QT Interval Prolongation in Korean and Japanese Healthy Subjects</ProtocolTitle><Reference>12-166; NCT01876316</Reference><Sponsor>Inje University</Sponsor><Trial id="139433"/><TrialStartDate>NOVEMBER , 30, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>MVA-85A</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>A phase I study of a new tuberculosis (TB) vaccine, MVA-85A, in healthy volunteers with HIV</ProtocolTitle><Reference>NCT00731471; TB019</Reference><Sponsor>University of Oxford</Sponsor><Trial id="23059"/><TrialStartDate>AUGUST   , 31, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>CD4+</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>180</EnrollmentCount><Interventions>didanosine; efavirenz; efavirenz +  didanosine + lamivudine; ethambutol; ethambutol + isoniazid + rifampicin + pyrazinamide; isoniazid; isoniazid + rifampicin; lamivudine; nevirapine; nevirapine + didanosine + lamivudine; pyrazinamide; rifampicin</Interventions><Patients>116</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-Tuberculosis Treatment</ProtocolTitle><Reference>NCT00332306; trc23</Reference><Sponsor>Tuberculosis Research Centre</Sponsor><Trial id="10863"/><TrialStartDate>JUNE     , 30, 2006</TrialStartDate><TrialStatus>Suspended</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Solute carrier organic anion transporter family member 1B1</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>48</EnrollmentCount><Interventions>efavirenz; isoniazid; lamivudine; lopinavir + ritonavir; nevirapine; rifabutin; stavudine</Interventions><Patients>35</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa</ProtocolTitle><Reference>ANRS12150a; NCT00640887</Reference><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><Trial id="11187"/><TrialStartDate>FEBRUARY , 28, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Primflo</Controls><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>moxifloxacin</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>A randomized, open, balanced, two-component, two-period, crossover, with a single-dose study of comparative pharmacokinetics and bioequivalence of Primflo (moxifloxacin) 400 mg (Dr Reddy's Laboratories Ltd, India) and Avilox  (moxifloxacin) 400 mg (Bayer Healthcare AG, Germany), when taken orally on an empty stomach in healthy adult volunteers</ProtocolTitle><Reference>DRL_RUS/MD/2012rmox1</Reference><Sponsor>Dr Reddy's Laboratories Ltd</Sponsor><Trial id="167750"/><TrialStartDate>OCTOBER  , 10, 2012</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="11088">sutezolid</Drug><EnrollmentCount>59</EnrollmentCount><Interventions>PNU-100480</Interventions><Patients>59</Patients><ProtocolAcronym/><ProtocolTitle>Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers</ProtocolTitle><Reference>B1171002; NCT00990990</Reference><Sponsor>Sequella Inc</Sponsor><Trial id="60906"/><TrialStartDate>OCTOBER  , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>19</EnrollmentCount><Interventions>isoniazid; kanamycin; moxifloxacin; pyrazinamide; rifampicin</Interventions><Patients>19</Patients><ProtocolAcronym/><ProtocolTitle>Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis</ProtocolTitle><Reference>09-I-N061; 999909061; NCT00816426</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="192117"/><TrialStartDate>DECEMBER , 29, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>197</EnrollmentCount><Interventions>ethambutol; isoniazid; moxifloxacin; pyrazinamide; rifampicin</Interventions><Patients>58</Patients><ProtocolAcronym>IMPRESS</ProtocolAcronym><ProtocolTitle>Improving Retreatment Success</ProtocolTitle><Reference>CAP 011; IMPRESS; NCT02114684</Reference><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><Trial id="182040"/><TrialStartDate>NOVEMBER , 30, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Mitochondria</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="11036">linezolid</Drug><EnrollmentCount>41</EnrollmentCount><Interventions>linezolid</Interventions><Patients>41</Patients><ProtocolAcronym/><ProtocolTitle>Linezolid to Treat Extensively-Drug Resistant Tuberculosis</ProtocolTitle><Reference>08-I-N167; 999908167; NCT00727844</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="23143"/><TrialStartDate>JULY     , 31, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="16545">delamanid</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>OPC-67683</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis</ProtocolTitle><Reference>2009-014944-13; 242-08-210; NCT01131351</Reference><Sponsor>Otsuka Holdings Co Ltd</Sponsor><Trial id="66735"/><TrialStartDate>FEBRUARY , 28, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="5321">indinavir</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>indinavir; ritonavir</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>The Pharmacokinetics and Safety of indinavir/ritonavir With NRTIs in HIV/TB co-Infected Patients Receiving Rifampicin</ProtocolTitle><Reference>HIV-NAT 044; NCT00411996</Reference><Sponsor>The HIV Netherlands Australia Thailand Research Collaboration</Sponsor><Trial id="10871"/><TrialStartDate>DECEMBER , 31, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>CD4; Cytotoxic T-Lymphocytes; HIV viral load; Human immunodeficiency virus RNA; T-Helper Lymphocytes; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Kaletra; ethambutol; isoniazid; pyrazinamide; pyridoxine; rifampin</Controls><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><EnrollmentCount>71</EnrollmentCount><Interventions>Kaletra; ethambutol; isoniazid; pyrazinamide; pyridoxine; raltegravir; rifabutin</Interventions><Patients>71</Patients><ProtocolAcronym/><ProtocolTitle>Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV</ProtocolTitle><Reference>1U01AI068636; ACTG A5290; NCT01601626</Reference><Sponsor>AIDS Clinical Trials Group</Sponsor><Trial id="87585"/><TrialStartDate>JULY     , 13, 2013</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3474">lamivudine</Drug><EnrollmentCount>120</EnrollmentCount><Interventions>Rifafour; Rifafour; efavirenz; lamivudine; zidovudine</Interventions><Patients>120</Patients><ProtocolAcronym>PK-TB-HAART</ProtocolAcronym><ProtocolTitle>Bioavailability of the Fixed Dose Formulation Rifafour Containing Isoniazid, Rifampicin, Pyrazinamide, Ethambutol and the World Health Organization (WHO) Recommended First Line Antiretroviral Drugs Zidovudine, Lamivudine, Efavirenz Administered to New Tuberculosis (TB) Patients at Different Levels of Immunosuppression</ProtocolTitle><Reference>A40607; ISRCTN83323477; PK-TB-HAART</Reference><Sponsor>World Health Organization</Sponsor><Trial id="136052"/><TrialStartDate>MAY      , 29, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Albumin; Orosomucoid; Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44370">clindamycin</Drug><EnrollmentCount>63</EnrollmentCount><Interventions>clindamycin; rifampin; ticarcillin-clavulanate</Interventions><Patients>62</Patients><ProtocolAcronym>Staph</ProtocolAcronym><ProtocolTitle>Pharmacokinetics of Antistaphylococcal Antibiotics in Infants</ProtocolTitle><Reference>NCT01728363; NICHD-2012-02-Staph Trio; Pro00037820; Staph</Reference><Sponsor>Duke University</Sponsor><Trial id="98566"/><TrialStartDate>JANUARY  , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4481">stavudine</Drug><EnrollmentCount>661</EnrollmentCount><Interventions>efavirenz; efavirenz + lamivudine + stavudine; lamivudine; stavudine</Interventions><Patients>540</Patients><ProtocolAcronym>ANRS 1295 CAMELIA</ProtocolAcronym><ProtocolTitle>Early versus Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis</ProtocolTitle><Reference>ANRS 1295 CAMELIA; ANRS 1295 CAMELIA; CIPRA KH 001; NCT00226434; NCT00498823</Reference><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><Trial id="145651"/><TrialStartDate>JANUARY  , 31, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Alanine aminotransferase; CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>efavirenz; lamivudine; stavudine</Controls><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><EnrollmentCount>570</EnrollmentCount><Interventions>Arm A; Arm B; Triomune; ethambutol; ethambutol; isoniazid; isoniazid; lamivudine; nevirapine; pyrazinamide; pyrazinamide; rifampicin; rifampicin; stavudine</Interventions><Patients>570</Patients><ProtocolAcronym>CARINEMO</ProtocolAcronym><ProtocolTitle>Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients</ProtocolTitle><Reference>ANRS 12146 CARINEMO; ANRS 12146/12214; ANRS 12214; CARINEMO; NCT00495326</Reference><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><Trial id="10948"/><TrialStartDate>DECEMBER , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>200</EnrollmentCount><Interventions>ethambutol; isoniazid; moxifloxacin; pyrazinamide; rifampicin</Interventions><Patients>200</Patients><ProtocolAcronym/><ProtocolTitle>Latency in Pulmonary Tuberculosis</ProtocolTitle><Reference>LTB01; NCT01154959</Reference><Sponsor>Tuberculosis Research Centre</Sponsor><Trial id="67984"/><TrialStartDate>FEBRUARY , 28, 2010</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44316">zidovudine</Drug><EnrollmentCount>120</EnrollmentCount><Interventions>Rifafour; Rifafour; efavirenz; lamivudine; zidovudine</Interventions><Patients>120</Patients><ProtocolAcronym>PK-TB-HAART</ProtocolAcronym><ProtocolTitle>Bioavailability of the Fixed Dose Formulation Rifafour Containing Isoniazid, Rifampicin, Pyrazinamide, Ethambutol and the World Health Organization (WHO) Recommended First Line Antiretroviral Drugs Zidovudine, Lamivudine, Efavirenz Administered to New Tuberculosis (TB) Patients at Different Levels of Immunosuppression</ProtocolTitle><Reference>A40607; ISRCTN83323477; PK-TB-HAART</Reference><Sponsor>World Health Organization</Sponsor><Trial id="136052"/><TrialStartDate>MAY      , 29, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><EnrollmentCount>207</EnrollmentCount><Interventions>DRMPa200Z regimen; HRZE regimen; MPa100Z regimen; MPa200Z regimen; PA-824; Rifafour; ethambutol; isoniazid; moxifloxacin; pyrazinamide; pyrazinamide; rifampicin</Interventions><Patients>207</Patients><ProtocolAcronym/><ProtocolTitle>Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB)</ProtocolTitle><Reference>NC-002-(M-Pa-Z); NCT01498419</Reference><Sponsor>TB Alliance</Sponsor><Trial id="83489"/><TrialStartDate>MARCH    , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>lopinavir+ritonavir; rifabutin</Interventions><Patients>30</Patients><ProtocolAcronym>RIFLOPI</ProtocolAcronym><ProtocolTitle>Rifabutin With Lopinavir/ritonavir in Patients Coinfected With Tuberculosis and HIV in Burkina Faso</ProtocolTitle><Reference>PACTR201310000629390; RIFLOPI</Reference><Sponsor>Institut de Recherche en Sciences de la Sante (IRSS), Burkina Faso</Sponsor><Trial id="161441"/><TrialStartDate>NOVEMBER , 28, 2013</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>T-Lymphocytes</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><EnrollmentCount>42</EnrollmentCount><Interventions>ChAdOx1-85A; ChAdOx1-85A; MVA-85A</Interventions><Patients>42</Patients><ProtocolAcronym/><ProtocolTitle>Safety Study of ChAdOx1-85A Vaccination With and Without MVA-85A Boost in Healthy Adults</ProtocolTitle><Reference>NCT01829490; TB034; UKCRN 14241</Reference><Sponsor>University of Oxford</Sponsor><Trial id="120744"/><TrialStartDate>JULY     , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="13624">BCG vaccine, Organon</Drug><EnrollmentCount>120</EnrollmentCount><Interventions>BCG vaccine, Organon</Interventions><Patients>120</Patients><ProtocolAcronym/><ProtocolTitle>Challenge Model for Assessment of Human TB Immunity</ProtocolTitle><Reference>11-0033; HHSN272200800003C; N01AI80003C; NCT01868464</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="149358"/><TrialStartDate>JUNE     , 30, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><EnrollmentCount>74</EnrollmentCount><Interventions>PA-824; moxifloxacin</Interventions><Patients>74</Patients><ProtocolAcronym/><ProtocolTitle>Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers</ProtocolTitle><Reference>10-0058; N01AI80024C; NCT01674218</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="90512"/><TrialStartDate>SEPTEMBER, 30, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Blood pressure; Body temperature; Heart rate; QT interval; Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="16545">delamanid</Drug><EnrollmentCount>481</EnrollmentCount><Interventions>Optimized background regimen; delamanid</Interventions><Patients>481</Patients><ProtocolAcronym/><ProtocolTitle>A Placebo-Controlled, Phase II Trial to Evaluate OPC-67683 in Patients With Pulmonary Sputum Culture-Positive, Multidrug-Resistant Tuberculosis (TB)</ProtocolTitle><Reference>2007-005229-31; 242-07-204; NCT00685360; Trial 204</Reference><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><Trial id="15754"/><TrialStartDate>APRIL    , 30, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>kanamycin; moxifloxacin</Controls><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><EnrollmentCount>300</EnrollmentCount><Interventions>bedaqualine; ethionamide; isoniazid; levofloxacin; linezolid; pyrazinamide; terizidone</Interventions><Patients>300</Patients><ProtocolAcronym>NEXT</ProtocolAcronym><ProtocolTitle>An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multidrug-resistant Tuberculosis</ProtocolTitle><Reference>NCT02454205; NEXT; NEXT-5001</Reference><Sponsor>University of Cape Town</Sponsor><Trial id="230529"/><TrialStartDate>OCTOBER  , 31, 2015</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>ABCB1; CD4; CYP2B6; CYP3A5; Cytochrome P450 2B6; Cytochrome P450 3A5; Multidrug resistance protein 1; SLCO1B1; Solute carrier organic anion transporter family member 1B1; Total body mass; UDP-glucuronosyltransferase 2B7; UGT2B7; body mass index; plasma HIV-1 RNA load</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>efavirenz</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>800</EnrollmentCount><Interventions>efavirenz; rifampicin</Interventions><Patients>493</Patients><ProtocolAcronym>HIV-TB Pharmagene</ProtocolAcronym><ProtocolTitle>Optimization of Tuberculosis and HIV Co-treatment in Africa</ProtocolTitle><Reference>HIV-TB Pharmagene; PACTR2009040001261177</Reference><Sponsor>Karolinska Institutet</Sponsor><Trial id="131419"/><TrialStartDate>JANUARY  , 09, 2008</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>CD4 Positive T Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><EnrollmentCount>642</EnrollmentCount><Interventions>didanosine; efavirenz; lamivudine; lamivudine + efavirenz + didanosine; trimethoprim + sulfamethoxazole</Interventions><Patients>642</Patients><ProtocolAcronym>SAPIT</ProtocolAcronym><ProtocolTitle>A Study to Compare Three Existing Starting Points of Antiretroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients</ProtocolTitle><Reference>CAPRISA 003; NCT00398996; SAPIT</Reference><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><Trial id="201474"/><TrialStartDate>JUNE     , 30, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>36</EnrollmentCount><Interventions>bedaquiline</Interventions><Patients>36</Patients><ProtocolAcronym/><ProtocolTitle>A Study to Assess the Relative Bioavailability of TMC-207 Following Single-dose Administrations of Two Pediatric Formulations in Healthy Adult Participants</ProtocolTitle><Reference>2012-005492-13; CR100987; NCT01803373; TMC207TBC1002</Reference><Sponsor>Janssen Research &amp; Development LLC</Sponsor><Trial id="114087"/><TrialStartDate>APRIL    , 30, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7017">gatifloxacin</Drug><EnrollmentCount>429</EnrollmentCount><Interventions>ethambutol; gatifloxacin; isoniazid; moxifloxacin; pyrazinamide; rifampicin</Interventions><Patients>416</Patients><ProtocolAcronym/><ProtocolTitle>Thrice-Weekly, 4- Months Moxifloxacin or Gatifloxacin Regimens for Pulmonary TB</ProtocolTitle><Reference>CTRI/2012/10/003060</Reference><Sponsor>Indian Council of Medical Research</Sponsor><Trial id="150332"/><TrialStartDate>MAY      , 14, 2004</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>74</EnrollmentCount><Interventions>PA-824; moxifloxacin</Interventions><Patients>74</Patients><ProtocolAcronym/><ProtocolTitle>Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers</ProtocolTitle><Reference>10-0058; N01AI80024C; NCT01674218</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="90512"/><TrialStartDate>SEPTEMBER, 30, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount>120</EnrollmentCount><Interventions>ethambutol; isoniazid; levofloxacin; pyrazinamide; rifampicin</Interventions><Patients>114</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of Modified Anti-tubercular Regimens in Treatment of Tuberculosis in Patients With Underlying Compensated and Decompensated Chronic Liver Disease</ProtocolTitle><Reference>ILBS-ATT-01; NCT01677871</Reference><Sponsor>Institute of Liver and Biliary Sciences, India</Sponsor><Trial id="90788"/><TrialStartDate>SEPTEMBER, 30, 2012</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Blood pressure; Body temperature; Heart rate; Respiratory frequency</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="95442">ESAT-6CFP10</Drug><EnrollmentCount>32</EnrollmentCount><Interventions>ESAT-6CFP10</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>Phase I Clinical Human Tolerability Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10</ProtocolTitle><Reference>LTAO; LTAO-EC; NCT01999231</Reference><Sponsor>Anhui Zhifei Longcom Biopharmaceutical Co Ltd</Sponsor><Trial id="163196"/><TrialStartDate>SEPTEMBER, 30, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Antigen KI-67; CD4 T cells; Cytotoxic T-Lymphocytes; Interleukin 17; Ki67(+) T cells; T-Helper Lymphocytes; T-Lymphocytes; T-cell surface glycoprotein CD8 alpha chain; Th1 cytokine</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><EnrollmentCount>45</EnrollmentCount><Interventions>GSK-692342</Interventions><Patients>45</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety of a Candidate Tuberculosis (TB) Vaccine Given to Healthy Adults in a TB-Endemic Region</ProtocolTitle><Reference>110347; NCT00600782</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="11563"/><TrialStartDate>FEBRUARY , 29, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><EnrollmentCount>10</EnrollmentCount><Interventions>abacavir; lamivudine; raltegravir</Interventions><Patients>10</Patients><ProtocolAcronym/><ProtocolTitle>Raltegravir + ABC/3TC in HIV/TB Co-Infected Patients</ProtocolTitle><Reference>NCT01059422; RAL/ABC/3TC - HIV/TB</Reference><Sponsor>Central Research Institute of Epidemiology</Sponsor><Trial id="63729"/><TrialStartDate>OCTOBER  , 31, 2010</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55173">cadi-05</Drug><EnrollmentCount>1020</EnrollmentCount><Interventions>Mycobacterium w</Interventions><Patients>1020</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary Tuberculosis (TB) Retreatment Patients</ProtocolTitle><Reference>CR-01A/2003-10; NCT00265226; NI-705</Reference><Sponsor>Indian Government Department of Biotechnology</Sponsor><Trial id="10057"/><TrialStartDate>MARCH    , 31, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="81037">Wei Ka</Drug><EnrollmentCount>10000</EnrollmentCount><Interventions>Vaccae</Interventions><Patients>10000</Patients><ProtocolAcronym/><ProtocolTitle>Phase III Clinical Study of Efficacy and Safety of Vaccae to Prevent Tuberculosis</ProtocolTitle><Reference>ChiCTR-PRC-13003741; LTAO; NCT01979900; U1111-1149-6525</Reference><Sponsor>Anhui Zhifei Longcom Biopharmaceutical Co Ltd</Sponsor><Trial id="160177"/><TrialStartDate>OCTOBER  , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Alanine transaminase; Alkaline phosphatase; Bilirubin; Blood platelets; Hemoglobin; International Normalized Ratio; Leukocyte count</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>150</EnrollmentCount><Interventions>isoniazid; rifapentine</Interventions><Patients>150</Patients><ProtocolAcronym>DOT-LTBI</ProtocolAcronym><ProtocolTitle>Treatment of Latent Tuberculosis in Socially Marginalised Citizens</ProtocolTitle><Reference>2016-003567-20; A101A; DOT-LTBI; NCT03266991</Reference><Sponsor>Aarhus University Hospital</Sponsor><Trial id="310930"/><TrialStartDate>OCTOBER  , 27, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Alanine transaminase; Aspartate aminotransferase</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>283</EnrollmentCount><Interventions>isoniazid; rifapentine</Interventions><Patients>283</Patients><ProtocolAcronym/><ProtocolTitle>Toward a Safe and Reachable Preventive Therapy for LTBI: a Multicenter, Randomized, Controlled Study in Taiwan</ProtocolTitle><Reference>201309055MINC; NCT02208427</Reference><Sponsor>National Taiwan University Hospital</Sponsor><Trial id="207608"/><TrialStartDate>AUGUST   , 31, 2014</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="81363">AEC/BC02</Drug><EnrollmentCount>135</EnrollmentCount><Interventions>AEC/BC02</Interventions><Patients>135</Patients><ProtocolAcronym/><ProtocolTitle>Freeze-dried recombinant tuberculosis vaccine (AEC/BC02) phase I clinical human tolerance test</ProtocolTitle><Reference>201601; CTR20180066</Reference><Sponsor>Anhui Zhifei Longcom Biopharmaceutical Co Ltd</Sponsor><Trial id="329497"/><TrialStartDate/><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; pyridoxine; rifampin</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>ethambutol; isoniazid; moxifloxacin; pyrazinamide; pyridoxine; rifampin; rifapentine</Interventions><Patients>60</Patients><ProtocolAcronym>S31PK/PD</ProtocolAcronym><ProtocolTitle>Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis</ProtocolTitle><Reference>CDC-NCHHSTP-6719; NCT02563327; S31PK/PD</Reference><Sponsor>Centers for Disease Control and Prevention</Sponsor><Trial id="242269"/><TrialStartDate>MAY      , 30, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="11088">sutezolid</Drug><EnrollmentCount>32</EnrollmentCount><Interventions>sutezolid</Interventions><Patients>32</Patients><ProtocolAcronym/><ProtocolTitle>Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid</ProtocolTitle><Reference>NCT03199313; SUTEZOLID - CL001</Reference><Sponsor>TB Alliance</Sponsor><Trial id="303595"/><TrialStartDate>SEPTEMBER, 26, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>92</EnrollmentCount><Interventions>rifapentine</Interventions><Patients>92</Patients><ProtocolAcronym/><ProtocolTitle>Randomized, Open-label, Comparative Study to Evaluate the Rifapentine in the Treatment of Patients Newly Diagnosed with Pulmonary Tuberculosis Negative and Smear-with Preserved Sensitivity of Mycobacteria</ProtocolTitle><Reference>1/11</Reference><Sponsor>S.P.Inkomed Pvt. Ltd</Sponsor><Trial id="168261"/><TrialStartDate>SEPTEMBER, 27, 2011</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Immunoglobulin G</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="107803">GamTBvac</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>GamTBvac</Interventions><Patients>60</Patients><ProtocolAcronym>GamTBvac</ProtocolAcronym><ProtocolTitle>Evaluation of the Safety and Immunogenicity of the Recombinant Subunit Vaccine 'GamTBvac' Against the Tuberculosis</ProtocolTitle><Reference>GAMTBVAC PH1; GamTBvac; NCT03255278</Reference><Sponsor>Gamalei Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation Collaborator</Sponsor><Trial id="309614"/><TrialStartDate>JANUARY  , 15, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>levofloxacin</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount>14</EnrollmentCount><Interventions>levofloxacin [Laboratorios Serral(MX)]</Interventions><Patients>14</Patients><ProtocolAcronym/><ProtocolTitle>Study to assess the bioequivalence of two oral formulations of levofloxacin tablets: FLEVOX (SERRAL, SA de CV), versus TAVANIC (Sanofi-Aventis of Mexico, SA de CV), after administration of a single dose- 500 mg to healthy adult subjects of both genders, in the fasting state</ProtocolTitle><Reference>LVFL-SRRL-03</Reference><Sponsor>Laboratorios Serral</Sponsor><Trial id="227604"/><TrialStartDate/><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Solute carrier organic anion transporter family member 1B1</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><EnrollmentCount>48</EnrollmentCount><Interventions>efavirenz; isoniazid; lamivudine; lopinavir + ritonavir; nevirapine; rifabutin; stavudine</Interventions><Patients>35</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa</ProtocolTitle><Reference>ANRS12150a; NCT00640887</Reference><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><Trial id="11187"/><TrialStartDate>FEBRUARY , 28, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44284">amoxicillin + clavulanate potassium, GSK</Drug><EnrollmentCount>43</EnrollmentCount><Interventions>Augmentin; faropenem; rifampicin; rifampicin</Interventions><Patients>36</Patients><ProtocolAcronym/><ProtocolTitle>Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers</ProtocolTitle><Reference>Faro-WBA; NCT02393586</Reference><Sponsor>National University Hospital (Singapore) Pte Ltd</Sponsor><Trial id="224811"/><TrialStartDate>FEBRUARY , 28, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Alanine transaminase; Alkaline phosphatase; Aspartate aminotransferase; Bilirubin; Blood cells; Creatinine; T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>2500</EnrollmentCount><Interventions>isoniazid; pyridoxine; rifapentine</Interventions><Patients>2500</Patients><ProtocolAcronym/><ProtocolTitle>Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals</ProtocolTitle><Reference>HIV-NAT 255; NCT03785106</Reference><Sponsor>The HIV Netherlands Australia Thailand Research Collaboration</Sponsor><Trial id="364544"/><TrialStartDate>MARCH    , 31, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>bedaquiline; delamanid; moxifloxacin</Controls><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="44303">midazolam hydrochloride</Drug><EnrollmentCount>75</EnrollmentCount><Interventions>bedaquiline; delamanid; midazolam; moxifloxacin; sutezolid</Interventions><Patients>75</Patients><ProtocolAcronym>SUDOCU</ProtocolAcronym><ProtocolTitle>PanACEA Sutezolid Dose-finding and Combination Evaluation</ProtocolTitle><Reference>NCT03959566; PANACEA-SUDOCU-01; SUDOCU</Reference><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><Trial id="381674"/><TrialStartDate>AUGUST   , 31, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="68617">ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis</Drug><EnrollmentCount>107</EnrollmentCount><Interventions>ID-93</Interventions><Patients>107</Patients><ProtocolAcronym/><ProtocolTitle>Phase IIa Clinical Trial of ID93 + GLA-SE Vaccine in BCG-vaccinated Healthy Healthcare Workers</ProtocolTitle><Reference>CT-QTP101-001; NCT03806686</Reference><Sponsor>Quratis Co Ltd</Sponsor><Trial id="366580"/><TrialStartDate>MAY      , 31, 2018</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>4 beta-Hydroxycholesterol/Cholesterol ratio</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Lamprene; ethambutol (Myambutol); isoniazid (Nydrazid); kanamycin (Kantrex); moxifloxacin; prothionamide (Peteha); pyrazinamide (Zinamide)</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>530</EnrollmentCount><Interventions>Lamprene; Regimen A locally-used WHO-approved MDR-TB regimen; bedaquiline; ethambutol (Myambutol); isoniazid (Nydrazid); kanamycin (Kantrex); levofloxacin; moxifloxacin; prothionamide (Peteha); pyrazinamide (Zinamide)</Interventions><Patients>530</Patients><ProtocolAcronym>STREAM</ProtocolAcronym><ProtocolTitle>The Evaluation of a Standard Treatment Regimen of Anti-Tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><Reference>18148631; 78372190; 78372190/18148631 (Stage 1/2); CTRI/2017/09/009693; ISRCTN78372190; NCT02409290; STREAM</Reference><Sponsor>International Union Against Tuberculosis and Lung Diseases</Sponsor><Trial id="228190"/><TrialStartDate>APRIL    , 30, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Creatinine; Human immunodeficiency virus RNA; T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C0">Phase 0 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>419</EnrollmentCount><Interventions>efavirenz; emtricitabine; lamivudine; tenofovir</Interventions><Patients>419</Patients><ProtocolAcronym/><ProtocolTitle>TasP in Correctional Facilities</ProtocolTitle><Reference>15-1473; NCT02946762; Z 31501</Reference><Sponsor>University of North Carolina</Sponsor><Trial id="280225"/><TrialStartDate>FEBRUARY , 01, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><EnrollmentCount>200</EnrollmentCount><Interventions>efavirenz; emtricitabine; emtricitabine; lopinavir + ritonavir; rifabutin; rifampicin; tenofovir disoproxil fumarate; tenofovir disoproxil fumarate</Interventions><Patients>200</Patients><ProtocolAcronym>RIFART</ProtocolAcronym><ProtocolTitle>RIFART</ProtocolTitle><Reference>EudraCT 2007-007935-14; MI2-RIFART-2005; RIFART</Reference><Sponsor>Azienda Ospedaliera Spedali Civili di Brescia</Sponsor><Trial id="131240"/><TrialStartDate>MARCH    , 15, 2005</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Interferon gamma</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="57308">RUTI</Drug><EnrollmentCount>27</EnrollmentCount><Interventions>RUTI</Interventions><Patients>27</Patients><ProtocolAcronym/><ProtocolTitle>Safety of RUTI Vaccination in MDR-TB Patients</ProtocolTitle><Reference>201600136; NCT02711735</Reference><Sponsor>Archivel Farma SL</Sponsor><Trial id="256039"/><TrialStartDate>JANUARY  , 01, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4229">rifabutin</Drug><EnrollmentCount/><Interventions>clarithromycin; levofloxacin; moxifloxacin; moxifloxacin; rifabutin</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>The research of new regimen for multidrug-resistant tuberculosis treatment</ProtocolTitle><Reference>ChiCTR-IOR-15007291</Reference><Sponsor>Beijing Chest Hospital, Beijing Tuberculosis &amp; Thoracic Tumor Research Institute, Capital Medical University</Sponsor><Trial id="244777"/><TrialStartDate>OCTOBER  , 01, 2008</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>WHO regimen therapy</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount/><Interventions>Deltyba; Lamprene; Levaquin; Sirturo; Zyvox</Interventions><Patients/><ProtocolAcronym>DRAMATIC</ProtocolAcronym><ProtocolTitle>Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB</ProtocolTitle><Reference>DRAMATIC; H38212; NCT03828201</Reference><Sponsor>Boston University</Sponsor><Trial id="368916"/><TrialStartDate>JANUARY  , 31, 2020</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>5+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4492">faropenem</Drug><EnrollmentCount>45</EnrollmentCount><Interventions>Augmentin; cefadroxil; cefadroxil; ethambutol; faropenem; faropenem; isoniazid; pyrazinamide; rifampicin</Interventions><Patients>45</Patients><ProtocolAcronym/><ProtocolTitle>Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers</ProtocolTitle><Reference>2015-CT0284; FAROPENEM_TB; NCT02381470; PHRR160323-001194</Reference><Sponsor>National University Hospital (Singapore) Pte Ltd, Syneos Health Inc</Sponsor><Trial id="224111"/><TrialStartDate>DECEMBER , 31, 2018</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Human immunodeficiency virus DNA; Human immunodeficiency virus RNA; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>efavirenz; lamivudine; tenofovir disoproxil fumarate</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>155</EnrollmentCount><Interventions>lamivudine; raltegravir; tenofovir disoproxil fumarate</Interventions><Patients>155</Patients><ProtocolAcronym>REFLATE TB</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Two Raltegravir Doses in Naive HIV-1-Infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><Reference>2008-004970-41; ANRS 12 180; ANRS 12180 REFLATE TB; NCT00822315; REFLATE TB</Reference><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><Trial id="40948"/><TrialStartDate>JULY     , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4492">faropenem</Drug><EnrollmentCount>43</EnrollmentCount><Interventions>Augmentin; faropenem; rifampicin; rifampicin</Interventions><Patients>36</Patients><ProtocolAcronym/><ProtocolTitle>Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers</ProtocolTitle><Reference>Faro-WBA; NCT02393586</Reference><Sponsor>National University Hospital (Singapore) Pte Ltd</Sponsor><Trial id="224811"/><TrialStartDate>FEBRUARY , 28, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44437">verapamil</Drug><EnrollmentCount>69</EnrollmentCount><Interventions>Verapamil; isoniazid; rifampicin</Interventions><Patients>69</Patients><ProtocolAcronym/><ProtocolTitle>Verapamil Dose-finding Study in Adult Patients with Tuberculosis</ProtocolTitle><Reference>CTRI/2016/05/006928</Reference><Sponsor>Indian Government Department of Biotechnology</Sponsor><Trial id="261260"/><TrialStartDate>JUNE     , 15, 2016</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="6050">metformin hydrochloride</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>metformin</Interventions><Patients>60</Patients><ProtocolAcronym/><ProtocolTitle>Effect of metformin on sputum smear conversion in pulmonary tuberculosis with type 2 diabetes mellitus</ProtocolTitle><Reference>TCTR20190128004</Reference><Sponsor>Khonkaen Hospital</Sponsor><Trial id="370128"/><TrialStartDate>MARCH    , 01, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Creatinine; Human immunodeficiency virus RNA; T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C0">Phase 0 Clinical</DevStatus><Drug id="14493">tenofovir disoproxil fumarate</Drug><EnrollmentCount>419</EnrollmentCount><Interventions>efavirenz; emtricitabine; lamivudine; tenofovir</Interventions><Patients>419</Patients><ProtocolAcronym/><ProtocolTitle>TasP in Correctional Facilities</ProtocolTitle><Reference>15-1473; NCT02946762; Z 31501</Reference><Sponsor>University of North Carolina</Sponsor><Trial id="280225"/><TrialStartDate>FEBRUARY , 01, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="4155">pravastatin</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>Vitamin B6; ethambutol; isoniazid; pravastatin; pyrazinamide; rifampin</Interventions><Patients>30</Patients><ProtocolAcronym>Stat-TB</ProtocolAcronym><ProtocolTitle>Statin Adjunctive Therapy for TB: A Phase IIb Dose-finding Study of Pravastatin in Adults With Tuberculosis</ProtocolTitle><Reference>38558; NCT03882177; Stat-TB</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="374083"/><TrialStartDate>JUNE     , 15, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="104087">FS-1</Drug><EnrollmentCount>480</EnrollmentCount><Interventions>FS-1; Standard DOTS</Interventions><Patients>480</Patients><ProtocolAcronym>FS-1</ProtocolAcronym><ProtocolTitle>FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis</ProtocolTitle><Reference>FS-1; NCT02607449; TP-004 V 1.0</Reference><Sponsor>Scientific Center for Anti-infectious Drugs, Kazakhstan</Sponsor><Trial id="246553"/><TrialStartDate>DECEMBER , 31, 2013</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Carbon monoxide diffusing capacity; Cytotoxic T-Lymphocytes; Forced Vital Capacity; Forced expiratory volume; Interferon gamma; Interleukin-2; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="53975">AERAS-402</Drug><EnrollmentCount>72</EnrollmentCount><Interventions>AERAS-402</Interventions><Patients>72</Patients><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Safety of AERAS-402 in Adults Recently Treated for Pulmonary TB</ProtocolTitle><Reference>C-010-402; NCT02414828</Reference><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><Trial id="226801"/><TrialStartDate>OCTOBER  , 31, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Standard of Care; ampicillin; benzylpenicillin; ceftriaxone; cotrimoxazole; gentamicin; prednisolone; sulfamethoxazole; trimethoprim</Controls><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="25182">valganciclovir</Drug><EnrollmentCount>624</EnrollmentCount><Interventions>Standard or Care; rifampicin + isoniazid + ethambutol; rifampicin + isoniazid + pyrazinamide; valganciclovir; valganciclovir</Interventions><Patients>624</Patients><ProtocolAcronym>EMPIRICAL</ProtocolAcronym><ProtocolTitle>Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia</ProtocolTitle><Reference>19/096; 2019-001749-42; EDCTP RIA2017MC-2013EMPIRICAL; EMPIRICAL; NCT03915366; PACTR201904797961340; U1111-1231-4736</Reference><Sponsor>Hospital Universitario 12 de Octubre</Sponsor><Trial id="377163"/><TrialStartDate>JANUARY  , 01, 2020</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>pryrazinamide</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><EnrollmentCount>750</EnrollmentCount><Interventions>Lamprene; bedaquiline; delamanid; levofloxacin; linezolid; moxifloxacin; pryrazinamide</Interventions><Patients>750</Patients><ProtocolAcronym>endTB</ProtocolAcronym><ProtocolTitle>Evaluating Newly Approved Drugs for Multidrug-resistant TB</ProtocolTitle><Reference>MSF ERB-1555; NCT02754765; endTB</Reference><Sponsor>Mdecins Sans Frontires France</Sponsor><Trial id="259506"/><TrialStartDate>DECEMBER , 31, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3616">meropenem</Drug><EnrollmentCount>448</EnrollmentCount><Interventions>amikacin; amoxicillin + clavulanate; azithromycin; bedaquiline; capreomycin; clarithromycin; clofazimine; cycloserine; delaminid; ethambutol; ethionamide; gatifloxacin; imipenem/cilastatin; isoniazid; kanamycin; levofloxacin; linezolid; meropenem; moxifloxacin; ofloxacin; para-aminosalicylic acid; pretomanid; prothionamide; pyrazinamide; rifabutin; rifampicin; streptomycin; sutezolid; terizidone; thioacetazone; whole genome sequencing</Interventions><Patients>448</Patients><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Reference>CAP 020; InDEX; NCT03237182</Reference><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><Trial id="307654"/><TrialStartDate>JUNE     , 14, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>bedaquiline; delamanid; moxifloxacin</Controls><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>75</EnrollmentCount><Interventions>bedaquiline; delamanid; midazolam; moxifloxacin; sutezolid</Interventions><Patients>75</Patients><ProtocolAcronym>SUDOCU</ProtocolAcronym><ProtocolTitle>PanACEA Sutezolid Dose-finding and Combination Evaluation</ProtocolTitle><Reference>NCT03959566; PANACEA-SUDOCU-01; SUDOCU</Reference><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><Trial id="381674"/><TrialStartDate>AUGUST   , 31, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>500</EnrollmentCount><Interventions>amikacin; bedaquiline; clarithromycin; clofazimine; cycloserine; ethambutol; linezolid; moxifloxacin; prothionamide; pyrazinamide; sodium para-aminosalicylate</Interventions><Patients>500</Patients><ProtocolAcronym/><ProtocolTitle>The Effect of 18-month Regimen Containing Six Anti-tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><Reference>2018ZX10722301-001; NCT03830671</Reference><Sponsor>Beijing Chest Hospital</Sponsor><Trial id="369109"/><TrialStartDate>MARCH    , 08, 2019</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>16</EnrollmentCount><Interventions>bedaquiline; lopinavir + ritonavir</Interventions><Patients>16</Patients><ProtocolAcronym/><ProtocolTitle>TMC207-TiDP13-C110: Interaction Study With Lopinavir/Ritonavir in Healthy Volunteer</ProtocolTitle><Reference>CR002545; NCT00828529; NCT00980291</Reference><Sponsor>Janssen Diagnostics BVBA</Sponsor><Trial id="42128"/><TrialStartDate>FEBRUARY , 28, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="16545">delamanid</Drug><EnrollmentCount>5610</EnrollmentCount><Interventions>delamanid; isoniazid; pyridoxine</Interventions><Patients>5610</Patients><ProtocolAcronym>PHOENIx MDR-TB</ProtocolAcronym><ProtocolTitle>Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients</ProtocolTitle><Reference>12041; A5300B/I2003B/PHOENIX; NCT03568383; PHOENIx MDR-TB</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="344335"/><TrialStartDate>JUNE     , 03, 2019</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>C-reactive protein; Cytokines; IFN-gamma; Total IgE; anti-Mtb72F-T-cell; anti-Mtb72F-antibody</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><EnrollmentCount>38</EnrollmentCount><Interventions>AS02; MTB72F vaccine (tuberculosis), GSK/Aeras</Interventions><Patients>38</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02A in Healthy PPD-Positive Adults</ProtocolTitle><Reference>102374; NCT00146744</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="9528"/><TrialStartDate>JULY     , 31, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Dinoprostone; Interferon beta; Interferon-alpha; Interleukin-1 receptor antagonist protein; Prostaglandin G/H synthase 2</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4718">zileuton</Drug><EnrollmentCount>90</EnrollmentCount><Interventions>Zyflo</Interventions><Patients>90</Patients><ProtocolAcronym/><ProtocolTitle>Optimization of Clinical Treatment Schemes for Multidrug - Resistant Pulmonary Tuberculosis Based on Host - Mediate</ProtocolTitle><Reference>ChiCTR-OPN-16009545</Reference><Sponsor>Shanghai Public Health Clinical Center</Sponsor><Trial id="276708"/><TrialStartDate>OCTOBER  , 20, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2587">azithromycin</Drug><EnrollmentCount>448</EnrollmentCount><Interventions>amikacin; amoxicillin + clavulanate; azithromycin; bedaquiline; capreomycin; clarithromycin; clofazimine; cycloserine; delaminid; ethambutol; ethionamide; gatifloxacin; imipenem/cilastatin; isoniazid; kanamycin; levofloxacin; linezolid; meropenem; moxifloxacin; ofloxacin; para-aminosalicylic acid; pretomanid; prothionamide; pyrazinamide; rifabutin; rifampicin; streptomycin; sutezolid; terizidone; thioacetazone; whole genome sequencing</Interventions><Patients>448</Patients><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Reference>CAP 020; InDEX; NCT03237182</Reference><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><Trial id="307654"/><TrialStartDate>JUNE     , 14, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><EnrollmentCount>180</EnrollmentCount><Interventions>bedaquiline; linezolid; pretomanid</Interventions><Patients>180</Patients><ProtocolAcronym>ZeNiX</ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre-XDR-TB or Non-responsive/Intolerant MDR-TB</ProtocolTitle><Reference>NC-007- (B-Pa-L); NCT03086486; ZENIX (B-PA-L) NC-007; ZeNiX</Reference><Sponsor>TB Alliance</Sponsor><Trial id="293734"/><TrialStartDate>OCTOBER  , 31, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><EnrollmentCount>14</EnrollmentCount><Interventions>MVA-85A</Interventions><Patients>14</Patients><ProtocolAcronym/><ProtocolTitle>A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA-85A Vaccine in Healthy Volunteers</ProtocolTitle><Reference>NCT00423566; TB002</Reference><Sponsor>University of Oxford</Sponsor><Trial id="9320"/><TrialStartDate>SEPTEMBER, 30, 2002</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4+</ArmCount><Biomarkers>Leukotriene A-4 hydrolase</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Standard of care anti-tubercular therapy; Standard of care anti-tubercular therapy; dexamethasone; isoniazid; rifampicin; rifampicin + isoniazid + ethambutol + pyrazinamide</Controls><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="11036">linezolid</Drug><EnrollmentCount>100</EnrollmentCount><Interventions>Intensified anti-tubercular therapy; aspirin; dexamethasone; linezolid; rifampicin</Interventions><Patients>100</Patients><ProtocolAcronym>LASER-TBM</ProtocolAcronym><ProtocolTitle>Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM</ProtocolTitle><Reference>LASER-TBM; LASER-TBM; NCT03927313</Reference><Sponsor>University of Cape Town</Sponsor><Trial id="378146"/><TrialStartDate>JUNE     , 01, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Blood pressure; Body temperature; Heart rate; Interferon-alpha; Respiratory frequency</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="95442">ESAT-6CFP10</Drug><EnrollmentCount>1090</EnrollmentCount><Interventions>ESAT-6CFP10; tuberculin purified protein derivative (TB-PPD)</Interventions><Patients>1090</Patients><ProtocolAcronym/><ProtocolTitle>Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT-6CFP10 Allergen</ProtocolTitle><Reference>ChiCTR-DID-16007837; LTAO-EC III-PATIENT; NCT02623556</Reference><Sponsor>Anhui Zhifei Longcom Biopharmaceutical Co Ltd</Sponsor><Trial id="247763"/><TrialStartDate>DECEMBER , 31, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Human immunodeficiency virus RNA; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>efavirenz; lamivudine; tenofovir disoproxil fumarate</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="54488">raltegravir</Drug><EnrollmentCount>460</EnrollmentCount><Interventions>lamivudine; raltegravir; rifampin; tenofovir disoproxil fumarate</Interventions><Patients>460</Patients><ProtocolAcronym>REFLATE TB2</ProtocolAcronym><ProtocolTitle>Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><Reference>ANRS 12300 REFLATE TB2; NCT02273765; REFLATE TB2</Reference><Sponsor>INSERM</Sponsor><Trial id="214156"/><TrialStartDate>SEPTEMBER, 30, 2015</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44313">simvastatin</Drug><EnrollmentCount>321</EnrollmentCount><Interventions>simvastatin</Interventions><Patients>321</Patients><ProtocolAcronym/><ProtocolTitle>Simvastatin and sputum conversion in pulmonary tuberculosis: a double-blinded, randomized, controlled trial</ProtocolTitle><Reference>TCTR20180219002</Reference><Sponsor>Khonkaen Hospital</Sponsor><Trial id="330023"/><TrialStartDate>APRIL    , 01, 2018</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Human immunodeficiency virus RNA</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="4728">emtricitabine</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>dolutegravir; emtricitabine; isoniazid; rifapentine; tenofovir disoproxil fumarate</Interventions><Patients>60</Patients><ProtocolAcronym>IMPAACT4TB</ProtocolAcronym><ProtocolTitle>Safety, Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine Isoniazid in HIV+ Patients</ProtocolTitle><Reference>3HP DTG AUR1-6-212 IMPAACT4TB; IMPAACT4TB; NCT03435146</Reference><Sponsor>Aurum Institute</Sponsor><Trial id="329251"/><TrialStartDate>JANUARY  , 18, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers>Alanine transaminase; Blood platelets; Body temperature; CD40 ligand; Creatinine; Cytotoxic T-Lymphocytes; Hemoglobin; Interferon gamma; Interleukin-2; Leukocyte count; T-Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Menjugate; Polio Sabin; Prevnar; Tritanrix HB</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><EnrollmentCount>302</EnrollmentCount><Interventions>GSK-692342; GSK-692342a; Polio Sabin; Prevnar; Tritanrix HB</Interventions><Patients>302</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants</ProtocolTitle><Reference>112899; 2012-004380-44; NCT01098474; TUBERCULOSIS-013 PRI</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="65639"/><TrialStartDate>JULY     , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4229">rifabutin</Drug><EnrollmentCount>400</EnrollmentCount><Interventions>efavirenz; ethambutol; isoniazid; lamivudine; pyrazinamide; rifabutin; rifampicin; stavudine; zidovudine</Interventions><Patients>400</Patients><ProtocolAcronym/><ProtocolTitle>Acquired Immunodeficiency Syndrome (AIDS) and Tuberculosis (TB) Co-Infection Treatment Strategies Study of China</ProtocolTitle><Reference>2008ZX10001-008; NCT01344148</Reference><Sponsor>Shanghai Public Health Clinical Center</Sponsor><Trial id="76946"/><TrialStartDate>FEBRUARY , 28, 2009</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Arylacetamide deacetylase; Nuclear receptor subfamily 1 group I member 2; Nuclear receptor subfamily 1 group I member 3; Solute carrier organic anion transporter family member 1B1</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>1250</EnrollmentCount><Interventions>ethambutol; isoniazid; moxifloxacin; pyrazinamide; rifampicin; rifapentine</Interventions><Patients>827</Patients><ProtocolAcronym>RIFAQUIN</ProtocolAcronym><ProtocolTitle>An International, Multicenter, Controlled Clinical Trial to Evaluate High-Dose Rifapentine and a Quinolone in the Treatment of Pulmonary Tuberculosis</ProtocolTitle><Reference>10.1186/ISRCTN44153044; ISRCTN44153044; RIFAQUIN</Reference><Sponsor>St Georges University of London</Sponsor><Trial id="153990"/><TrialStartDate>AUGUST   , 15, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Human immunodeficiency virus DNA; Human immunodeficiency virus RNA; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>efavirenz; lamivudine; tenofovir disoproxil fumarate</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><EnrollmentCount>155</EnrollmentCount><Interventions>lamivudine; raltegravir; tenofovir disoproxil fumarate</Interventions><Patients>155</Patients><ProtocolAcronym>REFLATE TB</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Two Raltegravir Doses in Naive HIV-1-Infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><Reference>2008-004970-41; ANRS 12 180; ANRS 12180 REFLATE TB; NCT00822315; REFLATE TB</Reference><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><Trial id="40948"/><TrialStartDate>JULY     , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>CD4; Human immunodeficiency virus ribonucleic acid</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>MVA85A</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>The Safety and Immunogenicity of a TB Vaccine; MVA85A, in Healthy Volunteers Who Are Infected With HIV</ProtocolTitle><Reference>NCT00395720; TB010</Reference><Sponsor>University of Oxford</Sponsor><Trial id="10868"/><TrialStartDate>NOVEMBER , 30, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>47</EnrollmentCount><Interventions>efavirenz; lopinavir + ritonavir; nevirapine; rifabutin</Interventions><Patients>47</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-Infection in Vietnam</ProtocolTitle><Reference>ANRS12150b; NCT00651066</Reference><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><Trial id="11188"/><TrialStartDate>JUNE     , 30, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers>Alanine transaminase; Blood platelets; Body temperature; CD40 ligand; Creatinine; Cytotoxic T-Lymphocytes; Hemoglobin; Interferon gamma; Interleukin-2; Leukocyte count; T-Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Menjugate; Polio Sabin; Prevnar; Tritanrix HB</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4144">Prevnar</Drug><EnrollmentCount>302</EnrollmentCount><Interventions>GSK-692342; GSK-692342a; Polio Sabin; Prevnar; Tritanrix HB</Interventions><Patients>302</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants</ProtocolTitle><Reference>112899; 2012-004380-44; NCT01098474; TUBERCULOSIS-013 PRI</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="65639"/><TrialStartDate>JULY     , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>CD4; Human immunodeficiency virus RNA; T-Helper Lymphocytes</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><EnrollmentCount>40</EnrollmentCount><Interventions>lopinavir + ritonavir; rifampicin</Interventions><Patients>40</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics (PK) and Safety of Two Different Doses of Lopinavir/Ritonavir in HIV/Tuberculosis (TB) Co-Infected Patients Receiving Rifampicin Containing Anti-Tuberculosis Therapy</ProtocolTitle><Reference>HIV-NAT 104; NCT01138202</Reference><Sponsor>The HIV Netherlands Australia Thailand Research Collaboration</Sponsor><Trial id="67098"/><TrialStartDate>NOVEMBER , 30, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>CD4; albumin</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>156</EnrollmentCount><Interventions>efavirenz; lamivudine; lamivudine + efavirenz + tenofovir disoproxil fumarate; tenofovir disoproxil fumarate</Interventions><Patients>156</Patients><ProtocolAcronym>TIME</ProtocolAcronym><ProtocolTitle>Appropriate Timing of HAART in Co-infected HIV/TB Patients</ProtocolTitle><Reference>0435.3/1551; NCT01014481; TIME</Reference><Sponsor>Bamrasnaradura Infectious Diseases Institute</Sponsor><Trial id="61991"/><TrialStartDate>OCTOBER  , 31, 2009</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers>T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="14493">tenofovir disoproxil fumarate</Drug><EnrollmentCount>809</EnrollmentCount><Interventions>efavirenz; emtricitabine; tenofovir disoproxil fumarate; tenofovir disoproxil fumarate + emtricitabine</Interventions><Patients>780</Patients><ProtocolAcronym>STRIDE</ProtocolAcronym><ProtocolTitle>Immediate Versus Deferred Start of Anti-HIV Therapy in HIV Infected Adults Being Treated for Tuberculosis</ProtocolTitle><Reference>1U01AI068636; ACTG A5221; ACTG A5221; NCT00108862; STRIDE</Reference><Sponsor>AIDS Clinical Trials Group</Sponsor><Trial id="10681"/><TrialStartDate>AUGUST   , 31, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Cytokine</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>TiceBCG</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="13624">BCG vaccine, Organon</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>AERAS-422</Interventions><Patients>24</Patients><ProtocolAcronym>AERAS 422</ProtocolAcronym><ProtocolTitle>Study of AERAS-422 in Healthy Adults</ProtocolTitle><Reference>AERAS 422; C-007-422; NCT01340820</Reference><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><Trial id="76756"/><TrialStartDate>DECEMBER , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><EnrollmentCount>140</EnrollmentCount><Interventions>Aluvia; raltegravir; rifabutin</Interventions><Patients>140</Patients><ProtocolAcronym/><ProtocolTitle>EARNEST Rifabutin Pharmacokinetics (PK) Substudy</ProtocolTitle><Reference>ISRCTN13074752; NCT01663168</Reference><Sponsor>Joint Clinical Research Centre, Medical Research Council</Sponsor><Trial id="90175"/><TrialStartDate>MAY      , 03, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>CD40 ligand; Cytotoxic T-Lymphocytes; IFN-gamma; Interleukin-13; Interleukin-17A; Interleukin-2; Mononuclear leukocytes; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>GSK-692342</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>Study in Healthy Adults to Evaluate Gene Activation After Vaccination With GlaxoSmithKline (GSK) Biologicals Candidate Tuberculosis (TB) Vaccine GSK-692342</ProtocolTitle><Reference>116777; 2012-002541-37; NCT01669096</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="90314"/><TrialStartDate>AUGUST   , 21, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Rifafour</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>68</EnrollmentCount><Interventions>bedaquiline</Interventions><Patients>68</Patients><ProtocolAcronym/><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis</ProtocolTitle><Reference>NCT01215110; TMC207-CL001</Reference><Sponsor>TB Alliance</Sponsor><Trial id="71046"/><TrialStartDate>APRIL    , 30, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><EnrollmentCount>47</EnrollmentCount><Interventions>efavirenz; lopinavir + ritonavir; nevirapine; rifabutin</Interventions><Patients>47</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-Infection in Vietnam</ProtocolTitle><Reference>ANRS12150b; NCT00651066</Reference><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><Trial id="11188"/><TrialStartDate>JUNE     , 30, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>moxifloxacin</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Reference>14413; 2009-017070-21; NCT01073891</Reference><Sponsor>Bayer AG</Sponsor><Trial id="198748"/><TrialStartDate>MAY      , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><EnrollmentCount>52</EnrollmentCount><Interventions>PA-824; efavirenz; lopinavir + ritonavir; rifampin</Interventions><Patients>52</Patients><ProtocolAcronym/><ProtocolTitle>Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir or Rifampin</ProtocolTitle><Reference>11829; A5306; ACTG5306; NCT01571414</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="86312"/><TrialStartDate>MAY      , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Body temperature; Diastolic blood pressure; Heart rate; Peripheral mononuclear cells; Respiratory frequency; Systolic blood pressure; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="57308">RUTI</Drug><EnrollmentCount>95</EnrollmentCount><Interventions>RUTI</Interventions><Patients>90</Patients><ProtocolAcronym>RUTISAPH2</ProtocolAcronym><ProtocolTitle>Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI Following 1 Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection</ProtocolTitle><Reference>NCT01136161; RUTISAPH2; RUTISAPH2</Reference><Sponsor>Archivel Farma SL</Sponsor><Trial id="67014"/><TrialStartDate>JUNE     , 30, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Cytochrome (CYP) enzyme</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44303">midazolam hydrochloride</Drug><EnrollmentCount>13</EnrollmentCount><Interventions>caffeine; dextromethorphan; losartan; midazolam; omeprazole; rifampicin</Interventions><Patients>13</Patients><ProtocolAcronym/><ProtocolTitle>The Influence of Rifampicin Discontinuation on Rifampicin-Induced Cytochrome P450 Enzyme Activity</ProtocolTitle><Reference>JPRN-UMIN000004083</Reference><Sponsor>Hamamatsu University School of Medicine</Sponsor><Trial id="122291"/><TrialStartDate>JULY     , 01, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Cytochrome (CYP) enzyme</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44305">omeprazole</Drug><EnrollmentCount>13</EnrollmentCount><Interventions>caffeine; dextromethorphan; losartan; midazolam; omeprazole; rifampicin</Interventions><Patients>13</Patients><ProtocolAcronym/><ProtocolTitle>The Influence of Rifampicin Discontinuation on Rifampicin-Induced Cytochrome P450 Enzyme Activity</ProtocolTitle><Reference>JPRN-UMIN000004083</Reference><Sponsor>Hamamatsu University School of Medicine</Sponsor><Trial id="122291"/><TrialStartDate>JULY     , 01, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Alanine transaminase; Bilirubin; C-reactive protein; Glucose; Hemoglobin; Leukocyte count; Serum potassium; Serum sodium; White blood cell</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><EnrollmentCount>240</EnrollmentCount><Interventions>prednisone</Interventions><Patients>240</Patients><ProtocolAcronym>Pred-ART</ProtocolAcronym><ProtocolTitle>Preventing TB-IRIS in High-risk Patients: a Randomized, Placebo-controlled Trial of Prednisone</ProtocolTitle><Reference>CIDRI_001; DOH-27-0813-4336; NCT01924286; PACTR201304000511413; Pred-ART; SP.2011.41304.074</Reference><Sponsor>University of Cape Town</Sponsor><Trial id="150793"/><TrialStartDate>AUGUST   , 30, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><EnrollmentCount>113</EnrollmentCount><Interventions>linezolid</Interventions><Patients>113</Patients><ProtocolAcronym/><ProtocolTitle>A Phase II Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients</ProtocolTitle><Reference>LIN-CL001; NCT02279875</Reference><Sponsor>TB Alliance</Sponsor><Trial id="215072"/><TrialStartDate>NOVEMBER , 30, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="74849">SSI H56-IC31</Drug><EnrollmentCount>25</EnrollmentCount><Interventions>SSI H56-IC31</Interventions><Patients>25</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity Study of AERAS-456 Vaccine for Tuberculosis</ProtocolTitle><Reference>C-032-456; NCT01967134</Reference><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><Trial id="158535"/><TrialStartDate>NOVEMBER , 30, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol hydrochloride; isoniazid; linezolid; pyrazinamide; rifampicin</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><EnrollmentCount>64</EnrollmentCount><Interventions>LCB01-0371</Interventions><Patients>64</Patients><ProtocolAcronym/><ProtocolTitle>A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK</ProtocolTitle><Reference>2016-0642; KCT0003975; LCB01-0371-15-2-01; NCT02836483</Reference><Sponsor>LegoChem Bioscience Inc</Sponsor><Trial id="265899"/><TrialStartDate>DECEMBER , 10, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>4+</ArmCount><Biomarkers>CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>100</EnrollmentCount><Interventions>efavirenz; lamivudine; nevirapine; nevirapine</Interventions><Patients>100</Patients><ProtocolAcronym/><ProtocolTitle>Once-Daily Dose of Nevirapine (400 mg) Versus Twice Daily Dose (200 mg) of Nevirapine in HIV and Tuberculosis Infection</ProtocolTitle><Reference>CTRI/2012/08/002923</Reference><Sponsor>National AIDS Control Organization</Sponsor><Trial id="126486"/><TrialStartDate>SEPTEMBER, 01, 2012</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><EnrollmentCount>109</EnrollmentCount><Interventions>bedaquiline; bedaquiline; linezolid; pretomanid</Interventions><Patients>109</Patients><ProtocolAcronym/><ProtocolTitle>A Phase III Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Reference>NCT02333799; NIX-TB-(B-L-PA)</Reference><Sponsor>TB Alliance</Sponsor><Trial id="219499"/><TrialStartDate>MARCH    , 31, 2015</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Rifafour</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>85</EnrollmentCount><Interventions>PA-824; Rifafour; TMC-207; moxifloxacin; pyrazinamide</Interventions><Patients>65</Patients><ProtocolAcronym/><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With</ProtocolTitle><Reference>NC-001; NC-001-(J-M-Pa-Z); NCT01215851</Reference><Sponsor>TB Alliance</Sponsor><Trial id="71107"/><TrialStartDate>OCTOBER  , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><EnrollmentCount>150</EnrollmentCount><Interventions>efavirenz; ethambutol; isoniazid; lamivudine; nevirapine; pyrazinamide; rifampicin; zidovudine</Interventions><Patients>355</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis</ProtocolTitle><Reference>NCT00698334; SKS/NACO/2006</Reference><Sponsor>All India Institute of Medical Sciences</Sponsor><Trial id="161275"/><TrialStartDate>APRIL    , 30, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>C24; MDR1; N-acetyltransferase; P-glycoprotein</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>230</EnrollmentCount><Interventions>isoniazid; rifapentine</Interventions><Patients>230</Patients><ProtocolAcronym>TBTC-26 PK</ProtocolAcronym><ProtocolTitle>Rifapentine Pharmacokinetics in Children During Treatment of Latent TB Infection</ProtocolTitle><Reference>CDC-NCHSTP-4679; NCT00164450; TBTC-26 PK</Reference><Sponsor>Centers for Disease Control and Prevention</Sponsor><Trial id="10687"/><TrialStartDate>SEPTEMBER, 30, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><EnrollmentCount>150</EnrollmentCount><Interventions>isoniazid; rifabutin</Interventions><Patients>102</Patients><ProtocolAcronym>TBTC-23A</ProtocolAcronym><ProtocolTitle>Pharmacokinetics of Intermittent Isoniazid and Rifabutin in HIV-TB</ProtocolTitle><Reference>23A; CDC-NCHSTP-2173; NCT00023348; TBTC-23A</Reference><Sponsor>Centers for Disease Control and Prevention</Sponsor><Trial id="10652"/><TrialStartDate>JULY     , 31, 1999</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>CD4+</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><EnrollmentCount>180</EnrollmentCount><Interventions>didanosine; efavirenz; efavirenz +  didanosine + lamivudine; ethambutol; ethambutol + isoniazid + rifampicin + pyrazinamide; isoniazid; isoniazid + rifampicin; lamivudine; nevirapine; nevirapine + didanosine + lamivudine; pyrazinamide; rifampicin</Interventions><Patients>116</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-Tuberculosis Treatment</ProtocolTitle><Reference>NCT00332306; trc23</Reference><Sponsor>Tuberculosis Research Centre</Sponsor><Trial id="10863"/><TrialStartDate>JUNE     , 30, 2006</TrialStartDate><TrialStatus>Suspended</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers>CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><EnrollmentCount>142</EnrollmentCount><Interventions>efavirenz; nevirapine</Interventions><Patients>145</Patients><ProtocolAcronym>N2R</ProtocolAcronym><ProtocolTitle>Efavirenz-Based Versus Nevirapine-Based Antiretroviral Therapy Among HIV-Infected Patients Receiving Rifampin</ProtocolTitle><Reference>210041000824904203; N2R; NCT00483054</Reference><Sponsor>Bamrasnaradura Infectious Diseases Institute</Sponsor><Trial id="10947"/><TrialStartDate>JANUARY  , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>8053</EnrollmentCount><Interventions>isoniazid; rifapentine; rifapentine+isoniazid</Interventions><Patients>7731</Patients><ProtocolAcronym>PREVENT TB</ProtocolAcronym><ProtocolTitle>A 3 Months of Weekly Rifapentine and Isoniazid for M Tuberculosis Infection</ProtocolTitle><Reference>CDC TBTC Study 26; CDC-NCHSTP-3041; NCT00023452; PREVENT TB; TBTC Study 26; TBTC Study 26/ACTG 5259</Reference><Sponsor>Centers for Disease Control and Prevention</Sponsor><Trial id="10659"/><TrialStartDate>JUNE     , 30, 2001</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>36</EnrollmentCount><Interventions>moxifloxacin</Interventions><Patients>36</Patients><ProtocolAcronym/><ProtocolTitle>Moxifloxacin_QT Study in Chinese Healthy Volunteer</ProtocolTitle><Reference>DCTC_2012001; NCT01653990</Reference><Sponsor>Peking University Third Hospital</Sponsor><Trial id="89715"/><TrialStartDate>JULY     , 31, 2012</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="16545">delamanid</Drug><EnrollmentCount>37</EnrollmentCount><Interventions>delamanid; optimized background regimen therapy</Interventions><Patients>13</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis</ProtocolTitle><Reference>2012-004473-25; 242-12-232; CTR# 2012-CT0060; NCT01856634; PHRR160526-001027</Reference><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><Trial id="132087"/><TrialStartDate>JUNE     , 14, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7017">gatifloxacin</Drug><EnrollmentCount>217</EnrollmentCount><Interventions>gatifloxacin; isoniazid; moxifloxacin; ofloxacin; pyrazinamide; rifampicin</Interventions><Patients>217</Patients><ProtocolAcronym/><ProtocolTitle>A Comparative Study of the Bactericidal and Sterilising Activity of Three Fluoroquinolones: Gatifloxacin, Moxifloxacin and Ofloxacin Substituted for Ethambutol in the Two Month Initial Phase of the Standard Anti-Tuberculosis Treatment Regimen Also Containing Rifampicin, Isoniazid and Pyrazinamide (South Africa)</ProtocolTitle><Reference>ISRCTN13670619; RPC078</Reference><Sponsor>United Nations International Children's Fund</Sponsor><Trial id="152200"/><TrialStartDate>NOVEMBER , 25, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>75</EnrollmentCount><Interventions>bedaquiline; isoniazid; rifampin</Interventions><Patients>75</Patients><ProtocolAcronym/><ProtocolTitle>Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC-207 in Treatment of Pulmonary Tuberculosis</ProtocolTitle><Reference>PMID:18505852</Reference><Sponsor>Johnson &amp; Johnson</Sponsor><Trial id="150059"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Interferon gamma</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>MVA-85A</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>IMX-461</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>Phase I Trial Evaluating Safety and Immunogenicity of MVA-85A-IMX3-13 Compared to MVA-85A in BCG Vaccinated Adults</ProtocolTitle><Reference>NCT01879163; TB028; UKCRN 15787</Reference><Sponsor>University of Oxford</Sponsor><Trial id="142322"/><TrialStartDate>JULY     , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Alanine transaminase; Bilirubin; C-reactive protein; Glucose; Hemoglobin; Leukocyte count; Serum potassium; Serum sodium; White blood cell</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="14493">tenofovir disoproxil fumarate</Drug><EnrollmentCount>240</EnrollmentCount><Interventions>prednisone</Interventions><Patients>240</Patients><ProtocolAcronym>Pred-ART</ProtocolAcronym><ProtocolTitle>Preventing TB-IRIS in High-risk Patients: a Randomized, Placebo-controlled Trial of Prednisone</ProtocolTitle><Reference>CIDRI_001; DOH-27-0813-4336; NCT01924286; PACTR201304000511413; Pred-ART; SP.2011.41304.074</Reference><Sponsor>University of Cape Town</Sponsor><Trial id="150793"/><TrialStartDate>AUGUST   , 30, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>CD4 + cell</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="49219">tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences</Drug><EnrollmentCount>63</EnrollmentCount><Interventions>efavirenz; isoniazid; tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences</Interventions><Patients>63</Patients><ProtocolAcronym/><ProtocolTitle>Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment</ProtocolTitle><Reference>C43-06; NCT00737724</Reference><Sponsor>Instituto Nacional de Enfermedades Respiratorias</Sponsor><Trial id="169697"/><TrialStartDate>MARCH    , 31, 2008</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>T-Lymphocytes</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="84564">ChAdOx1-85A</Drug><EnrollmentCount>42</EnrollmentCount><Interventions>ChAdOx1-85A; ChAdOx1-85A; MVA-85A</Interventions><Patients>42</Patients><ProtocolAcronym/><ProtocolTitle>Safety Study of ChAdOx1-85A Vaccination With and Without MVA-85A Boost in Healthy Adults</ProtocolTitle><Reference>NCT01829490; TB034; UKCRN 14241</Reference><Sponsor>University of Oxford</Sponsor><Trial id="120744"/><TrialStartDate>JULY     , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>1650</EnrollmentCount><Interventions>moxifloxacin</Interventions><Patients>1650</Patients><ProtocolAcronym/><ProtocolTitle>A Clinical Trial to Study the Effectiveness and Safety of 3- and 4-Month Regimens as Compared to the Standard 6-Month Regimen for the Treatment of Infectious Pulmonary Tuberculosis Patients</ProtocolTitle><Reference>CTRI/2008/091/000024</Reference><Sponsor>Indian Council of Medical Research</Sponsor><Trial id="121916"/><TrialStartDate>MAY      , 30, 2007</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="89744">MTBVAC</Drug><EnrollmentCount>36</EnrollmentCount><Interventions>BCG; MTBVAC</Interventions><Patients>36</Patients><ProtocolAcronym>MTBVAC</ProtocolAcronym><ProtocolTitle>Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC Vaccine in Comparison With BCG Vaccine</ProtocolTitle><Reference>MTBVAC; MTBVAC-01; NCT02013245</Reference><Sponsor>Biofabri SL</Sponsor><Trial id="164024"/><TrialStartDate>JANUARY  , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="9354">picroliv</Drug><EnrollmentCount>260</EnrollmentCount><Interventions>picroliv</Interventions><Patients>260</Patients><ProtocolAcronym/><ProtocolTitle>Evaluation of Hepatoprotective Effect of Picroliv in Patients Receiving Multi Drug Therapy of Tuberculosis</ProtocolTitle><Reference>CTRI/2012/08/002850; KGMC-CDRI</Reference><Sponsor>Central Drug Research Institute</Sponsor><Trial id="127798"/><TrialStartDate>MARCH    , 01, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bilirubin; Blood platelets; Carbon dioxide; Chlorine; Creatine kinase; Creatinine; Eosinophils; Erythrocytes; Estimated glomerular filtration rate; Glucose; Hematocrit; Hemoglobin; High-density lipoprotein cholesterol; High-density lipoprotein cholesterol; Human immunodeficiency virus RNA; Lactate dehydrogenase; Leukocyte count; Lipase; Lipids; Lymphocytes; Mean corpuscular volume; Monocytes; Neutrophils; Ox-LDL/ LDL-C ratio; Ox-LDL/ LDL-C ratio; Phosphate; Potassium; Sodium; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; Total cholesterol; Total cholesterol; Triglycerides; Triglycerides; Urea</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>efavirenz; ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>113</EnrollmentCount><Interventions>Group 1; Group 2; dolutegravir; ethambutol; isoniazid; pyrazinamide; rifampicin</Interventions><Patients>113</Patients><ProtocolAcronym>INSPIRING</ProtocolAcronym><ProtocolTitle>Open-Label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV)-Tuberculosis (TB) Co-infection</ProtocolTitle><Reference>117175; ING117175; INSPIRING; NCT02178592</Reference><Sponsor>ViiV Healthcare Ltd</Sponsor><Trial id="201302"/><TrialStartDate>JANUARY  , 23, 2015</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>C-C motif chemokine 2; C-C motif chemokine 3; C-C motif chemokine 4; C-X-C motif chemokine 9; Cytokines; Interferon gamma; Interleukin 1 beta; Interleukin-10; Interleukin-6; Interleukin-8; Macrophage migration inhibitory factor; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="6748">Recombivax HB</Drug><EnrollmentCount>185</EnrollmentCount><Interventions>BCG Vaccine; BCG Vaccine; Recombivax HB; Recombivax HB</Interventions><Patients>185</Patients><ProtocolAcronym>ELVIS</ProtocolAcronym><ProtocolTitle>A Trial Investigating the Influence of BCG and Hepatitis B Immunization at Birth on Neonatal Immune Responses: The Early Life Vaccines and Immunity Study</ProtocolTitle><Reference>ELVIS; NCT02444611; VAC/01 ELVIS</Reference><Sponsor>Murdoch Childrens Research Institute</Sponsor><Trial id="229498"/><TrialStartDate>MARCH    , 31, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>1002</EnrollmentCount><Interventions>isoniazid; rifapentine</Interventions><Patients>1002</Patients><ProtocolAcronym>iAdhere</ProtocolAcronym><ProtocolTitle>Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT</ProtocolTitle><Reference>2012-002094-58; CDC-NCHHSTP 6222; NCT01582711; Study 33; TBTC STUDY 33; UITB-TBTC-Estudio33; iAdhere</Reference><Sponsor>Centers for Disease Control and Prevention, Tuberculosis Investigation Unit of Barcelona</Sponsor><Trial id="177457"/><TrialStartDate>SEPTEMBER, 30, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="87251">Perchlozone</Drug><EnrollmentCount>40</EnrollmentCount><Interventions>Perchlozone</Interventions><Patients>40</Patients><ProtocolAcronym/><ProtocolTitle>An open, phase I study to study the pharmacokinetics, safety and tolerability of Perhlozone (400 mg capsules) in healthy volunteers after a single dose</ProtocolTitle><Reference>PERHL-11-2011</Reference><Sponsor>Pharmasyntez</Sponsor><Trial id="167779"/><TrialStartDate>MARCH    , 20, 2012</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Immunoglobulin G; Interferon gamma; Interleukin-2; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="107803">GamTBvac</Drug><EnrollmentCount>180</EnrollmentCount><Interventions>GamTBvac</Interventions><Patients>180</Patients><ProtocolAcronym/><ProtocolTitle>Phase II Clinical Trial of Safety and Immunogenicity of Recombinant Subunit Tuberculosis Vaccine GamTBvac</ProtocolTitle><Reference>01-GAMTBVAC-2018; NCT03878004</Reference><Sponsor>Gamalei Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation Collaborator</Sponsor><Trial id="373676"/><TrialStartDate>DECEMBER , 01, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="53041">artesunate + amodiaquine combination tablet (malaria), DNDi/sanofi-aventis</Drug><EnrollmentCount>36</EnrollmentCount><Interventions>artesunate; artesunate + amodiaquine; desethylamodiaquine; dihydroartemisinin; dihydroartemisinin + piperaquine; piperaquine</Interventions><Patients>36</Patients><ProtocolAcronym>ARTEM-TB STUDY</ProtocolAcronym><ProtocolTitle>Evaluating Pharmacokinetic Interactions Between Artemisinin-Based Therapies and Rifampacin-Based Tuberculosis Treatment in African Patients</ProtocolTitle><Reference>ARTEM-TB STUDY; HS1294; PACTR201302000483287</Reference><Sponsor>Infectious Diseases Institute of Makerer University</Sponsor><Trial id="142485"/><TrialStartDate>JANUARY  , 31, 2013</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1A">Phase 1a Clinical</DevStatus><Drug id="101474">small molecule therapeutic, Beijing Union Pharmaceutical Factory/Institute of Materia Medica</Drug><EnrollmentCount>58</EnrollmentCount><Interventions>pyrifazimine</Interventions><Patients>58</Patients><ProtocolAcronym/><ProtocolTitle>The phase Ia clinical trial of pyrifazimine</ProtocolTitle><Reference>BUSPF-1801; CTR20181736; ChiCTR1800018780</Reference><Sponsor>Beijing Union Pharmaceutical Factory, Xiyuan Hospital China Academy Of Chinese Medical Sciences</Sponsor><Trial id="356451"/><TrialStartDate>OCTOBER  , 01, 2018</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>284</EnrollmentCount><Interventions>moxifloxacin; pretomanid; pyrazinamide</Interventions><Patients>284</Patients><ProtocolAcronym>STAND</ProtocolAcronym><ProtocolTitle>Shortening Treatment by Advancing Novel Drugs</ProtocolTitle><Reference>2014-CT0249; NC-006-(M-PA-Z); NC-006-(M-Pa-Z); NC-006-(M-Pa-Z) 21522; NCT02342886; NMRR-14-702-21522; PHRR150114-000899; STAND</Reference><Sponsor>TB Alliance</Sponsor><Trial id="221844"/><TrialStartDate>FEBRUARY , 28, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>5+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="46931">cefadroxil</Drug><EnrollmentCount>45</EnrollmentCount><Interventions>Augmentin; cefadroxil; cefadroxil; ethambutol; faropenem; faropenem; isoniazid; pyrazinamide; rifampicin</Interventions><Patients>45</Patients><ProtocolAcronym/><ProtocolTitle>Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers</ProtocolTitle><Reference>2015-CT0284; FAROPENEM_TB; NCT02381470; PHRR160323-001194</Reference><Sponsor>National University Hospital (Singapore) Pte Ltd, Syneos Health Inc</Sponsor><Trial id="224111"/><TrialStartDate>DECEMBER , 31, 2018</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>bedaquiline; delamanid; moxifloxacin</Controls><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="11088">sutezolid</Drug><EnrollmentCount>75</EnrollmentCount><Interventions>bedaquiline; delamanid; midazolam; moxifloxacin; sutezolid</Interventions><Patients>75</Patients><ProtocolAcronym>SUDOCU</ProtocolAcronym><ProtocolTitle>PanACEA Sutezolid Dose-finding and Combination Evaluation</ProtocolTitle><Reference>NCT03959566; PANACEA-SUDOCU-01; SUDOCU</Reference><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><Trial id="381674"/><TrialStartDate>AUGUST   , 31, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount/><Interventions>clarithromycin; levofloxacin; moxifloxacin; moxifloxacin; rifabutin</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>The research of new regimen for multidrug-resistant tuberculosis treatment</ProtocolTitle><Reference>ChiCTR-IOR-15007291</Reference><Sponsor>Beijing Chest Hospital, Beijing Tuberculosis &amp; Thoracic Tumor Research Institute, Capital Medical University</Sponsor><Trial id="244777"/><TrialStartDate>OCTOBER  , 01, 2008</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3474">lamivudine</Drug><EnrollmentCount>592</EnrollmentCount><Interventions>didanosine; efavirenz; lamivudine; standard TB therapy</Interventions><Patients>592</Patients><ProtocolAcronym/><ProtocolTitle>Effectiveness of Directly Observed Therapy in Combined HIV and Tuberculosis Treatment in Resource-Limited Settings</ProtocolTitle><Reference>CAPRISA 001; CAPRISA START; CIPRA; NCT00091936; START</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="8820"/><TrialStartDate>AUGUST   , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>pyrazinamide</Controls><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount>238</EnrollmentCount><Interventions>delamanid; levofloxacin; linezolid; pyrazinamide</Interventions><Patients>238</Patients><ProtocolAcronym>MDR-END</ProtocolAcronym><ProtocolTitle>Treatment Shortening of MDR-TB Using Existing and New Drugs</ProtocolTitle><Reference>MDR-END; NCT02619994</Reference><Sponsor>Seoul National University Hospital</Sponsor><Trial id="247456"/><TrialStartDate>JANUARY  , 31, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Cytokines; Cytotoxic T-Lymphocytes; T-Helper Lymphocytes; T-Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>BCG vaccine</Controls><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="89744">MTBVAC</Drug><EnrollmentCount>120</EnrollmentCount><Interventions>MTBVAC</Interventions><Patients>120</Patients><ProtocolAcronym/><ProtocolTitle>MTBVAC Study in Adults With and Without Latent Tuberculosis Infection in South Africa</ProtocolTitle><Reference>A-050; NCT02933281</Reference><Sponsor>International AIDS Vaccine Initiative</Sponsor><Trial id="275657"/><TrialStartDate>JANUARY  , 24, 2019</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Bilirubin; International Normalized Ratio; Leukotriene A-4 hydrolase; Transaminases</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount>640</EnrollmentCount><Interventions>dexamethasone</Interventions><Patients>640</Patients><ProtocolAcronym>LAST ACT</ProtocolAcronym><ProtocolTitle>Leukotriene A4 Hydrolase Stratified Trial of Adjunctive Corticosteroids for HIV-uninfected Adults With Tuberculous Meningitis</ProtocolTitle><Reference>27TB; LAST ACT; NCT03100786</Reference><Sponsor>Oxford University Clinical Research Unit, Vietnam</Sponsor><Trial id="293087"/><TrialStartDate>FEBRUARY , 08, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><EnrollmentCount>109</EnrollmentCount><Interventions>bedaquiline; bedaquiline; linezolid; pretomanid</Interventions><Patients>109</Patients><ProtocolAcronym/><ProtocolTitle>A Phase III Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Reference>NCT02333799; NIX-TB-(B-L-PA)</Reference><Sponsor>TB Alliance</Sponsor><Trial id="219499"/><TrialStartDate>MARCH    , 31, 2015</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>WHO approved regimen-based therapy</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount/><Interventions>Deltyba; Levaquin; Zyvox; pyrazinamide</Interventions><Patients/><ProtocolAcronym>DAZZLE</ProtocolAcronym><ProtocolTitle>Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin</ProtocolTitle><Reference>DAZZLE; H-36160; NCT02975570</Reference><Sponsor>Boston University</Sponsor><Trial id="280651"/><TrialStartDate>AUGUST   , 31, 2017</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Human immunodeficiency virus RNA; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>efavirenz; lamivudine; tenofovir disoproxil fumarate</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>460</EnrollmentCount><Interventions>lamivudine; raltegravir; rifampin; tenofovir disoproxil fumarate</Interventions><Patients>460</Patients><ProtocolAcronym>REFLATE TB2</ProtocolAcronym><ProtocolTitle>Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><Reference>ANRS 12300 REFLATE TB2; NCT02273765; REFLATE TB2</Reference><Sponsor>INSERM</Sponsor><Trial id="214156"/><TrialStartDate>SEPTEMBER, 30, 2015</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>630</EnrollmentCount><Interventions>Lamprene; bedaquiline; linezolid; moxifloxacin; pretomanid</Interventions><Patients>630</Patients><ProtocolAcronym>TB-PRACTECAL</ProtocolAcronym><ProtocolTitle>Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)</ProtocolTitle><Reference>1541; NCT02589782; TB-PRACTECAL</Reference><Sponsor>Medecins Sans Frontieres</Sponsor><Trial id="244304"/><TrialStartDate>JANUARY  , 31, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount>2006</EnrollmentCount><Interventions>levofloxacin</Interventions><Patients>2006</Patients><ProtocolAcronym>The V-QUIN MDR Trial</ProtocolAcronym><ProtocolTitle>A randomized, controlled trial of 6 months of daily levofloxacin for the prevention of tuberculosis among household contacts of patients with multi-drug resistant tuberculosis</ProtocolTitle><Reference>2014/929; 4040/QD-BYT; ACTRN12616000215426; ANZCTR369817; NHMRC APP#1081443; The V-QUIN MDR Trial; U1111-1177-9052</Reference><Sponsor>University of Sydney</Sponsor><Trial id="269403"/><TrialStartDate>MARCH    , 14, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Alanine transaminase; Aspartate aminotransferase; Creatinine</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>levofloxacin</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic study and safety of levofloxacin in pediatric tuberculosis treatment</ProtocolTitle><Reference>IRB 607/61; TCTR20190515001</Reference><Sponsor>Center of Excellence for Pediatric Infectious Diseases and Vaccines</Sponsor><Trial id="381490"/><TrialStartDate>MAY      , 12, 2019</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>Sirturo</Interventions><Patients>24</Patients><ProtocolAcronym>BDQ Crush</ProtocolAcronym><ProtocolTitle>TASK-002: Bioequivalence of Bedaquiline 400 mg Administered in Crushed Form Compared to Tablet Form in Healthy Male and Female Adults Under Fed Conditions</ProtocolTitle><Reference>BDQ Crush; NCT03032367; TASK-002</Reference><Sponsor>International Maternal Pediatric Adolescent AIDS Clinical Trials Group</Sponsor><Trial id="286376"/><TrialStartDate>NOVEMBER , 10, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7017">gatifloxacin</Drug><EnrollmentCount>448</EnrollmentCount><Interventions>amikacin; amoxicillin + clavulanate; azithromycin; bedaquiline; capreomycin; clarithromycin; clofazimine; cycloserine; delaminid; ethambutol; ethionamide; gatifloxacin; imipenem/cilastatin; isoniazid; kanamycin; levofloxacin; linezolid; meropenem; moxifloxacin; ofloxacin; para-aminosalicylic acid; pretomanid; prothionamide; pyrazinamide; rifabutin; rifampicin; streptomycin; sutezolid; terizidone; thioacetazone; whole genome sequencing</Interventions><Patients>448</Patients><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Reference>CAP 020; InDEX; NCT03237182</Reference><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><Trial id="307654"/><TrialStartDate>JUNE     , 14, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>C-reactive protein; Erythrocyte sedimentation rate; T-Helper Lymphocytes; T-Lymphocytes; T-cell surface glycoprotein CD4; Total body mass; Vitamin D</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12420">rosuvastatin</Drug><EnrollmentCount>50</EnrollmentCount><Interventions>rosuvastatin</Interventions><Patients>50</Patients><ProtocolAcronym/><ProtocolTitle>Effect of rosuvastatin on HIV TB coinfection</ProtocolTitle><Reference>CTRI/2017/03/008171</Reference><Sponsor>Armed Forces Medical College</Sponsor><Trial id="292154"/><TrialStartDate>APRIL    , 01, 2017</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="16545">delamanid</Drug><EnrollmentCount>48</EnrollmentCount><Interventions>delamanid; optimized multidrug background regimen therapy</Interventions><Patients>48</Patients><ProtocolAcronym/><ProtocolTitle>Evaluating the Pharmacokinetics, Safety and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB</ProtocolTitle><Reference>20721; CTRI/2018/01/011298; IMPAACT 2005; NCT03141060</Reference><Sponsor>National Institute of Allergy and Infectious Diseases, National Institutes of Health</Sponsor><Trial id="297373"/><TrialStartDate>JANUARY  , 30, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><EnrollmentCount>448</EnrollmentCount><Interventions>amikacin; amoxicillin + clavulanate; azithromycin; bedaquiline; capreomycin; clarithromycin; clofazimine; cycloserine; delaminid; ethambutol; ethionamide; gatifloxacin; imipenem/cilastatin; isoniazid; kanamycin; levofloxacin; linezolid; meropenem; moxifloxacin; ofloxacin; para-aminosalicylic acid; pretomanid; prothionamide; pyrazinamide; rifabutin; rifampicin; streptomycin; sutezolid; terizidone; thioacetazone; whole genome sequencing</Interventions><Patients>448</Patients><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Reference>CAP 020; InDEX; NCT03237182</Reference><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><Trial id="307654"/><TrialStartDate>JUNE     , 14, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="52139">ofloxacin</Drug><EnrollmentCount>448</EnrollmentCount><Interventions>amikacin; amoxicillin + clavulanate; azithromycin; bedaquiline; capreomycin; clarithromycin; clofazimine; cycloserine; delaminid; ethambutol; ethionamide; gatifloxacin; imipenem/cilastatin; isoniazid; kanamycin; levofloxacin; linezolid; meropenem; moxifloxacin; ofloxacin; para-aminosalicylic acid; pretomanid; prothionamide; pyrazinamide; rifabutin; rifampicin; streptomycin; sutezolid; terizidone; thioacetazone; whole genome sequencing</Interventions><Patients>448</Patients><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Reference>CAP 020; InDEX; NCT03237182</Reference><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><Trial id="307654"/><TrialStartDate>JUNE     , 14, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>4 beta-Hydroxycholesterol/Cholesterol ratio</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Lamprene; ethambutol (Myambutol); isoniazid (Nydrazid); kanamycin (Kantrex); moxifloxacin; prothionamide (Peteha); pyrazinamide (Zinamide)</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><EnrollmentCount>530</EnrollmentCount><Interventions>Lamprene; Regimen A locally-used WHO-approved MDR-TB regimen; bedaquiline; ethambutol (Myambutol); isoniazid (Nydrazid); kanamycin (Kantrex); levofloxacin; moxifloxacin; prothionamide (Peteha); pyrazinamide (Zinamide)</Interventions><Patients>530</Patients><ProtocolAcronym>STREAM</ProtocolAcronym><ProtocolTitle>The Evaluation of a Standard Treatment Regimen of Anti-Tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><Reference>18148631; 78372190; 78372190/18148631 (Stage 1/2); CTRI/2017/09/009693; ISRCTN78372190; NCT02409290; STREAM</Reference><Sponsor>International Union Against Tuberculosis and Lung Diseases</Sponsor><Trial id="228190"/><TrialStartDate>APRIL    , 30, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Directly observed therapy</Controls><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><EnrollmentCount>54</EnrollmentCount><Interventions>bedaquiline; clofazimine; linezolid; moxifloxacin; pretomanid</Interventions><Patients>54</Patients><ProtocolAcronym>PRACTECAL-PRO</ProtocolAcronym><ProtocolTitle>Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial</ProtocolTitle><Reference>NCT03942354; PRACTECAL-PRO; PRACTECAL-PRO</Reference><Sponsor>Medecins Sans Frontieres, Netherlands</Sponsor><Trial id="379769"/><TrialStartDate>JULY     , 01, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><EnrollmentCount>165</EnrollmentCount><Interventions>Zyvox; bedaquiline; clofazimine; delamanid</Interventions><Patients>165</Patients><ProtocolAcronym/><ProtocolTitle>Study on Tuberculosis Resistant to Treatment</ProtocolTitle><Reference>CTRI/2019/01/017310; Version Number: 3.1</Reference><Sponsor>Indian Council of Medical Research, Tuberculosis Research Centre</Sponsor><Trial id="369747"/><TrialStartDate>FEBRUARY , 01, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Directly observed therapy</Controls><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><EnrollmentCount>54</EnrollmentCount><Interventions>bedaquiline; clofazimine; linezolid; moxifloxacin; pretomanid</Interventions><Patients>54</Patients><ProtocolAcronym>PRACTECAL-PRO</ProtocolAcronym><ProtocolTitle>Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial</ProtocolTitle><Reference>NCT03942354; PRACTECAL-PRO; PRACTECAL-PRO</Reference><Sponsor>Medecins Sans Frontieres, Netherlands</Sponsor><Trial id="379769"/><TrialStartDate>JULY     , 01, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44279">amoxicillin</Drug><EnrollmentCount>45</EnrollmentCount><Interventions>amoxicillin; cefadroxil; clavulanic acid; ethambutol; faropenem; isoniazid; pyrazinamide; rifampicin</Interventions><Patients>45</Patients><ProtocolAcronym/><ProtocolTitle>Trial of faropenem and cefadroxil (in combination with amoxicillin/clavulanic acid and standard TB drugs) in patients with pulmonary tuberculosis: measurement of early bactericidal activity and effects on novel biomarkers</ProtocolTitle><Reference>2018-CT0454; 20180710115454; Faropenem_TB; PHRR181108-001980</Reference><Sponsor>National University Hospital (Singapore) Pte Ltd</Sponsor><Trial id="360329"/><TrialStartDate>NOVEMBER , 30, 2018</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Interferon gamma; Interleukin-2; T-Helper Lymphocytes; T-Lymphocytes; T-cell surface glycoprotein CD4; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="53784">Ag85B-ESAT-6 vaccine (IC31 adjuvant, tuberculosis), SSI/ Valneva</Drug><EnrollmentCount>240</EnrollmentCount><Interventions>Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Interventions><Patients>240</Patients><ProtocolAcronym>THYB-04</ProtocolAcronym><ProtocolTitle>THYB-04</ProtocolTitle><Reference>DoH-27-0612-3947; PACTR201403000646306; THYB-04</Reference><Sponsor>Statens Serum Institut</Sponsor><Trial id="285704"/><TrialStartDate>AUGUST   , 27, 2012</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Interferon gamma</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>MVA-85A</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="66409">IMX-461</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>IMX-461</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>Phase I Trial Evaluating Safety and Immunogenicity of MVA-85A-IMX3-13 Compared to MVA-85A in BCG Vaccinated Adults</ProtocolTitle><Reference>NCT01879163; TB028; UKCRN 15787</Reference><Sponsor>University of Oxford</Sponsor><Trial id="142322"/><TrialStartDate>JULY     , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2829">clarithromycin</Drug><EnrollmentCount>448</EnrollmentCount><Interventions>amikacin; amoxicillin + clavulanate; azithromycin; bedaquiline; capreomycin; clarithromycin; clofazimine; cycloserine; delaminid; ethambutol; ethionamide; gatifloxacin; imipenem/cilastatin; isoniazid; kanamycin; levofloxacin; linezolid; meropenem; moxifloxacin; ofloxacin; para-aminosalicylic acid; pretomanid; prothionamide; pyrazinamide; rifabutin; rifampicin; streptomycin; sutezolid; terizidone; thioacetazone; whole genome sequencing</Interventions><Patients>448</Patients><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Reference>CAP 020; InDEX; NCT03237182</Reference><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><Trial id="307654"/><TrialStartDate>JUNE     , 14, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-2; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="74849">SSI H56-IC31</Drug><EnrollmentCount/><Interventions>SSI H56-IC31</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>A Phase II Study of H56:IC31 in Healthy Adolescents</ProtocolTitle><Reference>A-043; NCT03265977; PACTR201704002006214</Reference><Sponsor>Aeras, Aeras Global TB Vaccine Foundation</Sponsor><Trial id="310653"/><TrialStartDate>JUNE     , 30, 2018</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59062">dolutegravir</Drug><EnrollmentCount>84</EnrollmentCount><Interventions>bedaquiline; bedaquiline; delamanid; delamanid; dolutegravir</Interventions><Patients>84</Patients><ProtocolAcronym/><ProtocolTitle>Evaluating the Safety, Tolerability and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Reference>12005; A5343; NCT02583048</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="243619"/><TrialStartDate>AUGUST   , 31, 2016</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bilirubin; Blood platelets; Calcium; Carbon dioxide; Chlorides; Creatine kinase; Creatinine; Diastolic blood pressure; Eosinophils; Erythrocytes; Glucose; Heart rate; Hematocrit; Hemoglobin; Leukocyte count; Lymphocytes; Mean corpuscular hemoglobin; Mean corpuscular volume; Monocytes; Neutrophils; Potassium; Reticulocytes; Sodium; Systolic blood pressure; Urea; gamma-Glutamyltransferase</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="69974">cabotegravir</Drug><EnrollmentCount>15</EnrollmentCount><Interventions>cabotegravir; cabotegravir; rifabutin</Interventions><Patients>15</Patients><ProtocolAcronym/><ProtocolTitle>Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects</ProtocolTitle><Reference>205712; NCT03149848</Reference><Sponsor>ViiV Healthcare Ltd</Sponsor><Trial id="298711"/><TrialStartDate>JUNE     , 06, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="81264">interferon gamma follow-on biologic, PHARMACLON LLC</Drug><EnrollmentCount>90</EnrollmentCount><Interventions>Ingaron</Interventions><Patients>90</Patients><ProtocolAcronym/><ProtocolTitle>Randomized, comparative, controlled, open-label clinical study of efficacy and safety of Ingaron (recombinant human interferon gamma) production of "NPP" FARMAKLON, Russia in the treatment of patients with pulmonary tuberculosis</ProtocolTitle><Reference>ING-08-12</Reference><Sponsor>PHARMACLON LLC</Sponsor><Trial id="194177"/><TrialStartDate>MAY      , 26, 2014</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Cytokines</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><EnrollmentCount>36</EnrollmentCount><Interventions>MVA-85A</Interventions><Patients>36</Patients><ProtocolAcronym>TB036</ProtocolAcronym><ProtocolTitle>Trial to Investigate the Effect of Schistosoma Mansoni Infection on the Response to Vaccination With MVA-85A in BCG-vaccinated African Adolescents</ProtocolTitle><Reference>NCT02178748; TB036; TB036</Reference><Sponsor>University of Oxford</Sponsor><Trial id="201409"/><TrialStartDate>JUNE     , 30, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers>Alanine transaminase; Aspartate aminotransferase; Bilirubin; T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid; isoniazid; pyridoxine</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>3000</EnrollmentCount><Interventions>efavirenz; isoniazid; pyridoxine; rifapentine</Interventions><Patients>3000</Patients><ProtocolAcronym>BRIEF TB</ProtocolAcronym><ProtocolTitle>Brief Rifapentine-Isoniazid Evaluation for TB Prevention</ProtocolTitle><Reference>10848; A5279; ACTG A5279; BRIEF TB; BRIEF TB/A5279; NCT01404312</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="79741"/><TrialStartDate>MAY      , 23, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>CPK</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="11088">sutezolid</Drug><EnrollmentCount>19</EnrollmentCount><Interventions>PNU-100480</Interventions><Patients>19</Patients><ProtocolAcronym/><ProtocolTitle>Safety, Tolerability And Pharmacokinetics Study Of Single-Doses Of PNU-100480 In Healthy Adults</ProtocolTitle><Reference>B1171001; NCT00871949</Reference><Sponsor>Sequella Inc</Sponsor><Trial id="50188"/><TrialStartDate>APRIL    , 30, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="52139">ofloxacin</Drug><EnrollmentCount>420</EnrollmentCount><Interventions>isoniazid; ofloxacin; pyrazinamide; rifampicin</Interventions><Patients>420</Patients><ProtocolAcronym/><ProtocolTitle>Randomized Clinical Trial to Study the Efficacy and Tolerability of a 4-Month Regimen Containing Ofloxacin Compared to the Standard 6-Month Regimen in the Treatment of Patients with Superficial Lymphnode Tuberculosis</ProtocolTitle><Reference>CTRI/2013/03/003481</Reference><Sponsor>Indian Council of Medical Research</Sponsor><Trial id="142516"/><TrialStartDate>OCTOBER  , 20, 2012</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Alanine transaminase; Aspartate aminotransferase; QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyraziminide; rifampicin</Controls><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>240</EnrollmentCount><Interventions>bedaquiline; moxifloxacin; pretomanid; pyraziminide</Interventions><Patients>240</Patients><ProtocolAcronym/><ProtocolTitle>A Phase II to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Reference>NC-005; NC-005-(J-M-PA-Z); NCT02193776</Reference><Sponsor>TB Alliance</Sponsor><Trial id="210646"/><TrialStartDate>OCTOBER  , 23, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Alanine transaminase; Bilirubin; C-reactive protein; Glucose; Hemoglobin; Leukocyte count; Serum potassium; Serum sodium; White blood cell</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4728">emtricitabine</Drug><EnrollmentCount>240</EnrollmentCount><Interventions>prednisone</Interventions><Patients>240</Patients><ProtocolAcronym>Pred-ART</ProtocolAcronym><ProtocolTitle>Preventing TB-IRIS in High-risk Patients: a Randomized, Placebo-controlled Trial of Prednisone</ProtocolTitle><Reference>CIDRI_001; DOH-27-0813-4336; NCT01924286; PACTR201304000511413; Pred-ART; SP.2011.41304.074</Reference><Sponsor>University of Cape Town</Sponsor><Trial id="150793"/><TrialStartDate>AUGUST   , 30, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>5</EnrollmentCount><Interventions>efavirenz; nevirapine</Interventions><Patients>5</Patients><ProtocolAcronym>OPTI-NNRTI</ProtocolAcronym><ProtocolTitle>A Study to Determine the Best Dose of Antivirals in Patients With Both TB and HIV</ProtocolTitle><Reference>NCT00523458; OPTI-NNRTI; Stanford Protocol ID: 95564</Reference><Sponsor>Stanford University</Sponsor><Trial id="11177"/><TrialStartDate>JULY     , 31, 2007</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>85A; 85B; CD4; CD8; Cytotoxic T-Lymphocytes; IFN-gamma; IL-2; T-Helper Lymphocytes; T-Lymphocytes; TB10.4; TNF-alpha</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="53975">AERAS-402</Drug><EnrollmentCount>26</EnrollmentCount><Interventions>AERAS-402</Interventions><Patients>26</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmette-Guerin (BCG)-Vaccinated Adults</ProtocolTitle><Reference>C-017-402; NCT01017536</Reference><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><Trial id="62096"/><TrialStartDate>DECEMBER , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="11036">linezolid</Drug><EnrollmentCount>19</EnrollmentCount><Interventions>linezolid</Interventions><Patients>19</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics of Linezolid in Adults with Pulmonary Tuberculosis</ProtocolTitle><Reference>PMC2737850; PMID:19564361</Reference><Sponsor/><Trial id="150522"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Solute carrier organic anion transporter family member 1B1</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><EnrollmentCount>48</EnrollmentCount><Interventions>efavirenz; isoniazid; lamivudine; lopinavir + ritonavir; nevirapine; rifabutin; stavudine</Interventions><Patients>35</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa</ProtocolTitle><Reference>ANRS12150a; NCT00640887</Reference><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><Trial id="11187"/><TrialStartDate>FEBRUARY , 28, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="54488">raltegravir</Drug><EnrollmentCount>10</EnrollmentCount><Interventions>abacavir; lamivudine; raltegravir</Interventions><Patients>10</Patients><ProtocolAcronym/><ProtocolTitle>Raltegravir + ABC/3TC in HIV/TB Co-Infected Patients</ProtocolTitle><Reference>NCT01059422; RAL/ABC/3TC - HIV/TB</Reference><Sponsor>Central Research Institute of Epidemiology</Sponsor><Trial id="63729"/><TrialStartDate>OCTOBER  , 31, 2010</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>CD4+</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2935">didanosine</Drug><EnrollmentCount>180</EnrollmentCount><Interventions>didanosine; efavirenz; efavirenz +  didanosine + lamivudine; ethambutol; ethambutol + isoniazid + rifampicin + pyrazinamide; isoniazid; isoniazid + rifampicin; lamivudine; nevirapine; nevirapine + didanosine + lamivudine; pyrazinamide; rifampicin</Interventions><Patients>116</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-Tuberculosis Treatment</ProtocolTitle><Reference>NCT00332306; trc23</Reference><Sponsor>Tuberculosis Research Centre</Sponsor><Trial id="10863"/><TrialStartDate>JUNE     , 30, 2006</TrialStartDate><TrialStatus>Suspended</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount>650</EnrollmentCount><Interventions>ethambutol hydrochloride; isoniazid; levofloxacin; pyrazinamide; pyridoxine hydrochloride; rifampin</Interventions><Patients>650</Patients><ProtocolAcronym/><ProtocolTitle>The Treatment of Tuberculosis in HIV-Infected Patients</ProtocolTitle><Reference>11199; ACTG 222; CPCRA 019; NCT00001033</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="10643"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Cyp 450</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Mycocox-4</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="69440">rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals</Drug><EnrollmentCount>100</EnrollmentCount><Interventions>Risorine; ethambutol; pyrazinamide</Interventions><Patients>100</Patients><ProtocolAcronym/><ProtocolTitle>Comparison of Sputum Conversion Rates, Plasma Rifampicin Levels and Cyp 450 Activity Pulmonary Tuberculosis Patients Have Received 8 Weeks of Intensive Phase Therapy With Standard Dose Regimen Versus Risorine Kit</ProtocolTitle><Reference>CRSC12004; CTRI/2012/11/003097</Reference><Sponsor>Cadila Pharmaceuticals Ltd</Sponsor><Trial id="142231"/><TrialStartDate>JUNE     , 10, 2012</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><EnrollmentCount>48</EnrollmentCount><Interventions>MVA-85A</Interventions><Patients>48</Patients><ProtocolAcronym/><ProtocolTitle>A Study of MVA-85A, in Asymptomatic Volunteers Infected With TB, HIV or Both</ProtocolTitle><Reference>NCT00480558; TB011</Reference><Sponsor>University of Oxford</Sponsor><Trial id="14589"/><TrialStartDate>JULY     , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="6242">abacavir</Drug><EnrollmentCount>10</EnrollmentCount><Interventions>abacavir; lamivudine; raltegravir</Interventions><Patients>10</Patients><ProtocolAcronym/><ProtocolTitle>Raltegravir + ABC/3TC in HIV/TB Co-Infected Patients</ProtocolTitle><Reference>NCT01059422; RAL/ABC/3TC - HIV/TB</Reference><Sponsor>Central Research Institute of Epidemiology</Sponsor><Trial id="63729"/><TrialStartDate>OCTOBER  , 31, 2010</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="11036">linezolid</Drug><EnrollmentCount>7</EnrollmentCount><Interventions>clarithromycin; linezolid; linezolid + clarithromycin</Interventions><Patients>7</Patients><ProtocolAcronym/><ProtocolTitle>Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients</ProtocolTitle><Reference>2011-000513-39; NCT01521364; NL35534.042.11; NTR3260</Reference><Sponsor>University Medical Center Groningen</Sponsor><Trial id="182646"/><TrialStartDate>DECEMBER , 31, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Alanine aminotransferase; CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>efavirenz; lamivudine; stavudine</Controls><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="4481">stavudine</Drug><EnrollmentCount>570</EnrollmentCount><Interventions>Arm A; Arm B; Triomune; ethambutol; ethambutol; isoniazid; isoniazid; lamivudine; nevirapine; pyrazinamide; pyrazinamide; rifampicin; rifampicin; stavudine</Interventions><Patients>570</Patients><ProtocolAcronym>CARINEMO</ProtocolAcronym><ProtocolTitle>Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients</ProtocolTitle><Reference>ANRS 12146 CARINEMO; ANRS 12146/12214; ANRS 12214; CARINEMO; NCT00495326</Reference><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><Trial id="10948"/><TrialStartDate>DECEMBER , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Visual acuity</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="31010">SQ-109</Drug><EnrollmentCount>365</EnrollmentCount><Interventions>SQ-109; ethambutol; isoniazid; moxifloxacin; pyrazinamide; pyridoxine; rifampicin</Interventions><Patients>365</Patients><ProtocolAcronym/><ProtocolTitle>Evaluation of SQ-109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design</ProtocolTitle><Reference>NCT01785186; PACTR201205000383208; PanACEA-MAMS-TB-01</Reference><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><Trial id="109063"/><TrialStartDate>APRIL    , 30, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Human immunodeficiency virus DNA; Human immunodeficiency virus RNA; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>efavirenz; lamivudine; tenofovir disoproxil fumarate</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="14493">tenofovir disoproxil fumarate</Drug><EnrollmentCount>155</EnrollmentCount><Interventions>lamivudine; raltegravir; tenofovir disoproxil fumarate</Interventions><Patients>155</Patients><ProtocolAcronym>REFLATE TB</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Two Raltegravir Doses in Naive HIV-1-Infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><Reference>2008-004970-41; ANRS 12 180; ANRS 12180 REFLATE TB; NCT00822315; REFLATE TB</Reference><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><Trial id="40948"/><TrialStartDate>JULY     , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><EnrollmentCount>661</EnrollmentCount><Interventions>efavirenz; efavirenz + lamivudine + stavudine; lamivudine; stavudine</Interventions><Patients>540</Patients><ProtocolAcronym>ANRS 1295 CAMELIA</ProtocolAcronym><ProtocolTitle>Early versus Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis</ProtocolTitle><Reference>ANRS 1295 CAMELIA; ANRS 1295 CAMELIA; CIPRA KH 001; NCT00226434; NCT00498823</Reference><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><Trial id="145651"/><TrialStartDate>JANUARY  , 31, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>295</EnrollmentCount><Interventions>bedaquiline</Interventions><Patients>295</Patients><ProtocolAcronym/><ProtocolTitle>Early Access of TMC-207 in Patients With Extensively Drug Resistant or Pre-XDR Pulmonary Tuberculosis</ProtocolTitle><Reference>2010-021125-12; CR017233; NCT01464762; TMC207TBC3001</Reference><Sponsor>Janssen Diagnostics BVBA</Sponsor><Trial id="82132"/><TrialStartDate>SEPTEMBER, 16, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Rifafour e</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><EnrollmentCount>105</EnrollmentCount><Interventions>PA-824; TMC-207; clofazimine; clofazimine; pyrazinamide; pyrazinamide</Interventions><Patients>105</Patients><ProtocolAcronym>NC-003</ProtocolAcronym><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC-207 (J)-PA-824 (Pa)-Pyrazinamide (Z)</ProtocolTitle><Reference>NC-003; NC-003-(C-J-Pa-Z); NCT01691534</Reference><Sponsor>TB Alliance</Sponsor><Trial id="92275"/><TrialStartDate>OCTOBER  , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="68617">ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis</Drug><EnrollmentCount>66</EnrollmentCount><Interventions>ID-93</Interventions><Patients>66</Patients><ProtocolAcronym/><ProtocolTitle>Phase I, ID93 + GLA-SE Vaccine Trial in BCG-vaccinated Healthy Adult Volunteers</ProtocolTitle><Reference>IDRI-TBVPX-114; NCT01927159</Reference><Sponsor>Infectious Disease Research Institute</Sponsor><Trial id="151743"/><TrialStartDate>SEPTEMBER, 30, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount>750</EnrollmentCount><Interventions>ethambutol; isoniazid; levofloxacin; pyrazinamide; rifampicin; streptomycin</Interventions><Patients>817</Patients><ProtocolAcronym>05TB</ProtocolAcronym><ProtocolTitle>A randomized, double-blind, placebo-controlled trial to investigate the effect of intensified treatment with high dose rifampicin and levofloxacin for adult patients with tuberculous meningitis</ProtocolTitle><Reference>05TB; 084253; 084253; ISRCTN61649292; OXTREC No 33/09</Reference><Sponsor>University of Oxford</Sponsor><Trial id="75317"/><TrialStartDate>APRIL    , 18, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Anti-Meningitis C antibodies; C-C motif chemokine 2; C-C motif chemokine 3; C-C motif chemokine 4; Cytokines; IgG; Interferon gamma; Interferon-alpha; Interleukin-1 alpha; Interleukin-1 beta; Interleukin-10; Interleukin-12; Interleukin-13; Interleukin-2; Interleukin-6</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15298">Pentacel</Drug><EnrollmentCount>28</EnrollmentCount><Interventions>BCG; Infanrix; Menitorix; NeisVac-C; Pentacel; Prevnar 13; Priorix; Rotarix</Interventions><Patients>28</Patients><ProtocolAcronym>BAM</ProtocolAcronym><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><Reference>2013-003488-71; BAM; NCT02002156; OVG-2013/04; UKCRN 15722</Reference><Sponsor>University of Oxford</Sponsor><Trial id="162886"/><TrialStartDate>JUNE     , 20, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4229">rifabutin</Drug><EnrollmentCount/><Interventions>efavirenz; rifabutin</Interventions><Patients/><ProtocolAcronym>USPHS-23</ProtocolAcronym><ProtocolTitle>Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen</ProtocolTitle><Reference>NCRR-M01RR00030-0162; NCT00018083; USPHS-23</Reference><Sponsor>National Institutes of Health</Sponsor><Trial id="10648"/><TrialStartDate>JULY     , 02, 2001</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Alanine aminotransferase; CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>efavirenz; lamivudine; stavudine</Controls><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>570</EnrollmentCount><Interventions>Arm A; Arm B; Triomune; ethambutol; ethambutol; isoniazid; isoniazid; lamivudine; nevirapine; pyrazinamide; pyrazinamide; rifampicin; rifampicin; stavudine</Interventions><Patients>570</Patients><ProtocolAcronym>CARINEMO</ProtocolAcronym><ProtocolTitle>Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients</ProtocolTitle><Reference>ANRS 12146 CARINEMO; ANRS 12146/12214; ANRS 12214; CARINEMO; NCT00495326</Reference><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><Trial id="10948"/><TrialStartDate>DECEMBER , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="28379">Glutoxim</Drug><EnrollmentCount>54</EnrollmentCount><Interventions>Glutoxim</Interventions><Patients>54</Patients><ProtocolAcronym/><ProtocolTitle>Glutoxim in the Surgical Treatment of Patients With Pulmonary Tuberculosis</ProtocolTitle><Reference>PMID:17598458</Reference><Sponsor/><Trial id="149224"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="49162">LL-3858</Drug><EnrollmentCount>40</EnrollmentCount><Interventions>LL-3858</Interventions><Patients>40</Patients><ProtocolAcronym/><ProtocolTitle>A phase IIa clinical trial for a novel molecule (LL-3858) developed by Lupin Limited which has the potential of treating the Pulmonary tuberculosis patients effectively</ProtocolTitle><Reference>CTRI/2009/091/000741; LRP/CTP/022/3858/II/01</Reference><Sponsor>Lupin Ltd</Sponsor><Trial id="103573"/><TrialStartDate>DECEMBER , 02, 2009</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><EnrollmentCount>15</EnrollmentCount><Interventions>lopinavir + ritonavir; rifabutin</Interventions><Patients>15</Patients><ProtocolAcronym/><ProtocolTitle>A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects</ProtocolTitle><Reference>M10-457; NCT00743470</Reference><Sponsor>Abbott Laboratories</Sponsor><Trial id="25327"/><TrialStartDate>AUGUST   , 31, 2008</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>120</EnrollmentCount><Interventions>Rifafour; Rifafour; efavirenz; lamivudine; zidovudine</Interventions><Patients>120</Patients><ProtocolAcronym>PK-TB-HAART</ProtocolAcronym><ProtocolTitle>Bioavailability of the Fixed Dose Formulation Rifafour Containing Isoniazid, Rifampicin, Pyrazinamide, Ethambutol and the World Health Organization (WHO) Recommended First Line Antiretroviral Drugs Zidovudine, Lamivudine, Efavirenz Administered to New Tuberculosis (TB) Patients at Different Levels of Immunosuppression</ProtocolTitle><Reference>A40607; ISRCTN83323477; PK-TB-HAART</Reference><Sponsor>World Health Organization</Sponsor><Trial id="136052"/><TrialStartDate>MAY      , 29, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Solute carrier organic anion transporter family member 1B1</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><EnrollmentCount>48</EnrollmentCount><Interventions>efavirenz; isoniazid; lamivudine; lopinavir + ritonavir; nevirapine; rifabutin; stavudine</Interventions><Patients>35</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa</ProtocolTitle><Reference>ANRS12150a; NCT00640887</Reference><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><Trial id="11187"/><TrialStartDate>FEBRUARY , 28, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="69440">rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>Risorine</Interventions><Patients>60</Patients><ProtocolAcronym/><ProtocolTitle>Combination of Two Drugs in Tuberculosis Treatment</ProtocolTitle><Reference>CTRI/2015/01/005475</Reference><Sponsor>SRM University</Sponsor><Trial id="224091"/><TrialStartDate/><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44316">zidovudine</Drug><EnrollmentCount>130</EnrollmentCount><Interventions>efavirenz; isoniazid; lamivudine; pyrazinamide; rifampicin; zidovudine</Interventions><Patients>130</Patients><ProtocolAcronym>IPEC-EFV</ProtocolAcronym><ProtocolTitle>Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X  800 mg</ProtocolTitle><Reference>CAAE-0017.1.009.000-03; IPEC-EFV; NCT00533390</Reference><Sponsor>Fundacao Oswaldo Cruz (Fiocruz)</Sponsor><Trial id="11181"/><TrialStartDate>JANUARY  , 31, 2007</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>CD4; albumin</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><EnrollmentCount>156</EnrollmentCount><Interventions>efavirenz; lamivudine; lamivudine + efavirenz + tenofovir disoproxil fumarate; tenofovir disoproxil fumarate</Interventions><Patients>156</Patients><ProtocolAcronym>TIME</ProtocolAcronym><ProtocolTitle>Appropriate Timing of HAART in Co-infected HIV/TB Patients</ProtocolTitle><Reference>0435.3/1551; NCT01014481; TIME</Reference><Sponsor>Bamrasnaradura Infectious Diseases Institute</Sponsor><Trial id="61991"/><TrialStartDate>OCTOBER  , 31, 2009</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Th1 cytokines</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="46927">doxycycline hyclate</Drug><EnrollmentCount>200</EnrollmentCount><Interventions>doxycycline (once-daily, oral controlled release), CollaGenex; doxycycline hyclate</Interventions><Patients>200</Patients><ProtocolAcronym>Map2Co</ProtocolAcronym><ProtocolTitle>Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana</ProtocolTitle><Reference>GZ:JA 1479/5-1; Map2Co; NCT02281643</Reference><Sponsor>kwame Nkrumah University of Science and Technology</Sponsor><Trial id="214864"/><TrialStartDate>OCTOBER  , 31, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>3900</EnrollmentCount><Interventions>isoniazid; rifapentine</Interventions><Patients>3738</Patients><ProtocolAcronym/><ProtocolTitle>Intervention study in rural residents (50 to 70 years old) with latent Mycobacterium tuberculosis infection</ProtocolTitle><Reference>ChiCTR-IOR-15007202</Reference><Sponsor>Chinese Academy of Medical Sciences &amp; Peking Union Medical College</Sponsor><Trial id="243294"/><TrialStartDate>JANUARY  , 01, 2014</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Heart rate; PR interval; QRS complex; QT interval; T-wave</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="71742">TBA-354</Drug><EnrollmentCount>48</EnrollmentCount><Interventions>TBA-354</Interventions><Patients>48</Patients><ProtocolAcronym/><ProtocolTitle>A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TBA-354 in Healthy Adult Subjects</ProtocolTitle><Reference>NCT02288481; TBA-354-CL-001</Reference><Sponsor>TB Alliance</Sponsor><Trial id="215600"/><TrialStartDate>JANUARY  , 31, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="90085">macozinone</Drug><EnrollmentCount>32</EnrollmentCount><Interventions>PBTZ-169</Interventions><Patients>32</Patients><ProtocolAcronym/><ProtocolTitle>Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PBTZ-169 in Multiple Dosing</ProtocolTitle><Reference>IM-006-13; NCT03776500</Reference><Sponsor>Innovative Medicines for Tuberculosis</Sponsor><Trial id="363587"/><TrialStartDate>FEBRUARY , 21, 2019</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>B-lymphocytes; Neutrophils; T-Lymphocytes</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>BCG vaccine</Controls><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="84564">ChAdOx1-85A</Drug><EnrollmentCount>72</EnrollmentCount><Interventions>ChAdOx1-85A; ChAdOx1-85A; MVA-85A</Interventions><Patients>72</Patients><ProtocolAcronym/><ProtocolTitle>EMaBS TB Vaccine Study</ProtocolTitle><Reference>NCT03681860; TB042</Reference><Sponsor>University of Oxford</Sponsor><Trial id="354327"/><TrialStartDate>DECEMBER , 01, 2018</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="44284">amoxicillin + clavulanate potassium, GSK</Drug><EnrollmentCount>88</EnrollmentCount><Interventions>Augmentin; Merrem; rifampin</Interventions><Patients>88</Patients><ProtocolAcronym/><ProtocolTitle>Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB</ProtocolTitle><Reference>FD-R-05724; IRB00119017; NCT03174184</Reference><Sponsor>Johns Hopkins University</Sponsor><Trial id="300655"/><TrialStartDate>AUGUST   , 23, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount>45</EnrollmentCount><Interventions>levofloxacin</Interventions><Patients>45</Patients><ProtocolAcronym/><ProtocolTitle>Population Pharmacokinetics and Pharmacodynamics Modeling to Optimize Dosage Regimen of Levofloxacin</ProtocolTitle><Reference>LEVO-57-356141; NCT02699658</Reference><Sponsor>Prince of Songkla University</Sponsor><Trial id="254949"/><TrialStartDate>OCTOBER  , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Alanine transaminase</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="105321">superboosted lopinavir + ritonavir (pediatric oral formulation, HIV infection), DNDi</Drug><EnrollmentCount>96</EnrollmentCount><Interventions>rifampicin; superboosted lopinavir + ritonavir (pediatric oral formulation, HIV infection), DNDi</Interventions><Patients>96</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB</ProtocolTitle><Reference>DNDiHIVPed001; NCT02348177</Reference><Sponsor>Drugs for Neglected Diseases Initiative</Sponsor><Trial id="220686"/><TrialStartDate>JANUARY  , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount>448</EnrollmentCount><Interventions>amikacin; amoxicillin + clavulanate; azithromycin; bedaquiline; capreomycin; clarithromycin; clofazimine; cycloserine; delaminid; ethambutol; ethionamide; gatifloxacin; imipenem/cilastatin; isoniazid; kanamycin; levofloxacin; linezolid; meropenem; moxifloxacin; ofloxacin; para-aminosalicylic acid; pretomanid; prothionamide; pyrazinamide; rifabutin; rifampicin; streptomycin; sutezolid; terizidone; thioacetazone; whole genome sequencing</Interventions><Patients>448</Patients><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Reference>CAP 020; InDEX; NCT03237182</Reference><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><Trial id="307654"/><TrialStartDate>JUNE     , 14, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>62</EnrollmentCount><Interventions>depot medroxyprogesterone acetate; efavirenz; isoniazid; rifampicin</Interventions><Patients>62</Patients><ProtocolAcronym>PRIDE-HT</ProtocolAcronym><ProtocolTitle>PK Study of Rifampicin Interactions With DMPA and Efaviranz in TB</ProtocolTitle><Reference>ACTG A5338; NCT02412436; PRIDE-HT; UM1AI068636</Reference><Sponsor>AIDS Clinical Trials Group</Sponsor><Trial id="227340"/><TrialStartDate>NOVEMBER , 03, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>amikacin; cycloserine; moxifloxacin; prothionamide; pyrazinamide</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>488</EnrollmentCount><Interventions>amikacin; clofazimine; cycloserine; ethambutol; linezolid; moxifloxacin; prothionamide; pyrazinamide</Interventions><Patients>488</Patients><ProtocolAcronym>GRACE-TB</ProtocolAcronym><ProtocolTitle>NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB</ProtocolTitle><Reference>GRACE-TB; KY2018-291; NCT03604848</Reference><Sponsor>Huashan Hospital</Sponsor><Trial id="348056"/><TrialStartDate>AUGUST   , 05, 2018</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Rifafour e275; ethambutol; isoniazid; pyrazinamide; rifampin</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4492">faropenem</Drug><EnrollmentCount>46</EnrollmentCount><Interventions>amoxicillin + clavulanate potassium, GSK; faropenem; meropenem</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>Phase II Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis</ProtocolTitle><Reference>NCT02349841; TASK-001</Reference><Sponsor>Task Foundation NPC</Sponsor><Trial id="220739"/><TrialStartDate>SEPTEMBER, 30, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Rifafour e275; ethambutol; isoniazid; pyrazinamide; rifampin</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3616">meropenem</Drug><EnrollmentCount>46</EnrollmentCount><Interventions>amoxicillin + clavulanate potassium, GSK; faropenem; meropenem</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>Phase II Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis</ProtocolTitle><Reference>NCT02349841; TASK-001</Reference><Sponsor>Task Foundation NPC</Sponsor><Trial id="220739"/><TrialStartDate>SEPTEMBER, 30, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Cytochrome P450 2B6</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>155</EnrollmentCount><Interventions>efavirenz; neucleotide reverse transcriptase inhibitors; rifampin</Interventions><Patients>155</Patients><ProtocolAcronym/><ProtocolTitle>Efavirenz (EFV) in HIV-Infected and HIV/Tuberculosis (TB) Coinfected Children</ProtocolTitle><Reference>10633; IMPAACT P1070; NCT00802802; P1070</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="37985"/><TrialStartDate>OCTOBER  , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><EnrollmentCount>284</EnrollmentCount><Interventions>moxifloxacin; pretomanid; pyrazinamide</Interventions><Patients>284</Patients><ProtocolAcronym>STAND</ProtocolAcronym><ProtocolTitle>Shortening Treatment by Advancing Novel Drugs</ProtocolTitle><Reference>2014-CT0249; NC-006-(M-PA-Z); NC-006-(M-Pa-Z); NC-006-(M-Pa-Z) 21522; NCT02342886; NMRR-14-702-21522; PHRR150114-000899; STAND</Reference><Sponsor>TB Alliance</Sponsor><Trial id="221844"/><TrialStartDate>FEBRUARY , 28, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>84</EnrollmentCount><Interventions>bedaquiline; bedaquiline; delamanid; delamanid; dolutegravir</Interventions><Patients>84</Patients><ProtocolAcronym/><ProtocolTitle>Evaluating the Safety, Tolerability and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Reference>12005; A5343; NCT02583048</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="243619"/><TrialStartDate>AUGUST   , 31, 2016</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>208</EnrollmentCount><Interventions>bedaquiline</Interventions><Patients>160</Patients><ProtocolAcronym/><ProtocolTitle>Anti-bacterial Activity, Safety, and Tolerability of TMC-207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB)</ProtocolTitle><Reference>2007-004462-40; CR011929; NCT00449644; NCT00614627; NCT00980265; TMC207-TIDP13-C208</Reference><Sponsor>Janssen R&amp;D (Ireland)</Sponsor><Trial id="9302"/><TrialStartDate>JUNE     , 30, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>pyrazinamide</Controls><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><EnrollmentCount>238</EnrollmentCount><Interventions>delamanid; levofloxacin; linezolid; pyrazinamide</Interventions><Patients>238</Patients><ProtocolAcronym>MDR-END</ProtocolAcronym><ProtocolTitle>Treatment Shortening of MDR-TB Using Existing and New Drugs</ProtocolTitle><Reference>MDR-END; NCT02619994</Reference><Sponsor>Seoul National University Hospital</Sponsor><Trial id="247456"/><TrialStartDate>JANUARY  , 31, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55569">VPM-1002</Drug><EnrollmentCount>12000</EnrollmentCount><Interventions>Immuvac; VPM-1002</Interventions><Patients>12000</Patients><ProtocolAcronym/><ProtocolTitle>To Study Effect of Two Vaccines in Preventing Spread of Tuberculosis in Persons Living With New Tuberculosis Patients</ProtocolTitle><Reference>CTRI/2019/01/017026; ICMR/ITRC/VAC/001/2018, Version 1.5, dated 3rd october 2018</Reference><Sponsor>Indian Council of Medical Research</Sponsor><Trial id="366261"/><TrialStartDate>JANUARY  , 25, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>WHO approved regimen-based therapy</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><EnrollmentCount/><Interventions>Deltyba; Levaquin; Zyvox; pyrazinamide</Interventions><Patients/><ProtocolAcronym>DAZZLE</ProtocolAcronym><ProtocolTitle>Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin</ProtocolTitle><Reference>DAZZLE; H-36160; NCT02975570</Reference><Sponsor>Boston University</Sponsor><Trial id="280651"/><TrialStartDate>AUGUST   , 31, 2017</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="70901">BTZ-043</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>BTZ-043</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>A Single Ascending Dose Study Of BTZ-043</ProtocolTitle><Reference>LMU-IMPH-BTZ043-01; NCT03590600</Reference><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><Trial id="346718"/><TrialStartDate>JUNE     , 07, 2018</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Directly observed therapy</Controls><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>54</EnrollmentCount><Interventions>bedaquiline; clofazimine; linezolid; moxifloxacin; pretomanid</Interventions><Patients>54</Patients><ProtocolAcronym>PRACTECAL-PRO</ProtocolAcronym><ProtocolTitle>Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial</ProtocolTitle><Reference>NCT03942354; PRACTECAL-PRO; PRACTECAL-PRO</Reference><Sponsor>Medecins Sans Frontieres, Netherlands</Sponsor><Trial id="379769"/><TrialStartDate>JULY     , 01, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>180</EnrollmentCount><Interventions>bedaquiline; linezolid; pretomanid</Interventions><Patients>180</Patients><ProtocolAcronym>ZeNiX</ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre-XDR-TB or Non-responsive/Intolerant MDR-TB</ProtocolTitle><Reference>NC-007- (B-Pa-L); NCT03086486; ZENIX (B-PA-L) NC-007; ZeNiX</Reference><Sponsor>TB Alliance</Sponsor><Trial id="293734"/><TrialStartDate>OCTOBER  , 31, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>170</EnrollmentCount><Interventions>moxifloxacin</Interventions><Patients>146</Patients><ProtocolAcronym/><ProtocolTitle>Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis</ProtocolTitle><Reference>FD-R-002135-01; NCT00082173</Reference><Sponsor>Food and Drug Administration, Johns Hopkins University</Sponsor><Trial id="8791"/><TrialStartDate>OCTOBER  , 31, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Cytochrome P450 3A4; Hemoglobin A, glycosylated; Total body mass; Urinary albumin to creatinine ratio</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>36</EnrollmentCount><Interventions>bedaquiline</Interventions><Patients>36</Patients><ProtocolAcronym>PANDEMIC</ProtocolAcronym><ProtocolTitle>A study on the uptake, distribution and excretion of bedaquiline, a medicine against tuberculosis, in people with type 2 diabetes</ProtocolTitle><Reference>2017-004490-14; 2017-004490-14 201700787; NTR7045; PANDEMIC</Reference><Sponsor>University Medical Center Groningen</Sponsor><Trial id="331962"/><TrialStartDate>JUNE     , 01, 2018</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bilirubin; Body temperature; Calcium; Creatinine; Diastolic blood pressure; Eosinophils; Glucose; Heart rate; Heart rate; Hematocrit; Hemoglobin; Ketones; Lymphocytes; Mean corpuscular hemoglobin; Monocytes; Neutrophils; PR interval; Potassium; QRS complex; QT interval; Reticulocytes; Sodium; Systolic blood pressure; Total cholesterol; Total protein; Triglycerides; Troponin; Urea nitrogen</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="70581">GSK-3036656</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>GSK-3036656</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>First Time in Human (FTIH) Safety and Pharmacokinetics (PK) Study of GSK-3036656 in Healthy Subjects</ProtocolTitle><Reference>201040; 2015-003654-41; NCT03075410</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="290705"/><TrialStartDate>APRIL    , 02, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="12135">celecoxib</Drug><EnrollmentCount>18</EnrollmentCount><Interventions>celecoxib; celecoxib; pyrazinamide; pyrazinamide; rifampicin; rifampicin</Interventions><Patients>18</Patients><ProtocolAcronym/><ProtocolTitle>Evaluating Celecoxib Activity in Mycobacterium Tuberculosis: A Whole Blood Bactericidal Activity Study in Healthy Volunteers</ProtocolTitle><Reference>CELECOXIB_WBA; NCT02602509</Reference><Sponsor>National University Hospital (Singapore) Pte Ltd</Sponsor><Trial id="245694"/><TrialStartDate>NOVEMBER , 30, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="57308">RUTI</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>RUTI</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>Clinical Trial to Study Four Different Doses of the Vaccine RUTI in Healthy Volunteers</ProtocolTitle><Reference>EudraCT Number: 2006-000690-29; FA/MI/01; NCT00546273</Reference><Sponsor>Germans Trias i Pujol Hospital</Sponsor><Trial id="8888"/><TrialStartDate>APRIL    , 30, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Alanine transaminase; Aspartate aminotransferase; Bilirubin; Blood pressure; Body temperature; Creatinine; Estimated glomerular filtration rate; Heart rate; Hemoglobin; Magnesium; Potassium; QT interval; Urea nitrogen</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><EnrollmentCount>48</EnrollmentCount><Interventions>pretomanid</Interventions><Patients>48</Patients><ProtocolAcronym/><ProtocolTitle>Single-Dose Study to Evaluate the PKs of Pretomanid in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function</ProtocolTitle><Reference>15-0037; HHSN272201300021I; NCT03896750</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="375406"/><TrialStartDate>MAY      , 09, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>WHO regimen therapy</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><EnrollmentCount/><Interventions>Deltyba; Lamprene; Levaquin; Sirturo; Zyvox</Interventions><Patients/><ProtocolAcronym>DRAMATIC</ProtocolAcronym><ProtocolTitle>Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB</ProtocolTitle><Reference>DRAMATIC; H38212; NCT03828201</Reference><Sponsor>Boston University</Sponsor><Trial id="368916"/><TrialStartDate>JANUARY  , 31, 2020</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="95442">ESAT-6CFP10</Drug><EnrollmentCount>1044</EnrollmentCount><Interventions>BCG; ESAT6-CFP10</Interventions><Patients>1044</Patients><ProtocolAcronym/><ProtocolTitle>Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18 to 65</ProtocolTitle><Reference>EC-IIB-HEALTHY; NCT02389322</Reference><Sponsor>Anhui Zhifei Longcom Biopharmaceutical Co Ltd</Sponsor><Trial id="224675"/><TrialStartDate>MARCH    , 31, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bilirubin; Blood platelets; Body temperature; Calcium; Chlorides; Creatinine; Diastolic blood pressure; Eosinophils; Erythrocytes; Glucose; Heart rate; Hematocrit; Hemoglobin; Ketones; Lactate dehydrogenase; Leukocyte count; Lymphocytes; Mean corpuscular hemoglobin; Mean corpuscular volume; Monocytes; Neutrophils; Nitrite; Potassium; QT interval; Respiratory frequency; Reticulocytes; Sodium; Systolic blood pressure; Total protein; Urea nitrogen; Urobilinogen; gamma-Glutamyltransferase</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Rifafour e-275</Controls><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="70581">GSK-3036656</Drug><EnrollmentCount>80</EnrollmentCount><Interventions>GSK-3036656</Interventions><Patients>80</Patients><ProtocolAcronym/><ProtocolTitle>An Early Bactericidal Activity, Safety and Tolerability of GSK-3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis</ProtocolTitle><Reference>201214; NCT03557281</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="343050"/><TrialStartDate>MARCH    , 27, 2019</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>standard of care treatment</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4492">faropenem</Drug><EnrollmentCount>56</EnrollmentCount><Interventions>clavulanate; faropenem; rifampicin; standard of care treatment</Interventions><Patients>56</Patients><ProtocolAcronym/><ProtocolTitle>Synergistically acting Rifampicin and Faropenem in Tuberculosis</ProtocolTitle><Reference>CTRI/2019/04/018577</Reference><Sponsor>Indian Council of Medical Research</Sponsor><Trial id="377088"/><TrialStartDate>MAY      , 31, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>bedaquiline; delamanid; moxifloxacin</Controls><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="16545">delamanid</Drug><EnrollmentCount>75</EnrollmentCount><Interventions>bedaquiline; delamanid; midazolam; moxifloxacin; sutezolid</Interventions><Patients>75</Patients><ProtocolAcronym>SUDOCU</ProtocolAcronym><ProtocolTitle>PanACEA Sutezolid Dose-finding and Combination Evaluation</ProtocolTitle><Reference>NCT03959566; PANACEA-SUDOCU-01; SUDOCU</Reference><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><Trial id="381674"/><TrialStartDate>AUGUST   , 31, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Interferon gamma</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="95442">ESAT-6CFP10</Drug><EnrollmentCount/><Interventions>ESAT-6CFP10</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>Recombinant Mycobacterium tuberculosis allergen ESAT6-CFP10 for 18 to 65 years old healthy people: randomized, blinded, parallel-group phase III clinical trial</ProtocolTitle><Reference>ChiCTR-IIR-16007904</Reference><Sponsor>Jiangsu Provincial Academy Of Environmental Science</Sponsor><Trial id="252783"/><TrialStartDate>FEBRUARY , 17, 2016</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Glucose</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>amikacin; clofazimine; cycloserine; ethambutol; isoniazid; kanamycin; levofloxacin; prothionamide; pyrazinamide</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><EnrollmentCount>220</EnrollmentCount><Interventions>clofazimine; cycloserine; levofloxacin; linezolid; prothionamide; pyrazinamide</Interventions><Patients>220</Patients><ProtocolAcronym>TB-TRUST</ProtocolAcronym><ProtocolTitle>Refining MDR-TB Treatment Regimens for Ultra Short Therapy</ProtocolTitle><Reference>KY2018-331; NCT03867136; TB-TRUST</Reference><Sponsor>Huashan Hospital</Sponsor><Trial id="372676"/><TrialStartDate>MAY      , 01, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Human immunodeficiency virus DNA; Human immunodeficiency virus RNA; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>efavirenz; lamivudine; tenofovir disoproxil fumarate</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="54488">raltegravir</Drug><EnrollmentCount>155</EnrollmentCount><Interventions>lamivudine; raltegravir; tenofovir disoproxil fumarate</Interventions><Patients>155</Patients><ProtocolAcronym>REFLATE TB</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Two Raltegravir Doses in Naive HIV-1-Infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><Reference>2008-004970-41; ANRS 12 180; ANRS 12180 REFLATE TB; NCT00822315; REFLATE TB</Reference><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><Trial id="40948"/><TrialStartDate>JULY     , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2829">clarithromycin</Drug><EnrollmentCount/><Interventions>clarithromycin; levofloxacin; moxifloxacin; moxifloxacin; rifabutin</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>The research of new regimen for multidrug-resistant tuberculosis treatment</ProtocolTitle><Reference>ChiCTR-IOR-15007291</Reference><Sponsor>Beijing Chest Hospital, Beijing Tuberculosis &amp; Thoracic Tumor Research Institute, Capital Medical University</Sponsor><Trial id="244777"/><TrialStartDate>OCTOBER  , 01, 2008</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44303">midazolam hydrochloride</Drug><EnrollmentCount>74</EnrollmentCount><Interventions>TBA-7371; TBA-7371; bupropion; midazolam</Interventions><Patients>74</Patients><ProtocolAcronym/><ProtocolTitle>A Phase I Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371</ProtocolTitle><Reference>NCT03199339; TBA-7371-CL001</Reference><Sponsor>TB Alliance</Sponsor><Trial id="303756"/><TrialStartDate>AUGUST   , 29, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="74480">doravirine</Drug><EnrollmentCount>11</EnrollmentCount><Interventions>doravirine; isoniazid; rifapentine</Interventions><Patients>11</Patients><ProtocolAcronym>DORIIS</ProtocolAcronym><ProtocolTitle>Doravirine, Rifapentine and Isoniazid Interaction</ProtocolTitle><Reference>12690; DORIIS; NCT03886701</Reference><Sponsor>Thomas Jefferson University</Sponsor><Trial id="374387"/><TrialStartDate>APRIL    , 30, 2019</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="44363">trimethoprim + sulphamethoxazole</Drug><EnrollmentCount>1354</EnrollmentCount><Interventions>isoniazid; trimethoprim + sulphamethoxazole</Interventions><Patients>1354</Patients><ProtocolAcronym/><ProtocolTitle>Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV</ProtocolTitle><Reference>IMPAACT P1041; NCT00080119; PACTG P1041; U01AI068632</Reference><Sponsor>International Maternal Pediatric Adolescent AIDS Clinical Trials Group</Sponsor><Trial id="187839"/><TrialStartDate>FEBRUARY , 29, 2004</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4481">stavudine</Drug><EnrollmentCount>400</EnrollmentCount><Interventions>efavirenz; ethambutol; isoniazid; lamivudine; pyrazinamide; rifabutin; rifampicin; stavudine; zidovudine</Interventions><Patients>400</Patients><ProtocolAcronym/><ProtocolTitle>Acquired Immunodeficiency Syndrome (AIDS) and Tuberculosis (TB) Co-Infection Treatment Strategies Study of China</ProtocolTitle><Reference>2008ZX10001-008; NCT01344148</Reference><Sponsor>Shanghai Public Health Clinical Center</Sponsor><Trial id="76946"/><TrialStartDate>FEBRUARY , 28, 2009</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><EnrollmentCount>33</EnrollmentCount><Interventions>TMC-207; TMC-207; rifabutin; rifampin</Interventions><Patients>33</Patients><ProtocolAcronym/><ProtocolTitle>TMC-207 +/- Rifabutin/Rifampin</ProtocolTitle><Reference>10-0043; HHSN272201500007I; N01AI80026C; NCT01341184</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="76765"/><TrialStartDate>OCTOBER  , 21, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Blood platelets; Cytochrome P450 2B6</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>35</EnrollmentCount><Interventions>efavirenz; lamivudine+ zidovudine; rifampicin + isoniazid (Rifinah); tenofovir disoproxil fumarate + emtricitabine; tenofovir+ lamivudine</Interventions><Patients>26</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid</ProtocolTitle><Reference>2014-002608-26; NCT02832778; SSAT062</Reference><Sponsor>St Stephens Aids Trust</Sponsor><Trial id="265766"/><TrialStartDate>OCTOBER  , 21, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="31010">SQ-109</Drug><EnrollmentCount>10</EnrollmentCount><Interventions>SQ-109</Interventions><Patients>10</Patients><ProtocolAcronym/><ProtocolTitle>Phase Ic Study of Safety and PK of SQ-109 300 mg Daily</ProtocolTitle><Reference>09-0111; N01AI80024C; NCT01358162</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="77682"/><TrialStartDate>NOVEMBER , 30, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4728">emtricitabine</Drug><EnrollmentCount>200</EnrollmentCount><Interventions>efavirenz; emtricitabine; emtricitabine; lopinavir + ritonavir; rifabutin; rifampicin; tenofovir disoproxil fumarate; tenofovir disoproxil fumarate</Interventions><Patients>200</Patients><ProtocolAcronym>RIFART</ProtocolAcronym><ProtocolTitle>RIFART</ProtocolTitle><Reference>EudraCT 2007-007935-14; MI2-RIFART-2005; RIFART</Reference><Sponsor>Azienda Ospedaliera Spedali Civili di Brescia</Sponsor><Trial id="131240"/><TrialStartDate>MARCH    , 15, 2005</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>CD4 Positive T Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44363">trimethoprim + sulphamethoxazole</Drug><EnrollmentCount>642</EnrollmentCount><Interventions>didanosine; efavirenz; lamivudine; lamivudine + efavirenz + didanosine; trimethoprim + sulfamethoxazole</Interventions><Patients>642</Patients><ProtocolAcronym>SAPIT</ProtocolAcronym><ProtocolTitle>A Study to Compare Three Existing Starting Points of Antiretroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients</ProtocolTitle><Reference>CAPRISA 003; NCT00398996; SAPIT</Reference><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><Trial id="201474"/><TrialStartDate>JUNE     , 30, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Alanine transaminase; Aspartate aminotransferase; QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyraziminide; rifampicin</Controls><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="13323">pretomanid</Drug><EnrollmentCount>240</EnrollmentCount><Interventions>bedaquiline; moxifloxacin; pretomanid; pyraziminide</Interventions><Patients>240</Patients><ProtocolAcronym/><ProtocolTitle>A Phase II to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Reference>NC-005; NC-005-(J-M-PA-Z); NCT02193776</Reference><Sponsor>TB Alliance</Sponsor><Trial id="210646"/><TrialStartDate>OCTOBER  , 23, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>CD4; Cytotoxic T-Lymphocytes; HIV viral load; Human immunodeficiency virus RNA; T-Helper Lymphocytes; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Kaletra; ethambutol; isoniazid; pyrazinamide; pyridoxine; rifampin</Controls><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="4229">rifabutin</Drug><EnrollmentCount>71</EnrollmentCount><Interventions>Kaletra; ethambutol; isoniazid; pyrazinamide; pyridoxine; raltegravir; rifabutin</Interventions><Patients>71</Patients><ProtocolAcronym/><ProtocolTitle>Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV</ProtocolTitle><Reference>1U01AI068636; ACTG A5290; NCT01601626</Reference><Sponsor>AIDS Clinical Trials Group</Sponsor><Trial id="87585"/><TrialStartDate>JULY     , 13, 2013</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3411">itraconazole</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>itraconazole</Interventions><Patients>60</Patients><ProtocolAcronym/><ProtocolTitle>A Comparative Study of Itraconazole in Various Doses Schedule in the Treatment of Pulmonary Aspergilloma in Treated  with the Patients of Pulmonary Tuberculosis</ProtocolTitle><Reference>CTRI/2013/02/003374</Reference><Sponsor>Sawai ManSingh Medical College</Sponsor><Trial id="131456"/><TrialStartDate>JULY     , 31, 2012</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><EnrollmentCount>12</EnrollmentCount><Interventions>MVA85A</Interventions><Patients>12</Patients><ProtocolAcronym/><ProtocolTitle>A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Received BCG Immunisation 1 Month Previously</ProtocolTitle><Reference>NCT00427453; TB004</Reference><Sponsor>University of Oxford</Sponsor><Trial id="10873"/><TrialStartDate>JUNE     , 30, 2003</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><EnrollmentCount>16</EnrollmentCount><Interventions>MVA85A</Interventions><Patients>16</Patients><ProtocolAcronym/><ProtocolTitle>A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG</ProtocolTitle><Reference>NCT00427830; TB005</Reference><Sponsor>University of Oxford</Sponsor><Trial id="10874"/><TrialStartDate>MAY      , 31, 2003</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers>Alanine transaminase; Blood platelets; Body temperature; CD40 ligand; Creatinine; Cytotoxic T-Lymphocytes; Hemoglobin; Interferon gamma; Interleukin-2; Leukocyte count; T-Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Menjugate; Polio Sabin; Prevnar; Tritanrix HB</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12862">Tritanrix HB</Drug><EnrollmentCount>302</EnrollmentCount><Interventions>GSK-692342; GSK-692342a; Polio Sabin; Prevnar; Tritanrix HB</Interventions><Patients>302</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants</ProtocolTitle><Reference>112899; 2012-004380-44; NCT01098474; TUBERCULOSIS-013 PRI</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="65639"/><TrialStartDate>JULY     , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers>25(OH)D3; Calcium; LL-37; Macrophages; Total body mass; Weight; cough clearance</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12014">VP-101</Drug><EnrollmentCount>288</EnrollmentCount><Interventions>chemotherapy; cholecalciferol (Vigantol oil); cholecalciferol (Vigantol oil); sodium phenylbutyrate; sodium phenylbutyrate</Interventions><Patients>288</Patients><ProtocolAcronym/><ProtocolTitle>Clinical Trial of Phenylbutyrate and Vitamin D in Tuberculosis (TB)</ProtocolTitle><Reference>NCT01580007; PR-09068</Reference><Sponsor>International Centre For Diarrhoeal Disease Research, Bangladesh</Sponsor><Trial id="142323"/><TrialStartDate>DECEMBER , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers>Body Mass Index; Glucose</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; gatifloxacin</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7017">gatifloxacin</Drug><EnrollmentCount>2070</EnrollmentCount><Interventions>gatifloxacin; isoniazid; rifampin</Interventions><Patients>1836</Patients><ProtocolAcronym>OFLOTUB</ProtocolAcronym><ProtocolTitle>A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis</ProtocolTitle><Reference>ICA4-CT 2002-10057; NCT00216385; OFLOTUB</Reference><Sponsor>Institut de Recherche pour le Developpement (IRD)</Sponsor><Trial id="10855"/><TrialStartDate>JANUARY  , 31, 2005</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>CD4+ T-lymphocytes; CD8+ T-lymphocytes; CD8-Positive T-Lymphocytes; Interferon-gamma; Interleukin-17A; Interleukin-2; Interlukenin-2; T-Helper Lymphocytes; TNF-alpha</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>BCG</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="55569">VPM-1002</Drug><EnrollmentCount>48</EnrollmentCount><Interventions>VPM-1-002</Interventions><Patients>48</Patients><ProtocolAcronym/><ProtocolTitle>Study to Evaluate Safety and Immunogenicity of VPM-1-002 in Comparison With BCG in Newborn Infants in South Africa</ProtocolTitle><Reference>DOH-27-0911-3677; NCT01479972; VPM1002-ZA-2.12TB</Reference><Sponsor>Vakzine Projekt Management GmbH</Sponsor><Trial id="82764"/><TrialStartDate>NOVEMBER , 30, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>44</EnrollmentCount><Interventions>rifapentine</Interventions><Patients>44</Patients><ProtocolAcronym/><ProtocolTitle>Evaluating the Pharmacokinetics of High-Dose Rifapentine When Given as a Single-Dose or in Divided Doses to Healthy Adults</ProtocolTitle><Reference>11859; A5311; ACTG 5311; NCT01574638</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="86389"/><TrialStartDate>JUNE     , 30, 2012</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol hydrochloride; isoniazid; linezolid; pyrazinamide; rifampicin</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="76307">delpazolid</Drug><EnrollmentCount>64</EnrollmentCount><Interventions>LCB01-0371</Interventions><Patients>64</Patients><ProtocolAcronym/><ProtocolTitle>A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK</ProtocolTitle><Reference>2016-0642; KCT0003975; LCB01-0371-15-2-01; NCT02836483</Reference><Sponsor>LegoChem Bioscience Inc</Sponsor><Trial id="265899"/><TrialStartDate>DECEMBER , 10, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="53784">Ag85B-ESAT-6 vaccine (IC31 adjuvant, tuberculosis), SSI/ Valneva</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Interventions><Patients>20</Patients><ProtocolAcronym>THYB-02</ProtocolAcronym><ProtocolTitle>A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis (TB) Subunit Vaccine in Purified Protein Derivative (PPD) Positive Volunteers</ProtocolTitle><Reference>NCT00929396; THYB-02; THYB-02</Reference><Sponsor>Statens Serum Institut</Sponsor><Trial id="58503"/><TrialStartDate>SEPTEMBER, 30, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-2; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><EnrollmentCount>2797</EnrollmentCount><Interventions>MVA-85A</Interventions><Patients>2797</Patients><ProtocolAcronym/><ProtocolTitle>A Study of MVA-85A in Healthy Infants</ProtocolTitle><Reference>084785; C-020-485; ISRCTN39705371; NCT00953927; Oxford TB020</Reference><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><Trial id="59405"/><TrialStartDate>JULY     , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Rifafour</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>85</EnrollmentCount><Interventions>PA-824; Rifafour; TMC-207; moxifloxacin; pyrazinamide</Interventions><Patients>65</Patients><ProtocolAcronym/><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With</ProtocolTitle><Reference>NC-001; NC-001-(J-M-Pa-Z); NCT01215851</Reference><Sponsor>TB Alliance</Sponsor><Trial id="71107"/><TrialStartDate>OCTOBER  , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><EnrollmentCount>9</EnrollmentCount><Interventions>Kaletra; rifampin; ritonavir</Interventions><Patients>9</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin</ProtocolTitle><Reference>20100325; NCT01700790</Reference><Sponsor>University of Miami</Sponsor><Trial id="93494"/><TrialStartDate>FEBRUARY , 29, 2016</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Immunoglobulin G; T-Lymphocytes</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="68617">ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>ID-93; ID-93 + GLA-SE</Interventions><Patients>60</Patients><ProtocolAcronym/><ProtocolTitle>Phase I ID-93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers</ProtocolTitle><Reference>IDRI-TBVPX-113; NCT01599897</Reference><Sponsor>Infectious Disease Research Institute</Sponsor><Trial id="87507"/><TrialStartDate>AUGUST   , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><EnrollmentCount>429</EnrollmentCount><Interventions>ethambutol; isoniazid; linezolid; pyrazinamide; rifampicin</Interventions><Patients>428</Patients><ProtocolAcronym/><ProtocolTitle>Linezolid Instead of Ethambutol in Treatment of Drug-susceptible Tuberculosis</ProtocolTitle><Reference>J-1310-026-523; NCT01994460</Reference><Sponsor>Seoul National University Hospital</Sponsor><Trial id="161831"/><TrialStartDate>JANUARY  , 31, 2014</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>400</EnrollmentCount><Interventions>efavirenz; ethambutol; isoniazid; lamivudine; pyrazinamide; rifabutin; rifampicin; stavudine; zidovudine</Interventions><Patients>400</Patients><ProtocolAcronym/><ProtocolTitle>Acquired Immunodeficiency Syndrome (AIDS) and Tuberculosis (TB) Co-Infection Treatment Strategies Study of China</ProtocolTitle><Reference>2008ZX10001-008; NCT01344148</Reference><Sponsor>Shanghai Public Health Clinical Center</Sponsor><Trial id="76946"/><TrialStartDate>FEBRUARY , 28, 2009</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><EnrollmentCount>140</EnrollmentCount><Interventions>Aluvia; raltegravir; rifabutin</Interventions><Patients>140</Patients><ProtocolAcronym/><ProtocolTitle>EARNEST Rifabutin Pharmacokinetics (PK) Substudy</ProtocolTitle><Reference>ISRCTN13074752; NCT01663168</Reference><Sponsor>Joint Clinical Research Centre, Medical Research Council</Sponsor><Trial id="90175"/><TrialStartDate>MAY      , 03, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>350</EnrollmentCount><Interventions>ethambutol; isoniazid; moxifloxacin; pyrazinamide; rifampin</Interventions><Patients>350</Patients><ProtocolAcronym>TBTC-27</ProtocolAcronym><ProtocolTitle>TBTC Study 27: Moxifloxacin versus Ethambutol for TB Treatment</ProtocolTitle><Reference>CDC-NCHSTP-3716; NCT00140309; TBTC-27</Reference><Sponsor>Centers for Disease Control and Prevention</Sponsor><Trial id="10684"/><TrialStartDate>JULY     , 31, 2003</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>52</EnrollmentCount><Interventions>PA-824; efavirenz; lopinavir + ritonavir; rifampin</Interventions><Patients>52</Patients><ProtocolAcronym/><ProtocolTitle>Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir or Rifampin</ProtocolTitle><Reference>11829; A5306; ACTG5306; NCT01571414</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="86312"/><TrialStartDate>MAY      , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Human immunodeficiency virus RNA</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="54488">raltegravir</Drug><EnrollmentCount>108</EnrollmentCount><Interventions>raltegravir; rifampicin</Interventions><Patients>108</Patients><ProtocolAcronym/><ProtocolTitle>Evaluating the Safety, Tolerance, and Pharmacokinetics of a Raltegravir-containing Antiretroviral Therapy (ART) Regimen in Infants and Children Infected With HIV and TB</ProtocolTitle><Reference>11831; IMPAACT P1101; NCT01751568; P1101</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="102102"/><TrialStartDate>MAY      , 31, 2014</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>1931</EnrollmentCount><Interventions>ethambutol; isoniazid; moxifloxacin; pyrazinamide; rifampicin</Interventions><Patients>1931</Patients><ProtocolAcronym>REMoxTB</ProtocolAcronym><ProtocolTitle>Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis</ProtocolTitle><Reference>10.1186/ISRCTN85595810; CTR20140130; CTRI/2011/05/001745; ISRCTN85595810; NCT00864383; NMRR-09-963-4872; PACTR201110000124315; REMoxTB; REMoxTB</Reference><Sponsor>TB Alliance</Sponsor><Trial id="49258"/><TrialStartDate>JANUARY  , 01, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>33</EnrollmentCount><Interventions>TMC-207; TMC-207; rifabutin; rifampin</Interventions><Patients>33</Patients><ProtocolAcronym/><ProtocolTitle>TMC-207 +/- Rifabutin/Rifampin</ProtocolTitle><Reference>10-0043; HHSN272201500007I; N01AI80026C; NCT01341184</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="76765"/><TrialStartDate>OCTOBER  , 21, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>MVA-85A</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>Safety of Tuberculosis Vaccine, MVA-85A, Administered by the Aerosol Route and the Intradermal Route</ProtocolTitle><Reference>NCT01497769; TB026</Reference><Sponsor>University of Oxford</Sponsor><Trial id="83464"/><TrialStartDate>SEPTEMBER, 30, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>moxifloxacin</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>88</EnrollmentCount><Interventions>TMC-207</Interventions><Patients>88</Patients><ProtocolAcronym/><ProtocolTitle>TMC207TBC1003 - A Study in Healthy Volunteers Investigating the Effect of Single-Dose TMC-207 on the QT/QTc Interval Under Fed Conditions</ProtocolTitle><Reference>CR017167; NCT01291563; TMC-207-TBC1003</Reference><Sponsor>Janssen Diagnostics BVBA</Sponsor><Trial id="74529"/><TrialStartDate>FEBRUARY , 28, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Albumin</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount/><Interventions>bedaquiline</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Efficacy and Safety of TMC-207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis</ProtocolTitle><Reference>2011-000653-23; CR100807; NCT01600963; PHRR130402-000059; TMC207-TIDP13-C210; U1111-1135-7013</Reference><Sponsor>Janssen Research &amp; Development LLC</Sponsor><Trial id="87533"/><TrialStartDate>MARCH    , 31, 2014</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>9</EnrollmentCount><Interventions>moxifloxacin</Interventions><Patients>9</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics and Safety of Moxifloxacin</ProtocolTitle><Reference>2010-023491-25; MFX468; NCT01329250</Reference><Sponsor>University Medical Center Groningen</Sponsor><Trial id="76086"/><TrialStartDate>MAY      , 31, 2011</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>T-Lymphocytes</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="45998">interferon alfa-2b</Drug><EnrollmentCount>70</EnrollmentCount><Interventions>interferon alfa-2b</Interventions><Patients>70</Patients><ProtocolAcronym/><ProtocolTitle>Interferon Alpha-2b in the Complex Therapy of Patients With Pulmonary Tuberculosis Concurrent With Broncho-obstructive Syndrome</ProtocolTitle><Reference>PMID:20095375</Reference><Sponsor/><Trial id="149989"/><TrialStartDate>JANUARY  , 01, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><EnrollmentCount>44</EnrollmentCount><Interventions>lamivudine; nelfinavir mesylate; rifabutin; stavudine; zidovudine</Interventions><Patients>44</Patients><ProtocolAcronym/><ProtocolTitle>Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis</ProtocolTitle><Reference>AACTG A5062; ACTG A5062; NCT00004736</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="10646"/><TrialStartDate>FEBRUARY , 25, 2000</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>nelfinavir; rifabutin</Interventions><Patients>20</Patients><ProtocolAcronym>TBTC-23B</ProtocolAcronym><ProtocolTitle>Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB</ProtocolTitle><Reference>23B; CDC-NCHSTP-2587; NCT00023400; TBTC-23B</Reference><Sponsor>Centers for Disease Control and Prevention</Sponsor><Trial id="10656"/><TrialStartDate>FEBRUARY , 29, 2000</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><EnrollmentCount>36</EnrollmentCount><Interventions>linezolid</Interventions><Patients>36</Patients><ProtocolAcronym>LiMiT</ProtocolAcronym><ProtocolTitle>Pilot Study Examining the Safety and Tolerability of Low Dose Linezolid in the Treatment of Multi-Drug Resistant Tuberculosis</ProtocolTitle><Reference>CDC-NCHHSTP-5356; LiMiT; NCT00664313</Reference><Sponsor>Centers for Disease Control and Prevention, Pfizer Inc</Sponsor><Trial id="11219"/><TrialStartDate>APRIL    , 30, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="8255">nelfinavir</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>nelfinavir; rifabutin</Interventions><Patients>20</Patients><ProtocolAcronym>TBTC-23B</ProtocolAcronym><ProtocolTitle>Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB</ProtocolTitle><Reference>23B; CDC-NCHSTP-2587; NCT00023400; TBTC-23B</Reference><Sponsor>Centers for Disease Control and Prevention</Sponsor><Trial id="10656"/><TrialStartDate>FEBRUARY , 29, 2000</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>CYP 2B6 516GG; CYP 2B6 516TT; CYP2B6 516G&gt;T; CYP2B6 516GT; Cytochrome P450 2B6</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>312</EnrollmentCount><Interventions>efavirenz; ethambutol; isoniazide; pyrazinamide; rifampin; stavudine + lamivudine</Interventions><Patients>312</Patients><ProtocolAcronym>ANRS 12154 PECAN</ProtocolAcronym><ProtocolTitle>Pharmacokinetics of efavirenz in combination of rimfampin in HIV-infected adults</ProtocolTitle><Reference>ANRS 12154 PECAN</Reference><Sponsor>INSERM, Institut Pasteur Du Cambodge</Sponsor><Trial id="145595"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><EnrollmentCount>5</EnrollmentCount><Interventions>efavirenz; nevirapine</Interventions><Patients>5</Patients><ProtocolAcronym>OPTI-NNRTI</ProtocolAcronym><ProtocolTitle>A Study to Determine the Best Dose of Antivirals in Patients With Both TB and HIV</ProtocolTitle><Reference>NCT00523458; OPTI-NNRTI; Stanford Protocol ID: 95564</Reference><Sponsor>Stanford University</Sponsor><Trial id="11177"/><TrialStartDate>JULY     , 31, 2007</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>5</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid</Controls><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><EnrollmentCount>70</EnrollmentCount><Interventions>gatifloxacin; levofloxacin; linezolid; moxifloxacin</Interventions><Patients>70</Patients><ProtocolAcronym>TBRU 10</ProtocolAcronym><ProtocolTitle>Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis</ProtocolTitle><Reference>01-553; NCT00396084; TBRU 10; TBRU 10</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="10869"/><TrialStartDate>FEBRUARY , 29, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="28379">Glutoxim</Drug><EnrollmentCount>42</EnrollmentCount><Interventions>Glutoxim</Interventions><Patients>42</Patients><ProtocolAcronym/><ProtocolTitle>Glutoxim in the Complex Treatment of Tuberculosis</ProtocolTitle><Reference>PMID:12087719</Reference><Sponsor>IM Sechenov Moscow Medical Academy</Sponsor><Trial id="149460"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>36</EnrollmentCount><Interventions>bedaquiline</Interventions><Patients>36</Patients><ProtocolAcronym/><ProtocolTitle>An Open-Label Study to Evaluate the Effects on Mycobacterium Tuberculosis, Safety, Tolerability and Pharmacokinetics of Single Doses of R-207910, in Treatment Naive Patients With Mycobacterium Tuberculosis Infection</ProtocolTitle><Reference>BAC2001; EudraCT 2004-002202-30; R207910BAC2001</Reference><Sponsor>Janssen Diagnostics BVBA, Johnson &amp; Johnson</Sponsor><Trial id="129536"/><TrialStartDate>OCTOBER  , 18, 2004</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Albumin</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>36</EnrollmentCount><Interventions>isoniazid; rifapentine</Interventions><Patients>35</Patients><ProtocolAcronym>TBTC-25</ProtocolAcronym><ProtocolTitle>Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine</ProtocolTitle><Reference>CDC-NCHSTP-2558; NCT00023387; TBTC Study 25PK; TBTC-25</Reference><Sponsor>Centers for Disease Control and Prevention</Sponsor><Trial id="10655"/><TrialStartDate>MARCH    , 31, 2000</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="11036">linezolid</Drug><EnrollmentCount>59</EnrollmentCount><Interventions>PNU-100480</Interventions><Patients>59</Patients><ProtocolAcronym/><ProtocolTitle>Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers</ProtocolTitle><Reference>B1171002; NCT00990990</Reference><Sponsor>Sequella Inc</Sponsor><Trial id="60906"/><TrialStartDate>OCTOBER  , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Body height; QT interval; Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="16545">delamanid</Drug><EnrollmentCount>37</EnrollmentCount><Interventions>delamanid</Interventions><Patients>37</Patients><ProtocolAcronym/><ProtocolTitle>A 6-Month Safety, Efficacy and PK Trial of Delamanid in Pediatric Patients With Multidrug Resistant Tuberculosis</ProtocolTitle><Reference>2012-004620-38; 2012-CT0079; 242-12-233; NCT01859923; P/281/2014; PHRR160526-001029</Reference><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><Trial id="133567"/><TrialStartDate>JULY     , 20, 2013</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>CD107a; CD154; CD4+ T cells; Cytotoxic T-Lymphocytes; Interferon-gamma; Interleukin-17; Interleukin-2; Interleukin-22; T-Helper Lymphocytes; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Bacillus Calmette-Guerin vaccine</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="48499">H4:IC31</Drug><EnrollmentCount>990</EnrollmentCount><Interventions>H4+IC31</Interventions><Patients>990</Patients><ProtocolAcronym/><ProtocolTitle>A Randomized, Placebo-Controlled, Partially-Blinded, Phase II Study to Evaluate Safety, Immunogenicity, and Prevention of Infection With Mycobacterium Tuberculosis of AERAS-404 and BCG Revaccination in Healthy Adolescents</ProtocolTitle><Reference>C-040-404; NCT02075203</Reference><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><Trial id="176219"/><TrialStartDate>FEBRUARY , 28, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers>Alanine transaminase; Aspartate aminotransferase; Bilirubin; T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid; isoniazid; pyridoxine</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>3000</EnrollmentCount><Interventions>efavirenz; isoniazid; pyridoxine; rifapentine</Interventions><Patients>3000</Patients><ProtocolAcronym>BRIEF TB</ProtocolAcronym><ProtocolTitle>Brief Rifapentine-Isoniazid Evaluation for TB Prevention</ProtocolTitle><Reference>10848; A5279; ACTG A5279; BRIEF TB; BRIEF TB/A5279; NCT01404312</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="79741"/><TrialStartDate>MAY      , 23, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>CD4 Positive T Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>642</EnrollmentCount><Interventions>didanosine; efavirenz; lamivudine; lamivudine + efavirenz + didanosine; trimethoprim + sulfamethoxazole</Interventions><Patients>642</Patients><ProtocolAcronym>SAPIT</ProtocolAcronym><ProtocolTitle>A Study to Compare Three Existing Starting Points of Antiretroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients</ProtocolTitle><Reference>CAPRISA 003; NCT00398996; SAPIT</Reference><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><Trial id="201474"/><TrialStartDate>JUNE     , 30, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid + rifampicin + pyrazinamide + ethambutol</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="98013">isoniazid + rifampicin + pyrazinamide + ethambutol</Drug><EnrollmentCount>300</EnrollmentCount><Interventions>FLOW e-monitor box; isoniazid + rifampicin + pyrazinamide + ethambutol; smartphone app</Interventions><Patients>300</Patients><ProtocolAcronym/><ProtocolTitle>Using electronic monitors and a smartphone app to improve treatment adherence of new pulmonary tuberculosis patients in Tibet, China</ProtocolTitle><Reference>ISRCTN52132803; TB REACH, GRANT NUMBER: STBP/TBREACH/GSA/W6-5</Reference><Sponsor>The Chinese Centre for Disease Control and Prevention</Sponsor><Trial id="359917"/><TrialStartDate>SEPTEMBER, 01, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>50</EnrollmentCount><Interventions>isoniazid; pyridoxine; rifapentine</Interventions><Patients>50</Patients><ProtocolAcronym/><ProtocolTitle>Evaluating the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-Infected and HIV-1-Uninfected Pregnant and Postpartum Women With Latent Tuberculosis Infection</ProtocolTitle><Reference>12026; IMPAACT 2001; NCT02651259</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="250483"/><TrialStartDate>FEBRUARY , 15, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin; streptomycin</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>864</EnrollmentCount><Interventions>ethambutol; isoniazid aminosalicylate; moxifloxacin; pyrazinamide; rifabutin</Interventions><Patients>80</Patients><ProtocolAcronym/><ProtocolTitle>Research on New Regimens for Retreatment Pulmonary Tuberculosis</ProtocolTitle><Reference>2013ZX10003009; NCT02331823</Reference><Sponsor>Shanghai Pulmonary Hospital</Sponsor><Trial id="220243"/><TrialStartDate>JUNE     , 30, 2013</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>B-lymphocytes; Neutrophils; T-Lymphocytes</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>BCG vaccine</Controls><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><EnrollmentCount>72</EnrollmentCount><Interventions>ChAdOx1-85A; ChAdOx1-85A; MVA-85A</Interventions><Patients>72</Patients><ProtocolAcronym/><ProtocolTitle>EMaBS TB Vaccine Study</ProtocolTitle><Reference>NCT03681860; TB042</Reference><Sponsor>University of Oxford</Sponsor><Trial id="354327"/><TrialStartDate>DECEMBER , 01, 2018</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>5+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44284">amoxicillin + clavulanate potassium, GSK</Drug><EnrollmentCount>45</EnrollmentCount><Interventions>Augmentin; cefadroxil; cefadroxil; ethambutol; faropenem; faropenem; isoniazid; pyrazinamide; rifampicin</Interventions><Patients>45</Patients><ProtocolAcronym/><ProtocolTitle>Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers</ProtocolTitle><Reference>2015-CT0284; FAROPENEM_TB; NCT02381470; PHRR160323-001194</Reference><Sponsor>National University Hospital (Singapore) Pte Ltd, Syneos Health Inc</Sponsor><Trial id="224111"/><TrialStartDate>DECEMBER , 31, 2018</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="90085">macozinone</Drug><EnrollmentCount>35</EnrollmentCount><Interventions>PBTZ-169</Interventions><Patients>35</Patients><ProtocolAcronym/><ProtocolTitle>Phase I Study of PBTZ-169</ProtocolTitle><Reference>NCT03036163; PBTZ169-Z00-C01-1</Reference><Sponsor>Nearmedic Plus</Sponsor><Trial id="286724"/><TrialStartDate>JANUARY  , 31, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Solute carrier organic anion transporter family member 1B1</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4481">stavudine</Drug><EnrollmentCount>48</EnrollmentCount><Interventions>efavirenz; isoniazid; lamivudine; lopinavir + ritonavir; nevirapine; rifabutin; stavudine</Interventions><Patients>35</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa</ProtocolTitle><Reference>ANRS12150a; NCT00640887</Reference><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><Trial id="11187"/><TrialStartDate>FEBRUARY , 28, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid</Controls><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="90085">macozinone</Drug><EnrollmentCount>16</EnrollmentCount><Interventions>PBTZ-169</Interventions><Patients>16</Patients><ProtocolAcronym/><ProtocolTitle>Phase IIa Study of PBTZ-169</ProtocolTitle><Reference>NCT03334734; PBTZ169-A15-C2A-1</Reference><Sponsor>Nearmedic Plus</Sponsor><Trial id="318771"/><TrialStartDate>DECEMBER , 16, 2016</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>conventional TB treatment</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>131</EnrollmentCount><Interventions>conventional TB treatment; moxifloxacin</Interventions><Patients>131</Patients><ProtocolAcronym/><ProtocolTitle>A clinical trial to study the effects of moxifloxacin with regular anti-tuberculosis drugs in Tuberculosis patients</ProtocolTitle><Reference>CTRI/2016/03/006713</Reference><Sponsor>Vels University</Sponsor><Trial id="255644"/><TrialStartDate>SEPTEMBER, 09, 2015</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>T-Lymphocytes; T-cell surface glycoprotein CD4; Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><EnrollmentCount>40</EnrollmentCount><Interventions>Kaletra; rifabutin</Interventions><Patients>40</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics and Safety of Rifabutin 150 mg qd Versus Rifabutin 300 mg tiw</ProtocolTitle><Reference>HIV-NAT 116; NCT02415985</Reference><Sponsor>The HIV Netherlands Australia Thailand Research Collaboration</Sponsor><Trial id="226826"/><TrialStartDate>JUNE     , 30, 2015</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>448</EnrollmentCount><Interventions>amikacin; amoxicillin + clavulanate; azithromycin; bedaquiline; capreomycin; clarithromycin; clofazimine; cycloserine; delaminid; ethambutol; ethionamide; gatifloxacin; imipenem/cilastatin; isoniazid; kanamycin; levofloxacin; linezolid; meropenem; moxifloxacin; ofloxacin; para-aminosalicylic acid; pretomanid; prothionamide; pyrazinamide; rifabutin; rifampicin; streptomycin; sutezolid; terizidone; thioacetazone; whole genome sequencing</Interventions><Patients>448</Patients><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Reference>CAP 020; InDEX; NCT03237182</Reference><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><Trial id="307654"/><TrialStartDate>JUNE     , 14, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>592</EnrollmentCount><Interventions>didanosine; efavirenz; lamivudine; standard TB therapy</Interventions><Patients>592</Patients><ProtocolAcronym/><ProtocolTitle>Effectiveness of Directly Observed Therapy in Combined HIV and Tuberculosis Treatment in Resource-Limited Settings</ProtocolTitle><Reference>CAPRISA 001; CAPRISA START; CIPRA; NCT00091936; START</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="8820"/><TrialStartDate>AUGUST   , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="59062">dolutegravir</Drug><EnrollmentCount>120</EnrollmentCount><Interventions>dolutegravir; efavirenz; isoniazid + ethambutol + pyrazinamide; rifampin</Interventions><Patients>120</Patients><ProtocolAcronym>SAEFRIF</ProtocolAcronym><ProtocolTitle>Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy</ProtocolTitle><Reference>NCT03982277; SAEFRIF; ST/224/219</Reference><Sponsor>Makerere University</Sponsor><Trial id="384080"/><TrialStartDate>APRIL    , 30, 2019</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Interferon gamma; SL cytokine</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="53019">GX-70</Drug><EnrollmentCount/><Interventions>GX-70</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity Study of GX-70 in TB Patient</ProtocolTitle><Reference>4-2016-1144; NCT03159975</Reference><Sponsor>Yonsei University</Sponsor><Trial id="298965"/><TrialStartDate>MARCH    , 31, 2018</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="16545">delamanid</Drug><EnrollmentCount>84</EnrollmentCount><Interventions>bedaquiline; bedaquiline; delamanid; delamanid; dolutegravir</Interventions><Patients>84</Patients><ProtocolAcronym/><ProtocolTitle>Evaluating the Safety, Tolerability and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Reference>12005; A5343; NCT02583048</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="243619"/><TrialStartDate>AUGUST   , 31, 2016</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>6</ArmCount><Biomarkers>C-reactive protein; Forced expiratory volume; Neopterin; Programmed cell death protein 1; Standardized uptake value; T-Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>rifabutin-modified TB therapy</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="13340">everolimus</Drug><EnrollmentCount>200</EnrollmentCount><Interventions>CC-11050; auranofin; everolimus; rifabutin-modified TB therapy; vitamin D3</Interventions><Patients>200</Patients><ProtocolAcronym>TBHDT</ProtocolAcronym><ProtocolTitle>TB Host Directed Therapy</ProtocolTitle><Reference>NCT02968927; TBHDT; TBHDT-AUR1-8-178</Reference><Sponsor>Aurum Institute</Sponsor><Trial id="279898"/><TrialStartDate>NOVEMBER , 30, 2016</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>pryrazinamide</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="16545">delamanid</Drug><EnrollmentCount>750</EnrollmentCount><Interventions>Lamprene; bedaquiline; delamanid; levofloxacin; linezolid; moxifloxacin; pryrazinamide</Interventions><Patients>750</Patients><ProtocolAcronym>endTB</ProtocolAcronym><ProtocolTitle>Evaluating Newly Approved Drugs for Multidrug-resistant TB</ProtocolTitle><Reference>MSF ERB-1555; NCT02754765; endTB</Reference><Sponsor>Mdecins Sans Frontires France</Sponsor><Trial id="259506"/><TrialStartDate>DECEMBER , 31, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>230</EnrollmentCount><Interventions>Viread; efavirenz; ethambutol; isoniazid; lamivudine; pyrazinamide; rifabutin; zidovudine</Interventions><Patients>230</Patients><ProtocolAcronym>RRHT</ProtocolAcronym><ProtocolTitle>Rifampicin versus Rifabutin in HIV/AIDS Patients Combined With Tuberculosis</ProtocolTitle><Reference>2017ZX10202101-002; NCT03478033; RRHT</Reference><Sponsor>Shanghai Public Health Clinical Center</Sponsor><Trial id="334027"/><TrialStartDate>APRIL    , 15, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>pyrazinamide</Controls><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="16545">delamanid</Drug><EnrollmentCount>238</EnrollmentCount><Interventions>delamanid; levofloxacin; linezolid; pyrazinamide</Interventions><Patients>238</Patients><ProtocolAcronym>MDR-END</ProtocolAcronym><ProtocolTitle>Treatment Shortening of MDR-TB Using Existing and New Drugs</ProtocolTitle><Reference>MDR-END; NCT02619994</Reference><Sponsor>Seoul National University Hospital</Sponsor><Trial id="247456"/><TrialStartDate>JANUARY  , 31, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Human immunodeficiency virus RNA; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>efavirenz; lamivudine; tenofovir disoproxil fumarate</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="14493">tenofovir disoproxil fumarate</Drug><EnrollmentCount>460</EnrollmentCount><Interventions>lamivudine; raltegravir; rifampin; tenofovir disoproxil fumarate</Interventions><Patients>460</Patients><ProtocolAcronym>REFLATE TB2</ProtocolAcronym><ProtocolTitle>Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><Reference>ANRS 12300 REFLATE TB2; NCT02273765; REFLATE TB2</Reference><Sponsor>INSERM</Sponsor><Trial id="214156"/><TrialStartDate>SEPTEMBER, 30, 2015</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="3616">meropenem</Drug><EnrollmentCount>88</EnrollmentCount><Interventions>Augmentin; Merrem; rifampin</Interventions><Patients>88</Patients><ProtocolAcronym/><ProtocolTitle>Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB</ProtocolTitle><Reference>FD-R-05724; IRB00119017; NCT03174184</Reference><Sponsor>Johns Hopkins University</Sponsor><Trial id="300655"/><TrialStartDate>AUGUST   , 23, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount>100</EnrollmentCount><Interventions>levofloxacin</Interventions><Patients>100</Patients><ProtocolAcronym>LEVOF</ProtocolAcronym><ProtocolTitle>MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Reference>LEVOF; LEVOF_L_00972; NCT00495339</Reference><Sponsor>Sanofi SA</Sponsor><Trial id="8644"/><TrialStartDate>JUNE     , 30, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>120</EnrollmentCount><Interventions>dolutegravir; efavirenz; isoniazid + ethambutol + pyrazinamide; rifampin</Interventions><Patients>120</Patients><ProtocolAcronym>SAEFRIF</ProtocolAcronym><ProtocolTitle>Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy</ProtocolTitle><Reference>NCT03982277; SAEFRIF; ST/224/219</Reference><Sponsor>Makerere University</Sponsor><Trial id="384080"/><TrialStartDate>APRIL    , 30, 2019</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>T-Helper Lymphocytes; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount>400</EnrollmentCount><Interventions>aspirin; isoniazid; levofloxacin; pyrazinamide; ranitidine; rifampicin</Interventions><Patients>400</Patients><ProtocolAcronym>SURE</ProtocolAcronym><ProtocolTitle>Short Intensive Treatment For Children With Tuberculous Meningitis</ProtocolTitle><Reference>ISRCTN40829906; SURE; SURE</Reference><Sponsor>University College London</Sponsor><Trial id="360104"/><TrialStartDate>JANUARY  , 02, 2018</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>gatifloxacin; levofloxacin; moxifloxacin; p-aminosalycilic acid; prothionamide</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7017">gatifloxacin</Drug><EnrollmentCount>320</EnrollmentCount><Interventions>clofazimine; gatifloxacin; levofloxacin; moxifloxacin; p-aminosalycilic acid; prothionamide</Interventions><Patients>140</Patients><ProtocolAcronym/><ProtocolTitle>Multicenter, controlled clinical study of the safety, tolerability and efficacy of clofazimine in the treatment of drug-resistant tuberculosis</ProtocolTitle><Reference>ChiCTR1800014800</Reference><Sponsor>Beijing Chest Hospital</Sponsor><Trial id="328802"/><TrialStartDate>DECEMBER , 01, 2009</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>13</ArmCount><Biomarkers>CD4 cells</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount>525</EnrollmentCount><Interventions>amikacin sulfate; aminosalicylic acid; capreomycin sulfate; clofazimine; cycloserine; ethambutol hydrochloride; ethionamide; isoniazid; levofloxacin; pyrazinamide; pyridoxine hydrochloride; rifampin; streptomycin sulfate</Interventions><Patients>156</Patients><ProtocolAcronym/><ProtocolTitle>A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiological Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients</ProtocolTitle><Reference>11215; ACTG 238; CPCRA 026; NCT00000796</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="8776"/><TrialStartDate>OCTOBER  , 31, 1998</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>2500</EnrollmentCount><Interventions>moxifloxacin; rifapentine</Interventions><Patients>2500</Patients><ProtocolAcronym/><ProtocolTitle>Rifapentine-containing tuberculosis treatment shortening regimens (S31/A5349)</ProtocolTitle><Reference>CTRI/2018/07/014966</Reference><Sponsor>Centers for Disease Control and Prevention</Sponsor><Trial id="347338"/><TrialStartDate>JULY     , 20, 2018</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Glucose</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>amikacin; clofazimine; cycloserine; ethambutol; isoniazid; kanamycin; levofloxacin; prothionamide; pyrazinamide</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount>220</EnrollmentCount><Interventions>clofazimine; cycloserine; levofloxacin; linezolid; prothionamide; pyrazinamide</Interventions><Patients>220</Patients><ProtocolAcronym>TB-TRUST</ProtocolAcronym><ProtocolTitle>Refining MDR-TB Treatment Regimens for Ultra Short Therapy</ProtocolTitle><Reference>KY2018-331; NCT03867136; TB-TRUST</Reference><Sponsor>Huashan Hospital</Sponsor><Trial id="372676"/><TrialStartDate>MAY      , 01, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="14493">tenofovir disoproxil fumarate</Drug><EnrollmentCount>230</EnrollmentCount><Interventions>Viread; efavirenz; ethambutol; isoniazid; lamivudine; pyrazinamide; rifabutin; zidovudine</Interventions><Patients>230</Patients><ProtocolAcronym>RRHT</ProtocolAcronym><ProtocolTitle>Rifampicin versus Rifabutin in HIV/AIDS Patients Combined With Tuberculosis</ProtocolTitle><Reference>2017ZX10202101-002; NCT03478033; RRHT</Reference><Sponsor>Shanghai Public Health Clinical Center</Sponsor><Trial id="334027"/><TrialStartDate>APRIL    , 15, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>4+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>delamanid; ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="16545">delamanid</Drug><EnrollmentCount>125</EnrollmentCount><Interventions>OPC-167832; OPC-167832; delamanid</Interventions><Patients>125</Patients><ProtocolAcronym/><ProtocolTitle>A Phase I/II Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis</ProtocolTitle><Reference>323-201-00003; NCT03678688; OPP1178898</Reference><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><Trial id="353987"/><TrialStartDate>OCTOBER  , 25, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Creatine kinase; Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-2; Regulatory T-Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="53975">AERAS-402</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>AERAS-402</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate Safety and Immunogenicity of AERAS-402 Administered in HIV-negative, BCG-vaccinated, QFT (+) and (-) Adults Without Evidence of TB</ProtocolTitle><Reference>C-012-402; NCT02430506</Reference><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><Trial id="228651"/><TrialStartDate>SEPTEMBER, 30, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>448</EnrollmentCount><Interventions>amikacin; amoxicillin + clavulanate; azithromycin; bedaquiline; capreomycin; clarithromycin; clofazimine; cycloserine; delaminid; ethambutol; ethionamide; gatifloxacin; imipenem/cilastatin; isoniazid; kanamycin; levofloxacin; linezolid; meropenem; moxifloxacin; ofloxacin; para-aminosalicylic acid; pretomanid; prothionamide; pyrazinamide; rifabutin; rifampicin; streptomycin; sutezolid; terizidone; thioacetazone; whole genome sequencing</Interventions><Patients>448</Patients><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Reference>CAP 020; InDEX; NCT03237182</Reference><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><Trial id="307654"/><TrialStartDate>JUNE     , 14, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>WHO regimen therapy</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><EnrollmentCount/><Interventions>Deltyba; Lamprene; Levaquin; Sirturo; Zyvox</Interventions><Patients/><ProtocolAcronym>DRAMATIC</ProtocolAcronym><ProtocolTitle>Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB</ProtocolTitle><Reference>DRAMATIC; H38212; NCT03828201</Reference><Sponsor>Boston University</Sponsor><Trial id="368916"/><TrialStartDate>JANUARY  , 31, 2020</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Standard of care</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2587">azithromycin</Drug><EnrollmentCount>1875</EnrollmentCount><Interventions>amoxicillin; azithromycin</Interventions><Patients>1875</Patients><ProtocolAcronym>ACT-TB</ProtocolAcronym><ProtocolTitle>Accuracy and Consequences of Using Trial-of-antibiotics for TB Diagnosis</ProtocolTitle><Reference>15232; ACT-TB; NCT03545373</Reference><Sponsor>London School of Hygiene and Tropical Medicine</Sponsor><Trial id="341686"/><TrialStartDate>FEBRUARY , 25, 2019</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Cytotoxic T-Lymphocytes; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="74849">SSI H56-IC31</Drug><EnrollmentCount>84</EnrollmentCount><Interventions>BCG; H4 + IC31; SSI H56-IC31</Interventions><Patients>84</Patients><ProtocolAcronym>A-042</ProtocolAcronym><ProtocolTitle>Phase Ib, Safety and Immunogenicity Trial of BCG Revaccination, H4:IC31 and H56:IC31 in Healthy, HIV-1-Uninfected Adolescents</ProtocolTitle><Reference>A-042; HVTN 602 / AERAS A-042; NCT02378207</Reference><Sponsor>Aeras</Sponsor><Trial id="223463"/><TrialStartDate>MAY      , 31, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="16545">delamanid</Drug><EnrollmentCount>165</EnrollmentCount><Interventions>Zyvox; bedaquiline; clofazimine; delamanid</Interventions><Patients>165</Patients><ProtocolAcronym/><ProtocolTitle>Study on Tuberculosis Resistant to Treatment</ProtocolTitle><Reference>CTRI/2019/01/017310; Version Number: 3.1</Reference><Sponsor>Indian Council of Medical Research, Tuberculosis Research Centre</Sponsor><Trial id="369747"/><TrialStartDate>FEBRUARY , 01, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>8</ArmCount><Biomarkers>Body Mass Index; Body height; Interferon gamma; Regulatory T-Lymphocytes; Th1 cells; Th2 cells; Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>albendazole; ivermectin; metronidazole</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3412">ivermectin</Drug><EnrollmentCount>120</EnrollmentCount><Interventions>Nutritional Supplementation Meal; albendazole; ivermectin; metronidazole; multivitamin therapy</Interventions><Patients>120</Patients><ProtocolAcronym>TB-LION</ProtocolAcronym><ProtocolTitle>Tuberculosis - Learning the Impact of Nutrition</ProtocolTitle><Reference>6005415; CTRI/2019/05/018968; H-37473; NCT03598842; TB-LION</Reference><Sponsor>Boston Medical Center Corp</Sponsor><Trial id="347635"/><TrialStartDate>JUNE     , 30, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Alanine transaminase; Aspartate aminotransferase; Blood cells; C-reactive protein; Erythrocyte sedimentation rate; FEV / FVC ratio; QT interval; Six-minute walk distance</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><EnrollmentCount>102</EnrollmentCount><Interventions>Lamprene</Interventions><Patients>102</Patients><ProtocolAcronym/><ProtocolTitle>Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)</ProtocolTitle><Reference>FD-R-5401; NCT02968212</Reference><Sponsor>Oregon Health Sciences University</Sponsor><Trial id="279727"/><TrialStartDate>APRIL    , 11, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4492">faropenem</Drug><EnrollmentCount>45</EnrollmentCount><Interventions>amoxicillin; cefadroxil; clavulanic acid; ethambutol; faropenem; isoniazid; pyrazinamide; rifampicin</Interventions><Patients>45</Patients><ProtocolAcronym/><ProtocolTitle>Trial of faropenem and cefadroxil (in combination with amoxicillin/clavulanic acid and standard TB drugs) in patients with pulmonary tuberculosis: measurement of early bactericidal activity and effects on novel biomarkers</ProtocolTitle><Reference>2018-CT0454; 20180710115454; Faropenem_TB; PHRR181108-001980</Reference><Sponsor>National University Hospital (Singapore) Pte Ltd</Sponsor><Trial id="360329"/><TrialStartDate>NOVEMBER , 30, 2018</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Blood pressure; Interferon gamma</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="95442">ESAT-6CFP10</Drug><EnrollmentCount>1802</EnrollmentCount><Interventions>Bacillus Calmette-Guerin (BCG) vaccine; ESAT-6CFP10; Tuberculin purified protein derivative (TB-PPD)</Interventions><Patients>1802</Patients><ProtocolAcronym/><ProtocolTitle>Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18 to 65 years (III-healthy)</ProtocolTitle><Reference>EC-III-HEALTHY; NCT02795260</Reference><Sponsor>Anhui Zhifei Longcom Biopharmaceutical Co Ltd</Sponsor><Trial id="262931"/><TrialStartDate>MAY      , 31, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><EnrollmentCount>500</EnrollmentCount><Interventions>amikacin; bedaquiline; clarithromycin; clofazimine; cycloserine; ethambutol; linezolid; moxifloxacin; prothionamide; pyrazinamide; sodium para-aminosalicylate</Interventions><Patients>500</Patients><ProtocolAcronym/><ProtocolTitle>The Effect of 18-month Regimen Containing Six Anti-tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><Reference>2018ZX10722301-001; NCT03830671</Reference><Sponsor>Beijing Chest Hospital</Sponsor><Trial id="369109"/><TrialStartDate>MARCH    , 08, 2019</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Creatinine; Human immunodeficiency virus RNA; T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C0">Phase 0 Clinical</DevStatus><Drug id="4728">emtricitabine</Drug><EnrollmentCount>419</EnrollmentCount><Interventions>efavirenz; emtricitabine; lamivudine; tenofovir</Interventions><Patients>419</Patients><ProtocolAcronym/><ProtocolTitle>TasP in Correctional Facilities</ProtocolTitle><Reference>15-1473; NCT02946762; Z 31501</Reference><Sponsor>University of North Carolina</Sponsor><Trial id="280225"/><TrialStartDate>FEBRUARY , 01, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Glucose</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2829">clarithromycin</Drug><EnrollmentCount>100</EnrollmentCount><Interventions>amikacin; clarithromycin; isoniazid; levofloxacin; prothionamide; pyrazinamide</Interventions><Patients>152</Patients><ProtocolAcronym/><ProtocolTitle>Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide</ProtocolTitle><Reference>2013ZX10003008-003; KY2013-260; NCT02120638</Reference><Sponsor>Huashan Hospital</Sponsor><Trial id="183613"/><TrialStartDate>APRIL    , 30, 2014</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount>160</EnrollmentCount><Interventions>levofloxacin; rifampicin</Interventions><Patients>160</Patients><ProtocolAcronym/><ProtocolTitle>Is Levofloxacin Better Than Rifampicin in the Treatment of Tuberculous Meningitis- a Randomized, Control Study</ProtocolTitle><Reference>CTRI/2012/11/003155</Reference><Sponsor>Sanjay Gandhi Postgraduate Institute of Medical Sciences</Sponsor><Trial id="129005"/><TrialStartDate>OCTOBER  , 01, 2009</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>6</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><EnrollmentCount>200</EnrollmentCount><Interventions>ethambutol; isoniazid; lopinavir + ritonavir; nevirapine; pyrazinamide; rifampicin</Interventions><Patients>39</Patients><ProtocolAcronym>DATiC</ProtocolAcronym><ProtocolTitle>Optimal Dosing of First-Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)</ProtocolTitle><Reference>DATiC; DATiC; NCT01637558</Reference><Sponsor>University of Cape Town</Sponsor><Trial id="89135"/><TrialStartDate>NOVEMBER , 30, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>MVA85A</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>A Study of two Doses of a New TB Vaccine, MVA85A, in Healthy Volunteers Previously Vaccinated With BCG</ProtocolTitle><Reference>NCT00465465; TB009</Reference><Sponsor>University of Oxford</Sponsor><Trial id="10944"/><TrialStartDate>OCTOBER  , 31, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>CD4/CD8 ratio; CD40; CD40 ligand; IL-2; Interferon gamma; M72-specific CD4+ cells; M72-specific CD8+ cells; TNF-alpha</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><EnrollmentCount>3595</EnrollmentCount><Interventions>GSK-692342</Interventions><Patients>3573</Patients><ProtocolAcronym/><ProtocolTitle>Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Healthy Adults</ProtocolTitle><Reference>115616; NCT01755598; PACTR201311000639144</Reference><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><Trial id="102580"/><TrialStartDate>AUGUST   , 19, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>CD4+ T-cell; Cytotoxic T-Lymphocytes; T-Helper Lymphocytes; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="71323">Ad5Ag85A</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>Ad5Ag85A</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>Study of the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine</ProtocolTitle><Reference>NCT00800670; REB 09-001</Reference><Sponsor>McMaster University</Sponsor><Trial id="77668"/><TrialStartDate>JUNE     , 30, 2009</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>CD4; Cytotoxic T-Lymphocytes; HIV viral load; Human immunodeficiency virus RNA; T-Helper Lymphocytes; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Kaletra; ethambutol; isoniazid; pyrazinamide; pyridoxine; rifampin</Controls><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="54488">raltegravir</Drug><EnrollmentCount>71</EnrollmentCount><Interventions>Kaletra; ethambutol; isoniazid; pyrazinamide; pyridoxine; raltegravir; rifabutin</Interventions><Patients>71</Patients><ProtocolAcronym/><ProtocolTitle>Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV</ProtocolTitle><Reference>1U01AI068636; ACTG A5290; NCT01601626</Reference><Sponsor>AIDS Clinical Trials Group</Sponsor><Trial id="87585"/><TrialStartDate>JULY     , 13, 2013</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>23</EnrollmentCount><Interventions>isoniazid; moxifloxacin; rifampicin</Interventions><Patients>23</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic Interaction Study in Indonesian Tuberculosis Patients Indonesia</ProtocolTitle><Reference>NCT00306319; Primo study; UMCN-AKF 05.02</Reference><Sponsor>Radboud University</Sponsor><Trial id="10860"/><TrialStartDate>JANUARY  , 31, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>5</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid</Controls><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>70</EnrollmentCount><Interventions>gatifloxacin; levofloxacin; linezolid; moxifloxacin</Interventions><Patients>70</Patients><ProtocolAcronym>TBRU 10</ProtocolAcronym><ProtocolTitle>Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis</ProtocolTitle><Reference>01-553; NCT00396084; TBRU 10; TBRU 10</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="10869"/><TrialStartDate>FEBRUARY , 29, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><EnrollmentCount>200</EnrollmentCount><Interventions>efavirenz; emtricitabine; emtricitabine; lopinavir + ritonavir; rifabutin; rifampicin; tenofovir disoproxil fumarate; tenofovir disoproxil fumarate</Interventions><Patients>200</Patients><ProtocolAcronym>RIFART</ProtocolAcronym><ProtocolTitle>RIFART</ProtocolTitle><Reference>EudraCT 2007-007935-14; MI2-RIFART-2005; RIFART</Reference><Sponsor>Azienda Ospedaliera Spedali Civili di Brescia</Sponsor><Trial id="131240"/><TrialStartDate>MARCH    , 15, 2005</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>moxifloxacin; rifampicin</Interventions><Patients>60</Patients><ProtocolAcronym/><ProtocolTitle>Intensified Treatment Regimens for TB Meningitis: PK, PD and Tolerability Study</ProtocolTitle><Reference>NCT01158755; TB-201006.01</Reference><Sponsor>Universitas Padjadjaran</Sponsor><Trial id="67996"/><TrialStartDate>OCTOBER  , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Alanine aminotransferase (ALAT); Aspartate aminotransferase (ASAT); Estimated glomerular filtration rate</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12543">ertapenem</Drug><EnrollmentCount>12</EnrollmentCount><Interventions>ertapenem</Interventions><Patients>12</Patients><ProtocolAcronym/><ProtocolTitle>PK/PD of Ertapenem in Patients with TB</ProtocolTitle><Reference>ETB/V0.2; NCT01730664</Reference><Sponsor>University Medical Center Groningen</Sponsor><Trial id="98848"/><TrialStartDate>JANUARY  , 26, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Alanine aminotransferase; CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>efavirenz; lamivudine; stavudine</Controls><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><EnrollmentCount>570</EnrollmentCount><Interventions>Arm A; Arm B; Triomune; ethambutol; ethambutol; isoniazid; isoniazid; lamivudine; nevirapine; pyrazinamide; pyrazinamide; rifampicin; rifampicin; stavudine</Interventions><Patients>570</Patients><ProtocolAcronym>CARINEMO</ProtocolAcronym><ProtocolTitle>Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients</ProtocolTitle><Reference>ANRS 12146 CARINEMO; ANRS 12146/12214; ANRS 12214; CARINEMO; NCT00495326</Reference><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><Trial id="10948"/><TrialStartDate>DECEMBER , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>BCG</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="55569">VPM-1002</Drug><EnrollmentCount>416</EnrollmentCount><Interventions>VPM-1002</Interventions><Patients>416</Patients><ProtocolAcronym/><ProtocolTitle>Study to Evaluate the Safety and Immunogenicity of VPM-1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South Africa</ProtocolTitle><Reference>DOH-27-1114-4798; NCT02391415; VPM1002-ZA-2.13TB</Reference><Sponsor>Serum Institute of India Ltd</Sponsor><Trial id="224781"/><TrialStartDate>JUNE     , 30, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="14493">tenofovir disoproxil fumarate</Drug><EnrollmentCount>200</EnrollmentCount><Interventions>efavirenz; emtricitabine; emtricitabine; lopinavir + ritonavir; rifabutin; rifampicin; tenofovir disoproxil fumarate; tenofovir disoproxil fumarate</Interventions><Patients>200</Patients><ProtocolAcronym>RIFART</ProtocolAcronym><ProtocolTitle>RIFART</ProtocolTitle><Reference>EudraCT 2007-007935-14; MI2-RIFART-2005; RIFART</Reference><Sponsor>Azienda Ospedaliera Spedali Civili di Brescia</Sponsor><Trial id="131240"/><TrialStartDate>MARCH    , 15, 2005</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>isoniazide; lopinavir + ritonavir; pirazinamide; rifampin</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>An Evaluation of the Pharmacological Interaction of Lopinavir/ritonavir and Rifampin</ProtocolTitle><Reference>A06-295; NCT00771498</Reference><Sponsor>Fundacao Oswaldo Cruz (Fiocruz)</Sponsor><Trial id="171009"/><TrialStartDate>NOVEMBER , 30, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="13624">BCG vaccine, Organon</Drug><EnrollmentCount>52</EnrollmentCount><Interventions>BCG SSI; TiceBCG</Interventions><Patients>52</Patients><ProtocolAcronym/><ProtocolTitle>A Clinical Challenge Study of BCG in Healthy Volunteers</ProtocolTitle><Reference>IRAS ID 146214; NCT02088892; TB031</Reference><Sponsor>University of Oxford</Sponsor><Trial id="177982"/><TrialStartDate>MARCH    , 31, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>IL-4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="17132">pascolizumab</Drug><EnrollmentCount>32</EnrollmentCount><Interventions>pascolizumab</Interventions><Patients>32</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Therapy for Pulmonary Tuberculosis</ProtocolTitle><Reference>2015-CT0301; DSRB 2012/02212; NCT01638520; PHRR160722-001308</Reference><Sponsor>National University Hospital (Singapore) Pte Ltd, Syneos Health Inc</Sponsor><Trial id="89066"/><TrialStartDate>JUNE     , 30, 2012</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>207</EnrollmentCount><Interventions>DRMPa200Z regimen; HRZE regimen; MPa100Z regimen; MPa200Z regimen; PA-824; Rifafour; ethambutol; isoniazid; moxifloxacin; pyrazinamide; pyrazinamide; rifampicin</Interventions><Patients>207</Patients><ProtocolAcronym/><ProtocolTitle>Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB)</ProtocolTitle><Reference>NC-002-(M-Pa-Z); NCT01498419</Reference><Sponsor>TB Alliance</Sponsor><Trial id="83489"/><TrialStartDate>MARCH    , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Anti-Meningitis C antibodies; C-C motif chemokine 2; C-C motif chemokine 3; C-C motif chemokine 4; Cytokines; IgG; Interferon gamma; Interferon-alpha; Interleukin-1 alpha; Interleukin-1 beta; Interleukin-10; Interleukin-12; Interleukin-13; Interleukin-2; Interleukin-6</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="11458">Menitorix</Drug><EnrollmentCount>28</EnrollmentCount><Interventions>BCG; Infanrix; Menitorix; NeisVac-C; Pentacel; Prevnar 13; Priorix; Rotarix</Interventions><Patients>28</Patients><ProtocolAcronym>BAM</ProtocolAcronym><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><Reference>2013-003488-71; BAM; NCT02002156; OVG-2013/04; UKCRN 15722</Reference><Sponsor>University of Oxford</Sponsor><Trial id="162886"/><TrialStartDate>JUNE     , 20, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="NS">Phase not specified</DevStatus><Drug id="88505">ethambutol hydrochloride (150 mg) + pyrazinamide (300 mg) + rifampicin (90 mg) + isoniazid (60 mg) (oral tablet, tuberculosis), Shenyang Hongqi Pharmaceutical/Liaoning Hongwuxing Pharmaceutical</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>ethambutol hydrochloride + pyrazinamide + rifampicin + isoniazid</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>Ethylamine pyrazine Lifestyle Isonicotinic piece IV bioequivalence trials</ProtocolTitle><Reference>CTR20131379; SYY-YQ-2013-0405</Reference><Sponsor>Shenyang Hongqi Pharmaceutical Co Ltd</Sponsor><Trial id="177165"/><TrialStartDate>NOVEMBER , 30, 2013</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Blood cells; HIV-1 RNA; Human immunodeficiency virus RNA; T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>105</EnrollmentCount><Interventions>efavirenz; ethambutol; isoniazid; pyrazinamide; rifampicin; tenofovir+lamivudine</Interventions><Patients>105</Patients><ProtocolAcronym>RIFAVIRENZ</ProtocolAcronym><ProtocolTitle>Interaction Between High-Dose Rifampicine and Efavirenz in Pulmonary Tuberculosis and HIV Co-infection</ProtocolTitle><Reference>ANRS 12292 RIFAVIRENZ; NCT01986543; RIFAVIRENZ</Reference><Sponsor>INSERM</Sponsor><Trial id="161096"/><TrialStartDate>DECEMBER , 31, 2013</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><EnrollmentCount>150</EnrollmentCount><Interventions>efavirenz; ethambutol; isoniazid; lamivudine; nevirapine; pyrazinamide; rifampicin; zidovudine</Interventions><Patients>355</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis</ProtocolTitle><Reference>NCT00698334; SKS/NACO/2006</Reference><Sponsor>All India Institute of Medical Sciences</Sponsor><Trial id="161275"/><TrialStartDate>APRIL    , 30, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>T-Lymphocytes; T-cell surface glycoprotein CD4; Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><EnrollmentCount>40</EnrollmentCount><Interventions>Kaletra; rifabutin</Interventions><Patients>40</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics and Safety of Rifabutin 150 mg qd Versus Rifabutin 300 mg tiw</ProtocolTitle><Reference>HIV-NAT 116; NCT02415985</Reference><Sponsor>The HIV Netherlands Australia Thailand Research Collaboration</Sponsor><Trial id="226826"/><TrialStartDate>JUNE     , 30, 2015</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Visual acuity</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>365</EnrollmentCount><Interventions>SQ-109; ethambutol; isoniazid; moxifloxacin; pyrazinamide; pyridoxine; rifampicin</Interventions><Patients>365</Patients><ProtocolAcronym/><ProtocolTitle>Evaluation of SQ-109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design</ProtocolTitle><Reference>NCT01785186; PACTR201205000383208; PanACEA-MAMS-TB-01</Reference><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><Trial id="109063"/><TrialStartDate>APRIL    , 30, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Cytokines; Interferon gamma; Interleukin-2; T helper 17 cells; T-Helper 22 cells; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="90231">DAR-901</Drug><EnrollmentCount>59</EnrollmentCount><Interventions>BCG; DAR-901</Interventions><Patients>59</Patients><ProtocolAcronym/><ProtocolTitle>Phase I Trial of DAR-901</ProtocolTitle><Reference>DAR-901-MDES; NCT02063555</Reference><Sponsor>Dartmouth-Hitchcock Medical Center</Sponsor><Trial id="173446"/><TrialStartDate>FEBRUARY , 28, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-17A; T-Helper Lymphocytes; T-Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Th1 cytokines</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>GSK-692342</Interventions><Patients>60</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity of a Candidate Tuberculosis Vaccine in Healthy HIV Negative Adolescents</ProtocolTitle><Reference>112898; NCT00950612</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="59304"/><TrialStartDate>DECEMBER , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>37</EnrollmentCount><Interventions>midazolam; rifapentine</Interventions><Patients>37</Patients><ProtocolAcronym>TBTC S29B</ProtocolAcronym><ProtocolTitle>Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers</ProtocolTitle><Reference>CDC-NCHHSTP-5779; NCT01162486; TBTC S29B; TBTC S29B</Reference><Sponsor>Johns Hopkins University</Sponsor><Trial id="68204"/><TrialStartDate>APRIL    , 30, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Arylacetamide deacetylase; Nuclear receptor subfamily 1 group I member 2; Nuclear receptor subfamily 1 group I member 3; Solute carrier organic anion transporter family member 1B1</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>1250</EnrollmentCount><Interventions>ethambutol; isoniazid; moxifloxacin; pyrazinamide; rifampicin; rifapentine</Interventions><Patients>827</Patients><ProtocolAcronym>RIFAQUIN</ProtocolAcronym><ProtocolTitle>An International, Multicenter, Controlled Clinical Trial to Evaluate High-Dose Rifapentine and a Quinolone in the Treatment of Pulmonary Tuberculosis</ProtocolTitle><Reference>10.1186/ISRCTN44153044; ISRCTN44153044; RIFAQUIN</Reference><Sponsor>St Georges University of London</Sponsor><Trial id="153990"/><TrialStartDate>AUGUST   , 15, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="11088">sutezolid</Drug><EnrollmentCount>448</EnrollmentCount><Interventions>amikacin; amoxicillin + clavulanate; azithromycin; bedaquiline; capreomycin; clarithromycin; clofazimine; cycloserine; delaminid; ethambutol; ethionamide; gatifloxacin; imipenem/cilastatin; isoniazid; kanamycin; levofloxacin; linezolid; meropenem; moxifloxacin; ofloxacin; para-aminosalicylic acid; pretomanid; prothionamide; pyrazinamide; rifabutin; rifampicin; streptomycin; sutezolid; terizidone; thioacetazone; whole genome sequencing</Interventions><Patients>448</Patients><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Reference>CAP 020; InDEX; NCT03237182</Reference><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><Trial id="307654"/><TrialStartDate>JUNE     , 14, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>450</EnrollmentCount><Interventions>isoniazid; rifapentine</Interventions><Patients>450</Patients><ProtocolAcronym/><ProtocolTitle>Taima TB: 3-HP Study</ProtocolTitle><Reference>20160044-01H; NCT02689089</Reference><Sponsor>Ottawa Hospital Research Institute</Sponsor><Trial id="254050"/><TrialStartDate>APRIL    , 30, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Rimactane (rifampicin 300 mg, Novartis Sandoz)</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="89460">rifampicin + isoniazid (fixed dose combination, tuberculosis), Pfizer</Drug><EnrollmentCount>21</EnrollmentCount><Interventions>rifampicin + isoniazid (fixed dose combination, tuberculosis), Pfizer</Interventions><Patients>21</Patients><ProtocolAcronym/><ProtocolTitle>Bioequivalence Study Comparing Rifampicin In A Fixed-dose Combination (Rifampicin + Isoniazid, Myrin 2) And The Reference Drug (Rifampicin, Rimactane)</ProtocolTitle><Reference>B3801001; NCT01311505</Reference><Sponsor>Pfizer Inc</Sponsor><Trial id="164313"/><TrialStartDate>APRIL    , 30, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Human immunodeficiency virus RNA</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>dolutegravir; emtricitabine; isoniazid; rifapentine; tenofovir disoproxil fumarate</Interventions><Patients>60</Patients><ProtocolAcronym>IMPAACT4TB</ProtocolAcronym><ProtocolTitle>Safety, Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine Isoniazid in HIV+ Patients</ProtocolTitle><Reference>3HP DTG AUR1-6-212 IMPAACT4TB; IMPAACT4TB; NCT03435146</Reference><Sponsor>Aurum Institute</Sponsor><Trial id="329251"/><TrialStartDate>JANUARY  , 18, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="71742">TBA-354</Drug><EnrollmentCount>18</EnrollmentCount><Interventions>TBA-354</Interventions><Patients>18</Patients><ProtocolAcronym/><ProtocolTitle>A Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects</ProtocolTitle><Reference>NCT02606214; TBA-354-CL-002</Reference><Sponsor>TB Alliance</Sponsor><Trial id="246089"/><TrialStartDate>NOVEMBER , 30, 2015</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="46931">cefadroxil</Drug><EnrollmentCount>45</EnrollmentCount><Interventions>amoxicillin; cefadroxil; clavulanic acid; ethambutol; faropenem; isoniazid; pyrazinamide; rifampicin</Interventions><Patients>45</Patients><ProtocolAcronym/><ProtocolTitle>Trial of faropenem and cefadroxil (in combination with amoxicillin/clavulanic acid and standard TB drugs) in patients with pulmonary tuberculosis: measurement of early bactericidal activity and effects on novel biomarkers</ProtocolTitle><Reference>2018-CT0454; 20180710115454; Faropenem_TB; PHRR181108-001980</Reference><Sponsor>National University Hospital (Singapore) Pte Ltd</Sponsor><Trial id="360329"/><TrialStartDate>NOVEMBER , 30, 2018</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Rifafour e275; ethambutol; isoniazid; pyrazinamide; rifampin</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44284">amoxicillin + clavulanate potassium, GSK</Drug><EnrollmentCount>46</EnrollmentCount><Interventions>amoxicillin + clavulanate potassium, GSK; faropenem; meropenem</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>Phase II Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis</ProtocolTitle><Reference>NCT02349841; TASK-001</Reference><Sponsor>Task Foundation NPC</Sponsor><Trial id="220739"/><TrialStartDate>SEPTEMBER, 30, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>kanamycin; moxifloxacin</Controls><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>300</EnrollmentCount><Interventions>bedaqualine; ethionamide; isoniazid; levofloxacin; linezolid; pyrazinamide; terizidone</Interventions><Patients>300</Patients><ProtocolAcronym>NEXT</ProtocolAcronym><ProtocolTitle>An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multidrug-resistant Tuberculosis</ProtocolTitle><Reference>NCT02454205; NEXT; NEXT-5001</Reference><Sponsor>University of Cape Town</Sponsor><Trial id="230529"/><TrialStartDate>OCTOBER  , 31, 2015</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Avelox</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>26</EnrollmentCount><Interventions>moxifloxacin (Dr Reddy's Laboratories Limited)</Interventions><Patients>26</Patients><ProtocolAcronym/><ProtocolTitle>Bioequivalency Study of Moxifloxacin Tablets, 400 mg Under Fasting Conditions</ProtocolTitle><Reference>054-12; NCT02322619</Reference><Sponsor>Dr Reddy's Laboratories Ltd</Sponsor><Trial id="218651"/><TrialStartDate>NOVEMBER , 30, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1A">Phase 1a Clinical</DevStatus><Drug id="90085">macozinone</Drug><EnrollmentCount>32</EnrollmentCount><Interventions>macozinone</Interventions><Patients>32</Patients><ProtocolAcronym/><ProtocolTitle>Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Ex-vivo Antitubercular Activity of PBTZ-169 Formulation</ProtocolTitle><Reference>IM-006-11; NCT03423030</Reference><Sponsor>Innovative Medicines for Tuberculosis</Sponsor><Trial id="328144"/><TrialStartDate>DECEMBER , 05, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>pryrazinamide</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>750</EnrollmentCount><Interventions>Lamprene; bedaquiline; delamanid; levofloxacin; linezolid; moxifloxacin; pryrazinamide</Interventions><Patients>750</Patients><ProtocolAcronym>endTB</ProtocolAcronym><ProtocolTitle>Evaluating Newly Approved Drugs for Multidrug-resistant TB</ProtocolTitle><Reference>MSF ERB-1555; NCT02754765; endTB</Reference><Sponsor>Mdecins Sans Frontires France</Sponsor><Trial id="259506"/><TrialStartDate>DECEMBER , 31, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="68617">ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis</Drug><EnrollmentCount>36</EnrollmentCount><Interventions>ID-93</Interventions><Patients>36</Patients><ProtocolAcronym/><ProtocolTitle>Phase I Clinical Trial of ID93 + GLA-SE Vaccine in BCG-vaccinated Healthy Adolescent</ProtocolTitle><Reference>CT-QTP101-002; NCT03806699</Reference><Sponsor>Quratis Co Ltd</Sponsor><Trial id="366672"/><TrialStartDate>APRIL    , 02, 2019</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="108779">GC-3107</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>GC-3107</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>Study to Investigate the Safety and Efficacy of GC-3107 (BCG Vaccine) in Healthy Adults</ProtocolTitle><Reference>GC3107_P1; NCT03363178</Reference><Sponsor>GC Pharma</Sponsor><Trial id="321760"/><TrialStartDate>DECEMBER , 14, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampin</Controls><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="4229">rifabutin</Drug><EnrollmentCount>183</EnrollmentCount><Interventions>isoniazid; pretomanid; pyrazinamide; rifabutin; rifampin</Interventions><Patients>183</Patients><ProtocolAcronym>APT</ProtocolAcronym><ProtocolTitle>Assessing PA-824 for Tuberculosis</ProtocolTitle><Reference>#FD-R-004794-01; APT; NA_00093014; NCT02256696</Reference><Sponsor>Johns Hopkins Hospital</Sponsor><Trial id="213394"/><TrialStartDate>APRIL    , 29, 2015</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Cytokines; Cytotoxic T-Lymphocytes; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>BCG vaccine SSI</Controls><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="89744">MTBVAC</Drug><EnrollmentCount>54</EnrollmentCount><Interventions>MTBVAC</Interventions><Patients>54</Patients><ProtocolAcronym>MTBVAC-Ph1b</ProtocolAcronym><ProtocolTitle>Dose-escalation, Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults</ProtocolTitle><Reference>MTBVAC-02; MTBVAC-Ph1b; NCT02729571</Reference><Sponsor>Biofabri SL</Sponsor><Trial id="257534"/><TrialStartDate>SEPTEMBER, 30, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Alanine transaminase; Blood urea nitrogen to creatinine ratio; Calcium; Magnesium; Potassium; Thyroid-stimulating hormone</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>amikacin; capreomycin; kanamycin; levofloxacin; para-aminosalicylic acid; pasiniazid; prothionamide; pyrazinamide</Controls><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount>500</EnrollmentCount><Interventions>RhIL-2; amikacin; capreomycin; kanamycin; levofloxacin; para-aminosalicylic acid; pasiniazid; prothionamide; pyrazinamide</Interventions><Patients>500</Patients><ProtocolAcronym/><ProtocolTitle>Study of Adjunctive Recombinant Human Interleukin-2 Therapy in Patients With MDR-TB (rhIL-2)</ProtocolTitle><Reference>NCT03069534; RHIL-2 THERAPY ON MDR-TB</Reference><Sponsor>Jiangsu Provincial Peoples Hospital</Sponsor><Trial id="289837"/><TrialStartDate>JUNE     , 01, 2009</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>pryrazinamide</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>750</EnrollmentCount><Interventions>Lamprene; bedaquiline; delamanid; levofloxacin; linezolid; moxifloxacin; pryrazinamide</Interventions><Patients>750</Patients><ProtocolAcronym>endTB</ProtocolAcronym><ProtocolTitle>Evaluating Newly Approved Drugs for Multidrug-resistant TB</ProtocolTitle><Reference>MSF ERB-1555; NCT02754765; endTB</Reference><Sponsor>Mdecins Sans Frontires France</Sponsor><Trial id="259506"/><TrialStartDate>DECEMBER , 31, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampin</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><EnrollmentCount>3900</EnrollmentCount><Interventions>ethambutol; isoniazid; levofloxacin; pyrazinamide; rifampin</Interventions><Patients>3900</Patients><ProtocolAcronym/><ProtocolTitle>Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis</ProtocolTitle><Reference>2015ZX10003001; NCT02901288</Reference><Sponsor>Beijing Chest Hospital</Sponsor><Trial id="271641"/><TrialStartDate>AUGUST   , 31, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>2500</EnrollmentCount><Interventions>moxifloxacin; rifapentine</Interventions><Patients>2500</Patients><ProtocolAcronym/><ProtocolTitle>Rifapentine-containing tuberculosis treatment shortening regimens (S31/A5349)</ProtocolTitle><Reference>CTRI/2018/07/014966</Reference><Sponsor>Centers for Disease Control and Prevention</Sponsor><Trial id="347338"/><TrialStartDate>JULY     , 20, 2018</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><EnrollmentCount>630</EnrollmentCount><Interventions>Lamprene; bedaquiline; linezolid; moxifloxacin; pretomanid</Interventions><Patients>630</Patients><ProtocolAcronym>TB-PRACTECAL</ProtocolAcronym><ProtocolTitle>Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)</ProtocolTitle><Reference>1541; NCT02589782; TB-PRACTECAL</Reference><Sponsor>Medecins Sans Frontieres</Sponsor><Trial id="244304"/><TrialStartDate>JANUARY  , 31, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>gatifloxacin; levofloxacin; moxifloxacin; p-aminosalycilic acid; prothionamide</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><EnrollmentCount>320</EnrollmentCount><Interventions>clofazimine; gatifloxacin; levofloxacin; moxifloxacin; p-aminosalycilic acid; prothionamide</Interventions><Patients>140</Patients><ProtocolAcronym/><ProtocolTitle>Multicenter, controlled clinical study of the safety, tolerability and efficacy of clofazimine in the treatment of drug-resistant tuberculosis</ProtocolTitle><Reference>ChiCTR1800014800</Reference><Sponsor>Beijing Chest Hospital</Sponsor><Trial id="328802"/><TrialStartDate>DECEMBER , 01, 2009</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="6050">metformin hydrochloride</Drug><EnrollmentCount>150</EnrollmentCount><Interventions>ethambutol; isoniazid; metformin hydrochloride; pyrazinamide; rifampicin</Interventions><Patients>150</Patients><ProtocolAcronym/><ProtocolTitle>Effect of metformin in treatment of non-diabetic pulmonary tuberculosis patients</ProtocolTitle><Reference>CTRI/2019/03/017926</Reference><Sponsor>Veer Surendra Sai Institute of Medical Sciences and Research</Sponsor><Trial id="372893"/><TrialStartDate>MARCH    , 07, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><EnrollmentCount>448</EnrollmentCount><Interventions>amikacin; amoxicillin + clavulanate; azithromycin; bedaquiline; capreomycin; clarithromycin; clofazimine; cycloserine; delaminid; ethambutol; ethionamide; gatifloxacin; imipenem/cilastatin; isoniazid; kanamycin; levofloxacin; linezolid; meropenem; moxifloxacin; ofloxacin; para-aminosalicylic acid; pretomanid; prothionamide; pyrazinamide; rifabutin; rifampicin; streptomycin; sutezolid; terizidone; thioacetazone; whole genome sequencing</Interventions><Patients>448</Patients><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Reference>CAP 020; InDEX; NCT03237182</Reference><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><Trial id="307654"/><TrialStartDate>JUNE     , 14, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>72</EnrollmentCount><Interventions>bedaquiline</Interventions><Patients>72</Patients><ProtocolAcronym/><ProtocolTitle>Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in HIV-Infected and HIV-Uninfected Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis</ProtocolTitle><Reference>11884; CTRI/2017/12/010751; IMPAACT P1108; NCT02906007; P1108</Reference><Sponsor>B. J. Medical College, Pune, National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="272021"/><TrialStartDate>AUGUST   , 18, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Rifafour e-275</Controls><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="85970">telacebec</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>telacebec</Interventions><Patients>60</Patients><ProtocolAcronym/><ProtocolTitle>A Phase II Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q-203)</ProtocolTitle><Reference>NCT03563599; Q203-TB-P2-ZA001</Reference><Sponsor>Qurient Therapeutics</Sponsor><Trial id="343604"/><TrialStartDate>JULY     , 23, 2018</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>4+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Standard of Care; ampicillin; benzylpenicillin; ceftriaxone; cotrimoxazole; gentamicin; prednisolone; sulfamethoxazole; trimethoprim</Controls><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="44384">ceftriaxone</Drug><EnrollmentCount>624</EnrollmentCount><Interventions>Standard or Care; rifampicin + isoniazid + ethambutol; rifampicin + isoniazid + pyrazinamide; valganciclovir; valganciclovir</Interventions><Patients>624</Patients><ProtocolAcronym>EMPIRICAL</ProtocolAcronym><ProtocolTitle>Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia</ProtocolTitle><Reference>19/096; 2019-001749-42; EDCTP RIA2017MC-2013EMPIRICAL; EMPIRICAL; NCT03915366; PACTR201904797961340; U1111-1231-4736</Reference><Sponsor>Hospital Universitario 12 de Octubre</Sponsor><Trial id="377163"/><TrialStartDate>JANUARY  , 01, 2020</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><EnrollmentCount>566</EnrollmentCount><Interventions>isoniazid; rifapentine</Interventions><Patients>566</Patients><ProtocolAcronym>SCRIPT-TB</ProtocolAcronym><ProtocolTitle>Short Course Rifapentine and Isoniazid for the Preventive Treatment of Tuberculosis</ProtocolTitle><Reference>2017ZX10201302-004; NCT03900858; SCRIPT-TB</Reference><Sponsor>Huashan Hospital</Sponsor><Trial id="375813"/><TrialStartDate>DECEMBER , 01, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>An Si Nuo Kang; isoniazid + rifampin + pyrazinamide + ethambutol</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="82091">ethambutol hydrochloride + rifampicin + isoniazid (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical</Drug><EnrollmentCount>474</EnrollmentCount><Interventions>An Si Nuo Kang; isoniazid + rifampin + pyrazinamide + ethambutol</Interventions><Patients>474</Patients><ProtocolAcronym/><ProtocolTitle>Appropriate course of the treatment of tuberculous pleurisy</ProtocolTitle><Reference>ChiCTR-IOR-15006408</Reference><Sponsor>Capital Medical University</Sponsor><Trial id="309137"/><TrialStartDate>JUNE     , 01, 2015</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>gatifloxacin; levofloxacin; moxifloxacin; p-aminosalycilic acid; prothionamide</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><EnrollmentCount>320</EnrollmentCount><Interventions>clofazimine; gatifloxacin; levofloxacin; moxifloxacin; p-aminosalycilic acid; prothionamide</Interventions><Patients>140</Patients><ProtocolAcronym/><ProtocolTitle>Multicenter, controlled clinical study of the safety, tolerability and efficacy of clofazimine in the treatment of drug-resistant tuberculosis</ProtocolTitle><Reference>ChiCTR1800014800</Reference><Sponsor>Beijing Chest Hospital</Sponsor><Trial id="328802"/><TrialStartDate>DECEMBER , 01, 2009</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><EnrollmentCount>630</EnrollmentCount><Interventions>Lamprene; bedaquiline; linezolid; moxifloxacin; pretomanid</Interventions><Patients>630</Patients><ProtocolAcronym>TB-PRACTECAL</ProtocolAcronym><ProtocolTitle>Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)</ProtocolTitle><Reference>1541; NCT02589782; TB-PRACTECAL</Reference><Sponsor>Medecins Sans Frontieres</Sponsor><Trial id="244304"/><TrialStartDate>JANUARY  , 31, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Follicle-stimulating hormone; Gait; Heart rate; Respiratory frequency</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="107010">TBI-223</Drug><EnrollmentCount>48</EnrollmentCount><Interventions>TBI-223</Interventions><Patients>48</Patients><ProtocolAcronym/><ProtocolTitle>A Phase 1 Study to Evaluate Safety, Tolerability, and PK of TBI-223 in Healthy Adults</ProtocolTitle><Reference>NCT03758612; TBI-223-CL-001</Reference><Sponsor>TB Alliance</Sponsor><Trial id="362067"/><TrialStartDate>JANUARY  , 16, 2019</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>rifafour e-275</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="16545">delamanid</Drug><EnrollmentCount>54</EnrollmentCount><Interventions>OPC-67683</Interventions><Patients>54</Patients><ProtocolAcronym/><ProtocolTitle>Safety, Efficacy and Pharmacokinetics of OPC-67683 in Patients With Pulmonary Tuberculosis</ProtocolTitle><Reference>242-06-101; NCT00401271</Reference><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><Trial id="8842"/><TrialStartDate>NOVEMBER , 30, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>165</EnrollmentCount><Interventions>Zyvox; bedaquiline; clofazimine; delamanid</Interventions><Patients>165</Patients><ProtocolAcronym/><ProtocolTitle>Study on Tuberculosis Resistant to Treatment</ProtocolTitle><Reference>CTRI/2019/01/017310; Version Number: 3.1</Reference><Sponsor>Indian Council of Medical Research, Tuberculosis Research Centre</Sponsor><Trial id="369747"/><TrialStartDate>FEBRUARY , 01, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>IFN-gamma; TNF-alpha</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><EnrollmentCount>110</EnrollmentCount><Interventions>GSK-692342</Interventions><Patients>110</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity of Two Formulations of Tuberculosis Vaccines GSK-692342 Given at 0, 1 Months to Healthy Adults</ProtocolTitle><Reference>106227; 106228; 108736; 108738; NCT00397943</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="9520"/><TrialStartDate>NOVEMBER , 30, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Directly observed therapy</Controls><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><EnrollmentCount>54</EnrollmentCount><Interventions>bedaquiline; clofazimine; linezolid; moxifloxacin; pretomanid</Interventions><Patients>54</Patients><ProtocolAcronym>PRACTECAL-PRO</ProtocolAcronym><ProtocolTitle>Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial</ProtocolTitle><Reference>NCT03942354; PRACTECAL-PRO; PRACTECAL-PRO</Reference><Sponsor>Medecins Sans Frontieres, Netherlands</Sponsor><Trial id="379769"/><TrialStartDate>JULY     , 01, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-2; Interleukin-2 receptor alpha chain ; Monocytes; Myeloid-derived suppressor cells; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="22216">etoricoxib</Drug><EnrollmentCount>39</EnrollmentCount><Interventions>SSI H56-IC31; SSI H56-IC31; etoricoxib; etoricoxib</Interventions><Patients>39</Patients><ProtocolAcronym>TBCOX2</ProtocolAcronym><ProtocolTitle>Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic</ProtocolTitle><Reference>2014-004986-26; 2015/692; NCT02503839; TBCOX2</Reference><Sponsor>Oslo University Hospital</Sponsor><Trial id="235355"/><TrialStartDate>NOVEMBER , 30, 2015</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Mycobacterium tuberculosis infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15954">bortezomib</Drug><EnrollmentCount/><Interventions>bortezomib</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>Evaluating Whole Blood Bactericidal Activity of Bortezomib Against Mycobacterium Tuberculosis in Healthy Volunteers</ProtocolTitle><Reference>2015/00743</Reference><Sponsor>National University Hospital (Singapore) Pte Ltd</Sponsor><Trial id="263359"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row></Rowset>